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Prostate cancer (PCa) is dependent on androgens for growth. Androgen 
deprivation therapy (ADT) curtails PCa progression, however this powerful 
selective pressure leads to aggressive, castrate resistant PCa. One castrate 
resistant prostate cancer subtype, neuroendocrine (NE) PCa, is characterised by 
increased abundance of NE cells. Transdifferentiation into androgen independent 
NE-like cells is thought to allow PCa epithelial cells to escape potent ADT, 
causing resistance. NE-like cells are thought to promote growth of surrounding 
tumour cells through paracrine communication. Exosomes are small extracellular 
vesicles released from all cells. They can be endocytosed by neighbouring cells 
and modify cellular function through their cargo (proteins and RNAs). Exosomes 
have been proposed to promote PCa NE-transdifferentiation (NEtD); by an 
unknown mechanism. This project aimed to isolate and characterise exosomes 
from NE-like cells and investigate their potential role in driving neuroendocrine 
PCa. 
 
LNCaP cells were cultured in media containing charcoal-stripped FCS to deplete 
androgens as an in vitro model of AD (androgen deprivation) to promote NEtD. 
NEtD was confirmed by analysing LNCaP morphology, immunoblotting and qRT-
PCR, investigating markers of the androgen receptor and NEtD. Exosomes are 
prevalent in FCS and may mask exosomes released from NE-like LNCaP cells, 
therefore exosomes were depleted from FCS/charcoal-stripped FCS by 
differential centrifugation. Exosome depletion did not affect LNCaP NEtD 
morphology or expression of androgen receptor and NEtD markers. However, AD 
increased expression of markers of the exosomal machinery (ALIX, CD9, HSP70 
TSG101, RAB27A, VAMP7) as seen by qRT-PCR, suggesting AD may enhance 
exosome production. Exosomes were isolated from LNCaP and NE-like LNCaP 
culture medium to analyse exosome size, number and content by dynamic light 
scattering and immunoblotting. AD increased exosomal number and CD9 
expression, suggesting NEtD is associated with increased exosome release. 
Exosome release from LNCaP cells was reduced by GW4869 and enhanced by 
Monensin. GW4869 regressed NEtD in AD LNCaP cells while Monensin induced 
NEtD in control LNCaP cells and enhanced AD LNCaP cells.
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1. Chapter 1: Introduction 
1.1 Cell-to-cell communication 
 
In multicellular systems, cell-to-cell communication is essential to maintain 
homeostasis, coordinate development and promote environmental adaptation 
and survival via migration, proliferation, differentiation and apoptosis of cells 
(Mittelbrunn and Sánchez-Madrid, 2012; Turturici et al., 2014; Vader et al., 2014). 
Classically, cells communicate by direct cell-to-cell contact, using adhesion 
molecules, gap junctions or released via soluble factors such as cytokines, 
chemokines, growth factors, neurotransmitters and their specific recognition cell-
surface receptors for proximal (autocrine, paracrine) or distal (endocrine) 
communication (Mittelbrunn and Sánchez-Madrid, 2012; Tetta et al., 2013).  
 
1.2 Extracellular vesicles 
 
Extracellular vesicles (EVs) are endogenous heterogenous lipid membrane-
bound vesicles, ranging from 30 – 2000 nm in diameter, released by all cells 
(Willms et al., 2016). Cell-derived EVs convey multifaceted biological messages 
between cells via their cargo, consisting of proteins, lipids and nucleic acids 
(Théry, 2011). Thus, EVs are widely accepted to provide a novel form of 
intercellular communication with exciting potential to reform the understanding of 
cellular communication in disease (Vader et al., 2014). EVs can be categorised 
into, exosomes and microvesicles; based on intracellular origin or mechanism of 
release (Willms et al., 2016). Intraluminal vesicles are formed by inward budding 
of the endosomal membrane during maturation of multivesicular endosomes to 
form multivesicular bodies and are secreted by fusion of multivesicular bodies 
with the plasma membrane, known as exosomes (Figure 1.1; Van Niel et al., 
2018). Microvesicles are produced by direct outward budding and fission of the 




1.2.1 Exosome biogenesis 
 
Exosome biogenesis occurs through the Endosomal Sorting Complex Required 
for Transport (ESCRT) pathway and the ceramide-mediated pathway (Figure 1.1; 
Bebelman et al., 2018). Sorting and packaging of ubiquitinated proteins is 
performed by tumour susceptibility gene 101 (TSG101) and ESCRT accessory 
protein ALG-interacting protein X (ALIX); (Figure 1.1; Schmidt and Teis, 2012). 
Intraluminal vesicles are formed by invaginations in the endosomal membrane, 
initiating maturation of early endosomes to multivesicular bodies (MVBs), which 
are degraded by lysosomes or transported to the plasma membrane (Figure 1.1; 
Van Niel et al., 2018). Multivesicular bodies are docked at the plasma membrane 
via Ras-associated binding protein 27A (RAB27A) (Figure 1.1; Ostrowski et al., 
2010). Then, Soluble N-ethylmale-imide-sensitive factor-Attachment Protein 
Receptors (SNARE) proteins such as vesicle associated membrane protein 7 
(VAMP7), induce fusion with the plasma membrane (Figure 1.1; Fader et al., 
2009) releasing intraluminal vesicles into the extracellular space, as exosomes, 
which are enriched in tetraspanins (CD9); (Figure 1.1; Andreu and Yáñez-Mó, 
2014). 
 
Trajkovic et al. (2008) elucidated ceramide-mediated exosome generation as an 
alternative exosome biogenesis pathway (Figure 1.1). Hydrolytic removal of the 
phosphocholine moiety of sphingomyelin via neutral sphingomyelinase produces 
ceramide (Trajkovic et al., 2008). Generation of ceramide in the limiting 
membrane of multivesicular bodies induces membrane invaginations and thus, 
intraluminal vesicle formation (Trajkovic et al., 2008). Ceramide’s cone-shaped 
structure may cause spontaneous membrane curvature of the endosomal 
membrane promoting domain-based budding, highlighting the role of lipids in 




Figure 1.1: Exosome biogenesis. Cargo is sorted and packaged by Endosomal 
Sorting Complex Required for Transport (ESCRT) or ceramide-mediated 
pathways. ESCRT-0 identifies and sorts ubiquitinated proteins and recruits 
ESCRT-1 by binding tumour susceptibility gene 101 (TSG101)/Vps23 subunit. 
Ubiquitinated proteins are transported to ESCRT-I and ESCRT-II, which drive 
invaginations in the endosomal membrane to form intraluminal vesicles (ILVs). 
ESCRT-III then forms a spherical structure to limit the budding neck, the ATPase, 
VPS4, drives membrane scission leading to intraluminal vesicle release. The 
accessory protein ALG interacting protein X (ALIX) intersects the canonical 
ESCRT pathway, contributing to exosomal cargo selection. Multivesicular bodies 
are transported to the plasma membrane and dock via RAS-associated binding 
protein 27a (RAB27A). Soluble N-ethylmale-imide-sensitive factor-Attachment 
Protein Receptors (SNARE) proteins such as vesicle associated membrane 
protein 7 (VAMP7), induce fusion with the plasma membrane releasing the 
intraluminal vesicles into the extracellular space as exosomes, enriched with 
tetraspanin proteins such as CD9, CD63 or CD8. In ceramide-mediated 
biogenesis,  ceramide is produced in the limiting membrane of multivesicular 
bodies inducing invaginations and thus, intraluminal vesicle formation. Created 




1.2.2 Microvesicle biogenesis 
 
The precise mechanisms involved in microvesicle formation are unknown 
(Muralidharan-Chari et al., 2010) however, it is widely accepted that their release 
arises via direct outward budding and pinching of the plasma membrane (Figure 
1.2; Tricarico et al., 2017). 
 
 
Figure 1.2: Microvesicle biogenesis. Budding of the plasma membrane 
incorporates cell surface proteins or cytosolic proteins bound to the inner leaflet 
of the plasma membrane. The vesicles are shed from the plasma membrane and 
can range from 50-1000 nm and are known as microvesicles. Created using 
Servier Medical Art by Servier. 
 
There is a partial overlap between exosomes and microvesicles biogenesis as 
ESCRT machinery is involved in the production of vesicles enriched in cell 
surface proteins reflecting their plasma membrane origin (Bebelman et al., 2018). 
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Acid sphingomyelinase can also induce ceramide-dependant microvesicle 
assembly (Bianco et al., 2009). There can often be commonality in exosomal and 
microvesicle cargo (Van Niel et al., 2018). However, cytosolic components are 
sorted into microvesicles via binding to the inner leaflet of the plasma membrane 
(Mcgough and Vincent, 2016). Post-translational  palmitoylation, prenylation and 
myristoylation of cargo is responsible for this process (Shen et al., 2011; Yang 
and Gould, 2013). A sub-population of microvesicles are termed apoptotic bodies 
and differ from microvesicles via their size (50-5000 nm) and release mechanism 
(Willms et al., 2016; Van Niel et al., 2018). Microvesicles are released 
constitutively, however, apoptotic bodies are only released during apoptosis via 
outward blebbing and fragmentation of the apoptotic cell (Vader et al., 2014). 
Unlike exosomes and microvesicles, apoptotic bodies contain nuclear and 
cytoplasmic organelle fragments thus, DNA, histones and components of the 
Golgi apparatus or endoplasmic reticulum are suggested markers for their 
identification (Vader et al., 2014). 
 
1.2.3 Extracellular vesicle content 
 
EVs were initially proposed as a mechanism to remove cellular waste from cell 
damage, or by-products of cell homeostasis, and thought to have no significant 
impact on neighbouring cells (Zhang et al., 2019). It is now known EVs contain 
complex cargo of proteins, lipids, and nucleic acids that can alter function of 
recipient cells by exosomal cell-to-cell communication and contribute to functional 
diversity of EVs (Mathivanan et al., 2012; Kim et al., 2013). 
 
Proteins commonly found in EVs are associated with biogenesis, such as ESCRT 
components (ALIX,TSG101); heat shock proteins (HSP70, HSP90); proteins 
responsible for transport and release (annexins, RAB27A, RAB11B); as well as 
tetraspanins (CD9, 63, 81), which take part in cell penetration, fusion and invasion 
(Abels and Breakefield, 2016). EVs are enriched in nucleic acids such as small 
RNAs (miRNAs), which undergo unidirectional transfer between cells, 
establishing an intercellular trafficking network, which elicits transient or 
phenotypic changes in recipient cells (Mittelbrunn and Sánchez-Madrid, 2012). 
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EVs are also enriched in lipids such as cholesterol, sphingomyelin, arachidonic 
acid and fatty acids, which account for their stability and structural rigidity (Zhang 
et al., 2019). To some degree, exosomal cargo is cell type dependent, reflecting 
the cell they are released from (Hessvik and Llorente, 2018). 
 
1.2.4 Extracellular vesicle uptake 
 
Internalisation of EVs and associated cargo by endocytosis can alter or 
reprogram the recipient cell function at proximal and distal ranges, presenting as 
a means of cell-to-cell communication (Zhang et al., 2019). EV internalisation 
may be dependent on recipient cell type, its physiologic state, and whether there 
is ligand-receptor recognition by the recipient cell (Zaborowski et al., 2015). For 
example, neurons employ clathrin-dependent endocytosis or phagocytosis 
(Morelli et al., 2004; Barrès et al., 2010), macropinocytosis by microglia (Feng et 
al., 2010), phagocytosis or receptor-mediated endocytosis by dendritic cells 
(Fitzner et al., 2011; Montecalvo et al., 2012), caveolin-mediated endocytosis in 
epithelial cells (Frühbeis et al., 2013), and cholesterol- and lipid raft-dependent 
endocytosis in tumour cells (Nanbo et al., 2013; Svensson et al., 2013). EVs can 
also fuse with the recipient cell membrane to release cargo into  the cytoplasm 
or via ligand-receptor binding to induce signalling in the recipient cells (Turturici 
et al., 2014). The uptake of EVs by recipient cells highlights their importance in 
cell-to-cell communication in healthy and diseased states. 
 
1.2.5 Extracellular vesicle isolation 
 
There are multiple methods of EV isolation including differential 
ultracentrifugation, size-based techniques such as ultrafiltration, precipitation and 
size exclusion chromatography (Witwer et al., 2013). 
 
The most widely applied method of exosome isolation is differential 
ultracentrifugation where EVs are separated by particle density, size and shape 
(Jeppesen et al., 2014). Differential ultracentrifugation uses several centrifugation 
steps, that sequentially increase in speed and time to pellet sequentially smaller 
particles (Li et al., 2017). Little or no sample pre-treatment is required and it is 
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cost-effective (Doyle and Wang, 2019). Differential ultracentrifugation does not 
exclusively remove EVs from biological fluids, often proteins such as albumin or 
immunoglobulins can co-sediment with EVs, interfering with EVs analysis 
(Caradec et al., 2014). Differential ultracentrifugation can also be time-
consuming, with limited capacity to process multiple samples at once due to large 
sample volumes required (Doyle and Wang, 2019). 
 
Other EV isolation methods include size-based techniques such as ultrafiltration, 
precipitation or, size exclusion chromatography (Witwer et al., 2013). 
Ultrafiltration employs nanomembranes or molecular weight cut offs to isolate 
exosomes from culture medium or bodily fluid (Zhang et al., 2018). This can 
shorten conventional ultracentrifugation time but vesicles can become obstructed 
or trapped in filters, resulting in exosomal loss (Doyle and Wang, 2019). Like 
viruses or other small particles, EVs can also be precipitated from biological fluids 
using  polyethylene glycol (PEG) buffer, which displaces water molecules causing 
EVs to precipitate out of solution (Rider et al., 2016). EVs can then be pelleted 
by centrifugation (Ludwig et al., 2018). Precipitation can co-isolate non-EV 
components such as proteins and protein aggregates therefore, it is 
recommended to combine precipitation with a purifying method (Doyle and Wang, 
2019). Size exclusion chromatography uses a porous column, causing particles 
in sample to eluate at different rates, larger particles will elute more rapidly while 
smaller particles will elute more slowly, the eluted fraction of a certain time should 
therefore, contain a population of particles of the same size (Szatanek et al., 
2015). Typically, size exclusion is used in conjunction with precipitation or 
ultracentrifugation to further purify exosomes (Welton et al., 2015). 
 
Currently, there is no standardised approach to exosome isolation (Witwer et al., 
2013) and the biochemical overlap between exosomes and other EVs such as 
microvesicles means many methods do not exclusively isolate exosomes (Li et 
al., 2017). The international society for extracellular vesicles (ISEV) created a set 
of recommendations to promote linearization of EV research, they recommend 
the use of one or more additional technique (ultrafiltration, density gradients or 
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chromatography) following primary method (differential ultracentrifugation or pre-
cipitation) to improve specificity of EVs subtype separation (Théry et al., 2018; 
Van Niel et al., 2018). 
 
1.2.6 Physical characterisation of extracellular vesicles 
 
Physical characterisation provides information on particle size and/or 
concentration of EVs via dynamic light scattering (DLS) nanoparticle tracking 
analysis (NTA) or transmission electron microscopy (TEM); (Doyle and Wang, 
2019). DLS employs a monochromatic and coherent laser beam; when the laser 
hits a particle in suspension, light is scattered in all directions (Szatanek et al., 
2017). DLS analyses fluctuations in intensity of scattered light in Brownian motion 
to estimate particle size and concentration to detect particles from 1 nm to 6 μm 
(Lane et al., 2015). A shortcoming of DLS is that scattered light intensity is more 
sensitive to the presence of larger particles; thus, scattered light caused by 
smaller particles is more difficult to detect so data can be skewed towards larger 
particles in heterogenous mixtures (Doyle and Wang, 2019). Like DLS, NTA also 
uses scattered light however, instead of fluctuations in intensity, NTA uses the 
diffusion coefficient to estimate particle size (Doyle and Wang, 2019). NTA uses 
a camera attached to a microscope to track particle displacement plotted as a 
function of time, enabling calculation of particle size and distribution (Szatanek et 
al., 2017). NTA can also analyse fluorescently labelled exosomes however, 
expression of the studied marker must be high and the fluorescent signal needs 
to be very bright in order to be detected (Dragovic et al., 2013, 2015). 
 
Transmission Electron Microscopy (TEM) uses short wavelengths of electrons to 
resolve characteristic features of exosomes such as their cup-shaped 
morphology (Raposo and Stoorvogel, 2013). Generally, TEM is employed as a 
method of visualisation after detection of the size and concentration by other 
techniques such as DLS or NTA (Zhang et al., 2018). 
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1.2.7 Biochemical and molecular characterisation of extracellular vesi-
cles 
 
Biochemical and molecular techniques such as immunoblotting, mass 
spectrometry, flow cytometry or miRNA profiling provide information on cargo 
isolated from EVs (Doyle and Wang, 2019). 
 
Where possible, when performing EV protein analysis five different categories of 
proteins should be employed including; transmembrane or GPI-anchored 
proteins localised in the plasma membrane or endosome such as non-tissues 
specific tetraspanins (CD63) or tissue specific tetraspanin such as CD9 (absent 
from NK, B and some mesenchymal stem cells), TSPAN8 (epithelial cells) or 
ERBB2; cytosolic proteins such as those associated with ESCRT-I/II/III (TSG101, 
ALIX, VSP4A/B, flotillin-1/2 or Hsp70); proteins that are major constituents of non-
EV membranes, which can often be co-isolated (albumin, protein/nucleic acid 
aggregates); proteins localised on intracellular compartments such as the 
nucleus (histones), mitochondria (cytochrome C) or secretory pathway (calnexin); 
or secreted luminal proteins that associate with EVs via surface receptors such 
as cytokines (interleukins) or growth factors (TGFB1/2); (Théry et al., 2018). 
Using a combination of these markers to characterise EVs will provide a more 
robust and standardised analysis approach to exosomal proteomic analysis 
(Bhome et al., 2018). 
 
Immunoblotting is the most commonly used method to detect exosomal proteins 
due to its wide accessibility (Théry et al., 2018). Immunoblotting requires cell 
lysis; therefore, this technique can provide data on exosomal cargo that may be 
involved in cell-to-cell communication. Exosomal cargo therefore, may represent 
potential biomarkers for disease, which are used to distinguish abnormal 
biological processes from normal processes (Verma et al., 2011). Immunoblotting 
is dependent on the use of specific antibodies; therefore, it is necessary to know 
what proteins you intend to investigate (Doyle and Wang, 2019). Unlike 
immunoblotting, mass spectrometry (MS) enables high-throughput peptide 
profiling and identification of previously unknown proteins (Shao et al., 2018). 
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Validation of protein candidates can then be performed using conventional 
protein techniques such as immunoblotting to provide an insight to exosomal 
protein cargo and the potential to use these as biomarkers for disease (Bandu et 
al., 2019), to provide quantitative and comparative EV proteomic analysis (Shao 
et al., 2018). Flow cytometry can be considered as a physical and biochemical 
form of exosome analysis as it allows visual observation of EV populations 
however, this requires knowledge regarding their protein composition (Doyle and 
Wang, 2019). The detection limit of most flow cytometers is 300 - 500 nm, which 
poses a challenge as exosomes have an average diameter of 30 - 100 nm (Shao 
et al., 2018). Exosomes must, therefore, be immobilised via beads by 
immunocapture or covalent conjugation (Doyle and Wang, 2019). Once 
immobilised exosomes are exposed to fluorescently conjugated antibodies 
against antigens on the exosomal surface (tetraspanin proteins); (Szatanek et al., 
2017). When sample passes the laser of the flow cytometer it emits a fluorescent 
signal, allowing high-throughput analysis and classification of EVs based on 
antigen expression (Szatanek et al., 2017). 
 
miRNA expression in EVs can be measured by qRT-PCR, microarray 
hybridization and next-generation sequencing (NGS); (Git et al., 2010). qRT-PCR 
is scaled up for miRNA profiling, as reactions are carried out in a highly parallel, 
high-throughput form by performing hundreds of reactions to measure different 
miRNAs using the same reaction conditions (Pritchard et al., 2012). In microarray 
hybridization probes can cover more than 1000 mature human miRNAs 
sequences found in the miRNA database, obtained miRNA array data can be 
validated via qRT-PCR (Schwarzenbach and Heidi, 2017).The major advantage 
of NGS are detection of novel and known miRNAs and specific identification of 
miRNA sequences via bioinformatic analysis (Pritchard et al., 2012). Drawbacks 
of this method are that miRNA sequence biases can be introduced during library 
construction and that computational support is needed to analyse the extensive 
data output (Schwarzenbach and Heidi, 2017). 
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1.3 Prostate cancer 
 
In the UK, prostate cancer (PCa) is the most prevalently diagnosed cancer in 
males, with 48,500 new cases identified annually (Cancer Research UK, 2020) it 
is the most common cause of cancer related death in men (Rawla, 2019). PCa 
results from expansion of malignant glandular cells forming a tumour known as 
an adenocarcinoma (Dunn and Kazer, 2011). PCa is dependent on androgens, 
potent mediators of PCa growth and progression and can metastasise to the 
lymph nodes and bone (Heinlein and Chang, 2004). PCa can be managed 
therapeutically however, advanced prostate cancer it is also lethal, which 
presents as a significant problem and major clinical and social burden (Rawla, 
2019). 
 
Currently, PCa is diagnosed by a blood test for the biomarker prostate specific 
antigen (PSA) or a digital rectal examination (Akbaş et al., 2015). However, PSA 
and digital rectal examination are considered to be non-specific for PCa and they 
can result in false positive results as increased serum PSA and enlarged prostate 
are also associated with prostatitis or benign prostate hyperplasia (Akbaş et al., 
2015). There is no reliable or widely available method to distinguish high risk 
tumours at an earlier stage as PSA is unable to discriminate clinically important 
cancers from low risk tumours (Pezaro et al., 2014). Population studies have also 
demonstrated that the normal range of PSA increases with age; thus, PSA 
concentration requires interpretation with the understanding of the clinical 
situation (Pezaro et al., 2014). Gleason grading and Tumour Node Metastasis 
(TNM) staging systems have enabled better characterisation of PCa tumours 
(Ranno et al., 2005). There is also the potential benefit of reducing over treatment 
of low grade PCa detected by PSA screening and identifying bespoke treatment 
options (Epstein et al., 2016). 
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1.3.1 The androgen receptor 
 
The androgen receptor (AR) is a ligand dependant transcription factor, essential 
for regulation of male sexual differentiation, development and growth (Culig and 
Santer, 2014). AR activation occurs via binding of circulating androgen hormone 
native ligands, testosterone and potent metabolite, 5α-dihydrotestosterone 
(DHT); (Tan et al., 2015). DHT binds with high affinity to AR, displacing heat 
shock proteins, which triggers AR translocation to the nucleus forming dimers 
that bind to androgen response elements (AREs). Transcription of androgen re-
lated genes is initiated such as KLK3, which promotes healthy function of the 
prostate and transmembrane protease serine 2 (TMPRSS2), known to promote 
PCa progression upon fusion with the transcription factor erythroblast transfor-
mation specific (ETS); (Shang et al., 2002; Heinlein and Chang, 2004; Jin et al., 
2013; Tan et al., 2015). 
 
1.3.2 Treatment options for PCa 
 
Treatment options for PCa include surgical tumour removal, radiation, 
chemotherapy, androgen deprivation therapy (ADT) or a combination of all, 
depending on whether the PCa is primary, advanced or metastatic (Bono, 2004). 
 
Increased diagnosis of early stage prostate cancer with PSA has increased the 
use of active surveillance, where serum PSA and prostate biopsies are closely 
monitored (Dunn and Kazer, 2011). When PCa is primary and localised, radical 
prostatectomy is considered, where the entire prostate gland is surgically 
removed (Bill-Axelson et al., 2014). A limitation to this treatment is that often men 
present with disease, which has already progressed beyond the prostate gland 
(Bill-Axelson et al., 2014). Radiotherapy is also used for localised PCa and is 
performed as external beam therapy, brachytherapy or a combination of both, 
depending if the PCa is considered to be of intermediate or high risk (Dietrich et 
al., 2015). The objective of radiotherapy is to deliver a curative dose of radiation 
to the prostate without damaging neighbouring tissues such as the bladder, 




Initially, androgens are essential for PCa growth therefore, removal of androgens 
through ADT is an effective way to delay PCa progression and improve patient 
outcomes (Akitake et al., 2018). Decreasing circulating androgens to castrate lev-
els, corresponding to a measurement of <0.5 ng/mL of testosterone, decreases 
PCa cell proliferation and induces apoptosis (Ritch and Cookson, 2016). ADT can 
be administered via drugs such as leuprolide, a gonadotropin releasing hormone 
(GnRH) agonist, that acts on the anterior pituitary to reduce luteinizing hormone 
by downregulating GnRH receptors. Anti-androgens such as flutamide can also 
be used alone or in conjunction with castration to block binding of ligands to the 
AR (Sharifi et al., 2005; Karantanos et al., 2013). 
 
After an initial response to ADT the majority of tumours relapse to a more 
advanced stage of PCa, castrate-resistant prostate cancer, which has a poor 
prognosis (Karantanos et al., 2013). Initiating synthesis of highly potent second-
generation anti-androgens; Abiraterone, which inhibits CYP17A to prevent 
androgen biosynthesis and Enzalutamide, a pure antagonist of the AR (Hotte and 
Saad, 2010). The high potency of Abiraterone and Enzalutamide places a strong 
selective pressure on PCa and causes further therapeutic resistance (Karantanos 
et al., 2013). 
 
When ADT is unable to contain PCa progression to metastatic (m)CRPC, chemo-
therapeutics become first line treatment. Docetaxel is the leading chemothera-
peutic for mCRPC, which binds to β-tubulin to induce apoptosis of the cells (Attard 
et al., 2006). The life extension of these drugs is poor with overall survival under 
two years, implementation of chemotherapeutics provides palliative care rather 
than curative (Petrylak et al., 2004). Radium-223, used for mCRPC is an emitting, 
bone seeking calcium mimetic able to selectively target and bind to areas of bone 
turnover in PCa patients with bone metastasis (Ritch and Cookson, 2016). 
 
The only treatment option for PCa with neuroendocrine differentiation are 
platinum-based therapeutics, most frequently cisplatin is used in combination 
with etoposide however, these therapeutics do not directly target mechanism of 
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neuroendocrine mediated PCa survival and drug resistance (Aparicio et al., 
2013). 
 
1.3.3 Castrate resistant prostate cancer 
 
Prolonged ADT generates a stressful tumour microenvironment consequently, 
alternative survival and growth pathways drive PCa to overcome selective 
pressure, which causes treatment resistance and formation of CRPC (Figure 1.3; 
Karantanos et al., 2013). CRPC is an advanced, more aggressive and lethal form 
of PCa that typically forms within 3 years of ADT (Ritch and Cookson, 2016). By 
definition patients with CRPC have castrate levels of circulating testosterone (< 
0.5 ng/mL) however, most tumours remain androgen dependant by constitutive 
activation of the AR, intratumoral androgen production, AR promiscuity or 
activation of downstream targets (Beltran et al., 2011). Despite castrate androgen 
concentrations, expression of androgen-dependant targets, such as a rise in 
serum PSA means PCa can proliferate in absence of androgens (Saraon et al., 
2011). Prognosis for patients with CRPC is usually 18-24 months however, once 
metastasised this is reduced to less than a year (Sharifi, et al., 2005; Sartor, 
2011). It is crucial that new biomarkers for CRPC are identified due to the lack of 




Figure 1.3: Progression of prostate cancer to castrate resistant prostate 
cancer. A. Prostate adenocarcinoma is an androgen-dependent tumour, which 
arises in the epithelial cells of the prostate. B. Surgery, radiotherapy and 
androgen deprivation therapy (ADT), are the primary treatments for prostate 
adenocarcinoma. C.  The adenocarcinoma may respond to treatment showing 
tumour regression or slowed growth rate. D. In response to treatment resistance 
can occur. E. Castrate resistant prostate cancer (CRPC) arises as a result of 
therapeutic resistance. F. Potent second-generation anti-androgens, 
immunotherapy and radiation implemented to delay disease progression. G. 
Formation of metastatic CRPC (mCRPC) occurs. H. Chemotherapeutics involved 
in palliative treatment to provide modest increase in overall survival. Created 
using Servier Medical Art by Servier. 
 
1.3.4 Neuroendocrine cells in the prostate  
 
Neuroendocrine (NE) cells are distributed throughout the epithelial layer of the 
healthy prostate (Liu and True, 2002). These cells function as neuronal and 
endocrine cells, and are involved in regulating differentiation and growth of 
normal prostate epithelia (Yuan et al., 2007). NE cells maintain tissue 
homeostasis by working in a paracrine manner to release potent neuropeptides 
such as neurotensin, bombesin and serotonin (Abrahamsson, 1999). Release of 
these peptides is thought to induce growth, survival, motility and metastatic 
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potential of neighbouring epithelial cells in prostate adenocarcinoma (Amorino 
and Parsons, 2004; Soundararajan et al., 2018). 
 
1.3.5 Neuroendocrine prostate cancer (NEPC) 
 
Therapy resistance and tumour relapse are very common in advanced PCa, 
which relates to the extensive intratumoral genetic and phenotypic heterogeneity 
of PCa (Figure 1.4; Patel et al., 2019). NEPC arises as lethal progression of 
CRPC and exists in variable differentiation states referred to as the NEPC 
disease continuum (Figure 1.4; Labrecque et al., 2019). Epithelial PCa cells 
undergo lineage switching to transdifferentiate into NE-like PCa cells as an 
adaptive mechanism to evade selective pressure of PCa therapies (ADT, 
radiotherapy, chemotherapy); (Beltran et al., 2019). In the prostate 
adenocarcinoma microenvironment, NE cells are thought to release potent 
neuropeptides to induce neuroendocrine transdifferentiation (NEtD) of 
neighbouring epithelial prostate cells to NE-like cells (Figure 1.5; Soundararajan 
et al., 2018).  Detection of neuronal biomarkers such as chromogranin A 
(CrgA/CHGA), neuron specific enolase (NSE/ EN02) and synaptophysin (SYP) 
and androgen biomarkers such as the AR and PSA by immunohistochemistry 
(IHC) allows clinical phenotyping of NEPC, however not all NEPC subtypes 
display a clear staining profile contributing to ineffective treatment and poor 
patient outcomes (Hu et al., 2015). However, these are not routinely used in the 
clinic (Dunn and Kazer, 2011). Highlighting the need for novel circulating 
biomarkers to provide a more accurate diagnosis of NEPC and ability to stratify 
NEPC from CRPC to provide more effective treatment options. 
 
Labrecque et al. (2019) described five phenotypes of NEPC based upon 
expression of AR or NE biomarkers described in Figure 1.4: ranging from PCa, 
which has near uniform expression of adenocarcinoma markers to double 
negative PCa that lack adenocarcinoma or neuronal markers representing 
distinct disease states or a continuum  (Labrecque et al., 2019). Once diagnosed 
with NEPC the overall survival of patients ranges from 7 months to 2 years 




Figure 1.4: Neuroendocrine transdifferentiation of prostate cancer. 
Schematic diagram showing the diversity of castrate resistant prostate cancer 
and neuroendocrine prostate cancer subtypes and the markers expressed in 
each, AR; androgen receptor, PSA; prostate specific antigen, CrgA; 
chromogranin, SYP; Synaptophysin.  AR PCa has uniform expression of 
adenocarcinoma markers, AR and PSA and does not express neuronal markers 
(ARPC). AR low PCa (ARLPC) has weak or heterogenous AR or PSA with no 
neuronal markers. Amphicrine or hybrid PCa (AMPC) co-expresses AR, PSA and 
neuronal markers CrgA and SYP. Small cell or neuroendocrine PCa (SCNPC) 
displays a neuroendocrine histology with no adenocarcinoma markers. Double 
negative PCa, lack detectable expression of AR, PSA, CrgA or SYP. Created 
using Servier Medical Art by Servier. 
 
Currently there is no means of stratifying NEPC from CRPC, thus patient 
prognosis is extremely poor when PCa reaches this stage (Labrecque et al., 
2019). The heterogeneity of PCa, lack of effective therapies and inability to stratify 
PCa types (CRPC and NEPC) highlights the need for new biomarkers and 
therapeutic targets for PCa subtypes to improve therapeutic options and patient 
prognosis (Patel et al., 2019). Lineage plasticity facilitates carcinogenesis, 
metastasis, and treatment resistance of the tumour (Meacham and Morrison, 
2013). Plasticity may display as reversible or irreversible changes of cellular 
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characteristics, as cells take on alternative morphologic, phenotypic, or 
epigenetic states (Graf and Enver, 2009). Therapeutic associated lineage 
plasticity induces differentiated tumour cells to develop different phenotypes, to 
revert back to a more ‘stem-like’ state and subsequently re-differentiate towards 
an alternative cell fate to evade therapeutic pressure (Beltran et al., 2019). Cells 
undergoing lineage switching preserve the molecular memory of their 
differentiated cancer cell precursor however, the alternative lineage facilitates 
subsequent tumour progression (Beltran et al., 2019). 
 
1.3.6 Proposed factors involved in NEtD of PCa 
 
The exact mechanism employed by PCa to shift the epithelial to NE-like pheno-
type is not fully understood and there have been many genes implicated in this 
process (Patel et al., 2019). Loss of tumour suppressors RB1 and TP53, leads to 
alterations in stem cell, developmental, and EMT status, mediated by lineage plu-
ripotency transcription factors SOX2 and EZH2 to facilitate transition from an ep-
ithelial to NE-like phenotype (Ku et al., 2017). Down-regulation of REST, a tran-
scriptional repressor of neuronal genes in non-neuronal cells via splicing con-
trolled by SRRM4 (Zhang et al., 2015), as well as activation of lineage associated 
transcription factors such as N-MYC (Lee et al., 2016), Onecut2 (Guo et al., 
2019), and BRN2 (Bhagirath et al., 2019) also are thought to contribute to the 
epithelial to NE-like transition. Other potential neuronal biomarkers include hu-
man achaete-scute homolog 1 (hASH1/ASCL1), regulator of cell commitment 
and differentiation, AD of LNCaP cells induced NEtD, re-exposure of LNCaP cells 
to androgen facilitated differentiation back to epithelial state. However, ASCL1 
remained localised in the nucleus, revealing the amphicrine status of the tumour 
and involvement in NEPC lineage plasticity (Fraser et al., 2019). 
 
1.4 Exosomes in cancer 
 
Cancer cells can sort oncogenes, oncoproteins, chemokine receptors, growth 
factors and immunomodulatory molecules into exosomes (Bebelman et al., 
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2018). This cargo can be taken up by neighbouring or distal recipient cells leading 
to neoplastic transition via horizontal gene transfer (Zhang et al., 2019).  
Tumour-derived exosomes are known to enhance tumour formation by 
manipulating the tumour microenvironment, initiating a tumour-promoting niche, 
tumour angiogenesis, immunosuppression and acquisition of malignant traits 
(Bebelman et al., 2018). The tumour promoting activity of exosomes is not limited 
to the local tumour microenvironment and tumour-derived exosomes can enter 
the circulation to reach distant organs, enabling pre-metastatic niche formation 
and outgrowth of disseminated tumours (Bebelman et al., 2018; Li and Nabet, 
2019). Transfer of the oncogene, MET to bone marrow progenitor cells by 
metastatic melanoma-derived exosomes directed pre-metastatic niche formation, 
encouraging lung metastases (Peinado et al., 2012). Uptake of pancreatic cancer 
cell derived exosomes by Kupffer cells induced TGF-β secretion, upregulation of 
fibronectin production, enhanced bone marrow-derived macrophage recruitment 
and pre-metastatic niche formation in the liver (Costa-Silva et al., 2015). This 
could be prevented by blockade of migration inhibitory factor found in the 
pancreatic cancer derived exosomes (Costa-Silva et al., 2015). 
 
Cancer patients have an increased number of circulating exosomes compared to 
healthy individuals, associated with the over expression of ESCRT components, 
syntenin and heparinase (Bebelman et al., 2018). Increased circulating 
exosomes may be caused by activation of oncogenic signalling pathways such 
as EGFRvIII and H-RASv12, which are thought to induce exosome production in 
cancer cells (Al-Nedawi et al., 2008; Lee et al., 2014; Takasugi et al., 2017). 
Environmental stresses can also influence EV release (Wang et al., 2014; Guo 
et al., 2017). In NEPC, therapeutic stressors force the lineage switching of 
epithelial cells, thus it is possible this process could be facilitated by stress-
induced exosome release. As a result, exosomes can be used as a read-out of 
the tumour biology as an easily accessible, non-invasive and real-time biomarker 
of NEPC formation, evolution and/or development.
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1.4.1 PCa patients and exosomes 
 
Urinary and plasma exosomes represent an opportunity to identify non-invasive 
biomarkers for PCa patients, which permit real‐time assessment of tumoral char-
acteristics, including genomic and proteomic information (Vlaeminck-Guillem, 
2018). 
 
Plasma-derived exosomes are increased in PCa patients compared to benign 
prostate hyperplasia patients or healthy individuals, this correlates with cancer 
aggressiveness, metastatic spread and/or Gleason score, providing more evi-
dence for the use of exosomes as biomarkers in PCa (Vlaeminck-Guillem, 2018). 
Circulating exosomes containing AR splice variant 7 (AR-V7) mRNA was shown 
as a prognostic marker for CRPC patients and associated with very low levels of 
castrate androgens (Joncas et al., 2019), evidencing the potential to stratify PCa 
subtypes via non-invasive real-time exosomal biomarkers. Actinin-4, a cross-link-
ing protein associated with cell motility, cancer invasion and metastasis was sig-
nificantly upregulated in exosomes from CRPC patients compared to adenocar-
cinoma patients (Ishizuya et al., 2020), showing the ability to distinguish PCa 
types via non-invasive, real-time exosomal biomarkers. Vesicle fusion by t-
SNARE, syntaxin 6, was increased in exosomes from PCa patients with a higher 
Gleason score, stage of primary tumour and decreased overall survival (Peak et 
al., 2020). Further, IHC showed higher syntaxin 6 expression in tissues from En-
zalutamide treated patients compared to non-Enzalutamide treated patients 
(Peak et al., 2020), suggesting exosomes can be employed as biomarkers to 
stratify PCa stage. Actinin-4, a cross-linking protein associated with cell motility, 
cancer invasion and metastasis was significantly upregulated in exosomes from 
CRPC patients compared to adenocarcinoma patients (Ishizuya et al., 2020), 




1.4.2 Exosomes and NEtD in PCa 
 
Exosomes released from androgen sensitive (LNCaP) and androgen 
independent (PC3 and DU145) PCa cell lines increase cellular proliferation of 
other PCa cells (Soekmadji et al., 2017), can transfer cell-specific cargo (Read et 
al., 2017; Bhagirath et al., 2019) and initiate formation of the pre-metastatic niche 
(Itoh et al., 2012). 
 
Exosomes may also mediate NEtD via crosstalk of exosomes released in the 
tumour microenvironment (Figure 1.5; Lin et al., 2017a). Read et al., (2017) 
reported that the AR and mutant variant, AR-V7, were secreted in EVs from 
LNCaP cells and could be transported to the nucleus of AR-null PC3 cells to 
promote active transcription. Proliferation of recipient PC3 cells was enhanced by 
the nuclear translocated AR in the absence of androgen (Read et al., 2017). 
Bhagirath et al. (2019) showed the neural transcription factors BRN2 and BRN4 
are packaged in exosomes and facilitate NEtD of LNCaP cells by horizontal gene 
transfer, highlighting the importance of exosomes in progression or maintenance 
of PCa. There is no cure and limited treatment options for NEPC therefore, 
understanding how exosomes may contribute to this disease may highlight the 
use of exosomes for NEPC diagnosis, monitoring of disease progression, 





Figure 1.5: Proposed involvement of exosomes in NEtD PCa. Exosomes are 
released from cells in the prostate adenocarcinoma microenvironment. It is 
proposed that there is exosome mediated crosstalk via epithelial cells, 
neuroendocrine cells and NE-like cells. The cargo released from NE-like 
exosomes may alter cellular function driving NEtD and aggressive tumour 
formation. Created using Servier Medical Art by Servier. 
 
1.4.3 In vitro model of NEtD PCa  
 
The aim of this research was to investigate the potential role of exosomes as a 
means of cell-to-cell communication involved in potentially driving or maintaining 
neuroendocrine transdifferentiation (NEtD) in PCa. NEPC can be modelled in 
vitro using charcoal stripped FCS to remove androgens from the culture medium 
and induce NEtD of LNCaP cells (Shen et al., 1997; Rapa et al., 2008; Fraser et 
al., 2019). Exosomes are released from all cells and therefore, are present in a 
significant concentration of many biological fluids (Jeppesen et al., 2014; Lötvall 
et al., 2014; Szatanek et al., 2015). Depletion of EVs from FCS is necessary to 
minimise co-isolation of FCS-derived EVs with EVs of interest (Figure 1.6; 
Szatanek et al., 2015). Depletion of EVs and androgens has not been previously 
reported in the literature therefore, the NEtD of LNCAP model was further 
developed to limit FCS exosome interference from PCa exosomes. The impact 
of AD-induced NEtD stress on exosome machinery and manipulation of exosome 
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biogenesis was then analysed to investigate the potential communicative role of 
exosomes in PCa. 
 
Figure 1.6: Schematic diagram indicating how ultracentrifugation can 
deplete exosomes from FCS. Firstly, FCS is cleared of any debris and non-
exosomal material by centrifuging for 10 minutes at 300 x g 4°C. The supernatant 
is then transferred into a fresh tube and centrifuged for 20 minutes at 16,500 x g 
4°C to remove larger non-exosomal material. After pre-clearing, FCS is 
ultracentrifuged for 18 hours overnight at 120,000 x g 4°C to sediment serum 
exosomes. After ultracentrifugation, the FCS separates into distinct light to dark 
layers. The light layer contains exosome-depleted serum, while the dark layer 
predominantly contains FCS exosomes and other non-EV products such as 
albumin (Caradec et al., 2014). Created using Servier Medical Art by Servier. 
24 
 




1. To establish a robust in vitro model to investigate exosome release 
from AD-induced NEtD LNCaP cells. 
 
2.  To investigate the impact of AD stress on exosomal machinery in 
LNCaP cells 
 
3. To isolate and characterise exosomes released from AD-induced 
NEtD LNCaP cells. 
 
4. To manipulate exosome release during AD induced NEtD to dissect 
whether exosomes play a role in NEtD of LNCaP cells. 
 
1.6 Thesis Hypothesis  
 
Exosomes released from NEtD LNCaP cells are involved in cell-to-cell 
communication in NEPC have the potential to be used as diagnostic biomarkers 
for NEPC.  
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2. Chapter 2: Materials and Methods 
2.1 Reagents and chemicals 
 
Unless otherwise stated all reagents and chemicals were obtained from Sigma-
Aldrich (Gillinham, UK), Thermofisher Scientific (Paisley, UK) or VWR Life 
Sciences (Leicestershire, UK). 
 
2.2 Cell culture techniques 
2.2.1 LNCaP cells 
 
The human prostate adenocarcinoma cell line, LNCaP, was purchased from 
American Type Culture Collection (ATCC); (CRL-1740). 
 
2.2.2 LNCaP culture conditions 
 
LNCaP cells were maintained as adherent monolayers in T75 tissue culture flasks 
(Corning, UK) with 10 mL Roswell Park Memorial Institute (RMPI) 1640 cell 
culture medium (Sigma, UK) supplemented with 10 % FCS (Gibco, UK), 2 mM L-
glutamine and 1 % penicillin/streptomycin (complete medium) in a humidified 
37°C, 5 % CO2 culture safe CO2 precision 190D incubator (LEEC, UK). 
 
2.2.3 Depletion of exosomes from Foetal Calf Serum by differential ultra-
centrifugation 
 
To deplete foetal calf serum (FCS) of exosomes, differential ultracentrifugation 
was performed according to protocol by Shelke et al. (2014).  FCS and charcoal 
stripped (CS)-FCS, were differentially centrifuged in 15 mL falcon tubes at 300 x 
g for 10 minutes at 4°C followed by 16,500 x g for 20 minutes at 4°C in a 
centrifuge using a JA14 rotor: (Beckman Coulter, USA). The supernatant was 
transferred into polycarbonate tubes (#355603; Beckman Coulter, USA) then 
ultracentrifuged (70.1 Ti rotor; (Beckman Coulter, USA)) at 120,000 x g for 18 
hours at 4°C. The light clarified layers of FCS/CS-FCS described by Théry et al. 
(2006) as exosome depleted (dFCS/dCS-FCS) were filter sterilised (22 µm 
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syringe filter; Star Lab, UK), then stored at -20°C, prior to supplementation into 
cell culture medium. 
 
2.2.4 Androgen deprivation of LNCaP cells 
 
For androgen deprivation (AD), 10 % CS-FCS (Sigma, UK), 2 mM L-glutamine 
and 1 % penicillin/streptomycin was supplemented into phenol-red free RPMI 
1640 culture medium (CS-complete). AD LNCaP cells were seeded at 1x106 in 
10 mL of complete culture medium in a T75 cell culture flask; control LNCaP cells 
were seeded at 2.5 x 105 in 10 mL complete medium. LNCaP cells were grown 
at 37°C, 5 % CO2 incubator (LEEC, UK). Control and AD LNCaP cells were 
seeded at different densities to compensate for the increased proliferation of 
control cells due to presence of androgen in the complete medium. To stimulate 
AD, after 24 hours, the complete medium was discarded, LNCaP cells were 
washed with 10 mL 0.9 % NaCl (Baxter, UK) and cultured with CS-complete 
medium. Complete medium was also renewed for control LNCaP cells. Control 
and AD LNCaP cells were cultured for 15 days; the culture medium was renewed 
every 3 to 4 days, LNCaP cells were not passaged during treatment. 
 
2.2.5 Exosome depletion of LNCaP cells 
 
For androgen deprivation with exosome depletion (dAD), LNCaP cells were 
maintained as above however, CS-complete medium was supplemented with 
10 % CS-FCS, pre-depleted of exosomes by ultracentrifugation (section 2.2.2). 
An exosome depleted control (dC) was produced by using complete medium 
supplemented with 10 % exosome depleted FCS. 
 
2.2.6 Sub Culturing LNCaP cells 
 
LNCaP cells were passaged once 70-90 % confluence was reached, the culture 
medium was removed and discarded. LNCaP cells were washed with 10 mL 
0.9 % NaCl (Baxter, UK) to remove residual media. To detach LNCaP cells, 2 mL 
of 1X trypsin (Gibco, UK), prepared from 10X trypsin with 0.9 % NaCl (Baxter, 
UK) was added to the flask to cover the monolayer of LNCaP cells and incubated 
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at 37°C for 2-5 minutes. Cell culture flasks were gently tapped to detach the cells, 
and ensure dissociation from the tissue culture flask. Once detached, 8 mL of 
complete medium was added to neutralise the trypsin and the LNCaP cell 
suspension was transferred to a 15 mL falcon tube. LNCaP cells were collected 
by centrifugation at 148 x g for 5 minutes at 20°C, in a Universal 320R centrifuge 
(Hettich, Germany). The medium was discarded and the cell pellet, which was 
resuspended by flicking of the tube and pipetting up and down in 10 mL fresh 
media. LNCaP cells were sub-cultured into T75 tissue culture flasks at a ratio of 
1:10. 
 
2.2.7 Cryopreservation of LNCaP cells 
 
LNCaP cells were grown to 70-90 % confluence, trypsinised and collected as 
outlined in section 2.2.6. Cryopreservation solution contained sterile dimethyl 
sulfoxide (DMSO; Sigma, UK) and FCS (Gibco, UK) at a ratio of 1:4. The media 
was removed and the pellet was resuspended in a 1:1 ratio of complete medium 
and cryopreservation solution. The LNCaP cells were transferred in 500 µL 
aliquots to 1.8 mL cryovial tubes (Simport, Canada) and placed into an 
isopropanol freezing module – Mr Frosty (Nalgene; Thermofisher Scientific, 
UK), and stored at -80°C for at least 24 hours before cryovials were transferred 
to liquid nitrogen (-196°C) for long term storage. 
 
2.2.8 Reviving LNCaP cells 
 
To revive LNCaP cells from liquid nitrogen, the cells were resuspended by gentle 
pipetting of 10 mL warmed (37°C) complete medium. Once thawed, cells were 
transferred into a 15 mL falcon tube and collected by centrifugation at 145 x g for 
5 minutes at room temperature in a Universal 320R centrifuge (Hettich, 
Germany). The cells were resuspended by gentle flicking and 10 mL of complete 
medium was added, the resuspended LNCaP cells were then transferred to a 
T75 culture flask. The LNCaP cells were incubated at 37°C in 5 % CO2 and left 
to adhere to the flask for three days, the medium was replaced every 3-4 days 




2.2.9 Counting LNCaP cells 
 
LNCaP cells were counted after passage (section 2.2.6) to ascertain the number 
of cells in the T75 flask. A glass coverslip was placed on the haemocytometer 
(Weber Scientific, USA), 10 µL of cell suspension was pipetted into each chamber 
of the haemocytometer. Cells were visualised under a Ziess Primovert light 
microscope (Ziess, UK) at 100X magnification and cells, in the central square of 
the haemocytometer grid were counted. The mean count across both chambers 
was representative of 1x104 cells per millilitre and was used to calculate the total 
number of cells in the 10 mL suspension. 
 
2.2.10 LNCaP morphology/microscopy 
 
Brightfield microscopy (Primovert; Ziess, UK) images were taken of control, 
exosome depleted control, AD and exosome depleted AD LNCaP cells at regular 
intervals. Images were taken at 100X, 200X and 400X magnification and saved 
as Jpeg files. 
 
2.2.11 Harvesting cells 
 
LNCaP cells were harvested on ice, the medium was collected and cleared as 
per section 2.2.2 for downstream isolation of exosomes (section 2.3.1). Cells 
were washed once with 10 mL of ice-cold phosphate buffered saline (PBS; 5 PBS 
tablets dissolved in 1 L of dH20; Sigma, UK). The PBS was removed, discarded 
and 1 mL of fresh PBS was added to the flask. Using a cell scraper (Corning, UK) 
LNCaP cells were scraped into 1 mL of PBS, transferred into a 1.5 mL 
microcentrifuge tube (Eppendorf, Germany) before centrifugation in 5415R 
refrigerated centrifuge (Eppendorf, Germany) at 145 x g for 5 minutes at 4°C to 





2.3 Assessing exosomes 
2.3.1 Exosome isolation from conditioned culture medium 
 
To isolate exosomes from culture medium the Exo-spin exosome purification 
kit (Cell Guidance Systems, UK) for cell culture media and other low-protein 
biological fluids was used per manufacturer’s instructions. Medium was collected 
from exosome depleted control and exosome depleted androgen deprived 
LNCaP cells. Clarified media was either stored at -80°C or used immediately to 
isolate exosomes. 
 
To precipitate exosomes, approximately 19 mL of exosome depleted control 
medium or exosome depleted AD medium was transferred to polycarbonate 
centrifuge tubes and 50 % of Exo-spin buffer (Cell Guidance Systems, UK) was 
added. Tubes were mixed by inversion then incubated at 4°C overnight. The next 
day, media with Exo-spin buffer was centrifuged at 16,000 x g for 1 hour at 4°C 
in an ultracentrifuge using a type 70.1 Ti rotor (Beckman Coulter, USA). The 
supernatant was removed and exosome pellets were resuspended in 100 µL of 
PBS using sterile plastic Pasteur pipettes. 
 
Exo-Spin columns (EX01) were prepared prior to application of sample by 
removing the outlet plug and placed into the collection tube. Preservative buffer 
was aspirated from the column and discarded. To equilibrate the column, 200 µL 
of PBS was added to the column bed and the column was centrifuged at 50 x g 
for 10 seconds at 4°C. The flow through was discarded and the column was 
placed into a 1.5 mL microcentrifuge tube. The 100 µL of PBS containing 
resuspended exosomes was applied to the top of the column. The column was 
centrifuged at 50 x g for 60 seconds at 4°C, the eluate was collected and stored 
at -80°C until subsequent identification of exosomes. The column was placed into 
a new microcentrifuge tube and 200 µL of PBS applied to the top of the column. 
This was centrifuged at 50 x g for 60 seconds at 4°C to collect the purified 
exosomes. The resulting 200 µL eluate of purified exosomes was aliquoted for 
analysis and stored at -80°C. 
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2.3.2 Assessing exosomes via Dynamic Light Scattering 
 
The particle size of exosome samples was analysed by dynamic light scattering 
(DLS), using a Zetasizer Nano-ZS (Malvern, UK). Exosome samples were 
prepared 1:100 in sterile PBS and transferred to 40 µL cuvettes (ZEN0040; 
Malvern, UK). Standard settings were applied (Refractive Index = 1.331, Viscosity 
= 0.89 and Temperature = 25°C) for 3 x 10 measurement runs.  After the runs 
were completed an output was provided and analysed using Dispersion 
Technology Software (DTS; V7.01) supplied by Malvern, UK. DTS generated a 
graph labelled “Intensity PSD (M)”, providing information on the mean diameter 
(nm), mean width (nm) and percentage of isolated particles in the sample as an 
average of the 3 runs. 
 
2.3.3 Exosome Lysis 
 
Exosomes suspended in PBS were lysed 1:1 with 1X radioimmunoassay 
precipitation (RIPA) buffer (150 mM, 5 mM EDTA pH 8, 50 mM Tris pH 8, 1% 
(w/v) NP-40, 0.5% (w/v) sodium deoxycholate, 0.1% (w/v) SDS containing 1% 
(w/v) halt protease inhibitor (Thermofisher Scientific, UK)) or 1:5 with 5X RIPA 
buffer (750 mM NaCl, 25nM EDTA pH 8, 250 mM Tris pH 8, 5% (w/v) NP-40, 
2.5% (w/v) sodium deoxycholate, 0.5% (w/v) SDS containing 1% (w/v) halt 
protease inhibitor). Exosomes were incubated on ice for 30 minutes then 
sonicated in a sonicating water bath for 3 x 5 seconds at 37°C. Lysates were 
centrifuged at 15,700 x g for 5 minutes at 4°C in a 5415R refrigerated centrifuge 
(Eppendorf, Germany). The supernatant containing soluble protein was 
transferred into a sterile, pre-chilled 1.5 mL micro-centrifuge tube and protein 
concentration was determined by Bradford assay (section 2.6.2) or stored at -
80°C. 
 
2.4 Synthetic inhibition and induction of exosome release 
2.4.1 Stock solutions 
 
A stock solution (2.2 mM) of sphingomyelinase inhibitor (Ludwig et al., 2019), 
GW4869 (hydrochloride chlorate); (Cayman Chemicals, USA) was produced by 
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dissolving GW4869 in DMSO. The solution was vortexed, aliquoted and stored 
at - 80°C. Monensin sodium salt (Cayman Chemicals, USA) stock solution (25 
mM) was generated by dissolving in molecular grade ethanol (EtOH) the solution 
was aliquoted and stored at -80°C until use. 
 
2.4.2 Treating LNCaP cells with GW4869 or Monensin 
 
LNCaP cells were seeded at 4x106 in 10 mL of complete medium in T75 flasks 
and incubated at 37°C 5% CO2 for 24 hours. The next day media was removed, 
and cells were washed with 10 mL 0.9 % NaCl (Baxter, UK) and replenished with 
10 mL of exosome depleted control medium or exosome depleted AD medium 
and cultured for 3 days.  On day 4, post seeding, cells were treated with either 25 
µM GW4869, or 2 µM Monensin or the corresponding drug vehicle control: 1 % 
(v/v) DMSO or 0.01 % (v/v) EtOH. After 24 hours the conditioned culture medium 
was collected, and cells harvested (section 2.2.11). 
 
2.5 MTT assay 
 
To assess cell metabolic activity the MTT assay was performed using methods 
from Mosmann (1983), LNCaP cells were seeded at 8 x 103 cells per well in 96-
well plates in 100 µL of complete medium and cultured at 37°C 5% CO2. After 24 
hours medium was removed and replaced with exosome depleted control or 
exosome depleted AD medium and cultured for a further 3 days. On day 4, 
GW4869 (100, 50, 25, 10, 5, 1 and 0.5 µM) or Monensin (20, 10, 5, 2, 1, 0.2, 0.1 
µM) were added and incubated for 24 hours. LNCaP cells were also treated with 
EtOH and DMSO as vehicle controls respectively.  
 
The next day, the media was removed and replaced with 100 µL of fresh media 
and10 µL of 5 mg/mL MTT stock solution for a final concentration of 0.5 mg/mL 
MTT. Wells containing media and MTT only or MTT, media and cells were 
included as controls. Media containing 2 % v/v Triton-X (Sigma, UK) was used 
as a positive control for cell death. To mix the MTT and media the plate was 
gently tapped, covered with foil to protect from the light, then returned to the 
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incubator at 37°C, 5 % CO2. After 2.5 hours media was removed and 100 µL of 
isopropanol was added to dissolve the formazan. The plate was shaken gently to 
ensure crystals were dissolved. Absorbance was analysed at 550 nm using a LT-
5000MS plate reader with Manta software (LabTech, UK). Raw data were 
analysed by subtracting the absorbance of MTT and media only from all readings. 
Absorbance of untreated control cells were taken to be 100% viable and all 
readings were expressed as a percentage of this. 
 
2.6 Protein analysis 
2.6.1 Cell lysis 
 
Cells were lysed in approximately 3 x the pellet volume of lysis buffer (50 mM Tris 
pH 8, 150 mM NaCl, 1mM EDTA pH 8, 1% NP-40 containing 1% Halt protease 
inhibitor) on ice for 30 minutes. Lysates were centrifuged at 3000 x g for 5 minutes 
at 4°C in a 5415R refrigerated centrifuge (Eppendorf, Germany). Supernatant, 
containing soluble protein was transferred into a sterile, pre-chilled 1.5 mL micro-
centrifuge tube and protein concentration was determined by Bradford assay or 
stored at -80°C. 
 
2.6.2 Protein quantification by Bradford analysis 
 
Bradford reagent was prepared by dissolving 50 mg of Coomassie Blue G250 in 
50 mL methanol, prior to adding 100 mL of 85 % phosphoric acid, then was made 
up to 1 L with dH20. This was filtered through a sterile 22 µm syringe filter (Star 
Lab, UK), to remove any precipitate, stored at 4°C and covered with foil to protect 
from light. 
 
A stock of 10 mg/mL bovine serum albumin (BSA) solution was prepared in dH20. 
known BSA concentrations were created by diluting the stock to 2, 1, 0.5, 0.25, 
0.125 and 0.0625 mg/mL in dH20. BSA standards were stored at 4°C until use. 
 
The protein concentration of lysates generated in section 2.6.1 were analysed by 
adding 200 µL of Bradford reagent to each well of a 96 well plate (Corning, UK), 
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1 µL of each BSA standard was added to the Bradford reagent. Protein samples 
were diluted 1:5 in dH20, then 1 µL of this was added in triplicate to the wells and 
mixed. The “blank well” contained Bradford reagent only. Samples were 
incubated at room temperature for 10 minutes before absorbance at 595 nm was 
measured using a LT-5000MS plate reader with Manta software (LabTech, UK). 
The blank background absorbance was subtracted from all samples. Sample 
concentrations were generated from the BSA standard curve using the equation 
of the line (y=mx+c). Protein concentration was multiplied by the dilution factor to 
obtain final protein concentration. 
 
2.6.3 Preparation of protein for immunoblotting  
Due to conditions required for downstream immunoblotting (section 2.6.5) 
samples were prepared in either native or reduced/denatured conditions. For 
denaturing/reducing conditions, samples were diluted with 4X loading sample 
buffer (LSB) (20 % (w/v) glycerol, 200 mM Tris pH 6.8, 4 % (w/v) SDS, 10 mM 
EDTA, 1 % bromophenol blue, supplemented with 100 mM of the reducing agent 
dithiothreitol (DTT)) to a final concentration of 1 µg/mL. Samples were denatured 
for 5 minutes at 100°C in a heat block. For native conditions, samples were 
prepared without reducing agents or denaturation and diluted with 4X LSB (20 % 
glycerol, 200 mM Tris pH 6.8, 4 % SDS, 10 mM EDTA, 1 % bromophenol blue) 
to a final concentration of 1 µg/mL. Samples were used immediately or stored at 
-20°C. 
 
2.6.4 Sodium Dodecyl Sulphate – Polyacrylamide Gel Electrophoresis 
(SDS-PAGE) 
 
Proteins were resolved by SDS-PAGE based on methods by Laemmli (1970). 
The resolving gels contained either 8,10 or 12 % (w/v) acrylamide (30 % w/v stock 
acrylamide; Thermofisher Scientific, UK, 375 mM Tris pH 8.85, 0.1 % (w/v) SDS 
and 0.08% (w/v) ammonium peroxodisulphate (AmPs). To polymerise the mixture 
0.005 % (w/v) N,N,N′,N′-Tetramethylethylenediamine (TEMED); (Sigma- Aldrich, 
Germany) was added. The resolving gel was pipetted into the glass plates 
assembled within a casting chamber, 200 µL of isopropanol was applied to the 
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top of the resolving gel to remove air bubbles. Once polymerisation had occurred, 
isopropanol was removed, and the gel rinsed with water.  Stacking gel was 
prepared (5 % (w/v) polyacrylamide, 130 mM Tris pH 6.8, 0.1 % SDS, and 0.12 % 
(w/v) AmPs) followed by the addition of 0.01 % (w/v) TEMED to promote 
polymerisation and the well comb was added immediately. 
 
Gels were removed from their casting chambers and placed into an 
electrophoresis tank (BioRad, USA) and submerged in 1X running buffer (25 mM 
Tris- HCL, 192 mM Glycine, 35 mM SDS). A pre-stained broad range protein 
marker (PageRuler Pre-stained Protein Ladder, 10 to 250 kDa; ThermoFisher 
Scientific, UK; 5 µL) was used to determine the size of the proteins of interest. 
The gels were electrophoresed at 185 V for approximately 50 minutes or until the 




Immunoblotting was performed based on methods by Towbin et al. (1979). 
Following protein separation via SDS-PAGE, immunoblots were prepared by 
submerging a cassette in 1X transfer buffer (25 mM Tris pH 8.5, 0.2 M Glycine 
and 20 % (w/v) methanol). The cassette was layered with a sponge, 2 x 3 MM 
paper, gel, nitrocellulose membrane (0.2 μm, Optiran BA-S 83), 2 x 3 MM paper 
and a sponge and compressed to remove air bubbles. The cassette was inserted 
into an electrophoresis tank and submerged with 1X transfer buffer. Proteins were 
electrophoretically transferred onto the nitrocellulose membrane at 100 V for 1 
hour. Once transfer was complete, the nitrocellulose was rinsed with PBS with 
1% tween (PBS-T) and stained with Ponceau S solution (0.1 % Ponceau S, 5 % 
acetic acid) to ensure equal transfer of proteins. It was washed three times in 1% 
PBS-T and blocked with 5 % (w/v) non-fat milk (Marvel) for 1 hour at room 
temperature with agitation on a shaker plate. 
 
Primary antibodies were prepared by dilution in 5% (w/v) non-fat milk in PBS-T 
as indicated in Table 2.1 and incubated on the nitrocellulose membrane overnight 
at 4°C. The membrane was washed three times in PBS-T before probing with the 
appropriate secondary antibody (Table 2.2) in 5 % (w/v) non-fat milk containing 
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0.01 % SDS for 45 minutes at room temperature. The membrane was then 
washed three times with PBS-T. Membranes were analysed by LI-COR Odyssey 
image system (Odyssey-3074, LI-COR, 51 Cambridge, UK) and Odyssey Image 
Studio v2.0 software (ThermoFisher Scientific, UK). Images were downloaded 
from the software and saved as Tiff files. 
 




















































































1:10000 LI-COR (926-32211) 
 
2.7 RNA extraction, quantification and reverse transcription  
2.7.1 Preparing DEPC treated water 
 
To produce nuclease-free water, distilled water was treated with 
diethylpyrocarbonate (DEPC); (Sigma, UK) to a final concentration of 0.1 %. The 
solution was mixed by vigorous shaking and incubated overnight at room 
temperature, then autoclaved for 1 hour at 121°C and 15 psi to inactivate DEPC. 
The DEPC water was cooled to room temperature before use. 
 
2.7.2 RNA extraction 
 
TRIsure (Bioline, UK) was used to extract total RNA from LNCaP cell pellets 
according to manufacturer’s instructions. The cell pellets (section 2.2.11) were 
retrieved from -80°C, and 1 mL of TRIsure was added to the cell pellet. To disrupt 
the cell membrane, the solution was pipetted up and down. Samples were 
incubated at room temperature for 5 minutes before 200 µL of chloroform was 
added. Samples were shaken vigorously for 15 seconds by hand, then incubated 
for 3 minutes at room temperature for phase separation. Samples were 
centrifuged at 13,000 x g for 15 minutes at 4°C in a 5415R refrigerated centrifuge 
(Eppendorf, Germany). The upper translucent phase containing RNA was 
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transferred to a fresh autoclaved microcentrifuge tube, and 500 µL of chilled 
isopropanol was added to precipitate the RNA. Samples were incubated on ice 
for 10 minutes followed by centrifugation of 12,000 x g for 10 minutes at 4°C in a 
5415R refrigerated centrifuge. The RNA pellet was washed with 1 mL chilled 
75 % ethanol in DEPC water by vortexing and centrifuged at 10,000 x g for 5 
minutes at 4°C in a 5415R refrigerated centrifuge. The supernatant was removed, 
and RNA pellet allowed to dry for 45 minutes to 1 hour at room temperature. RNA 
pellet was then resuspended in 30 µL of DEPC water and incubated in a heat 
block at 60°C for 10 minutes, RNA was stored at -80°C. 
 
2.7.3 RNA quantification by Nanodrop 2000 (Spectrophotometer) 
 
RNA concentration and purity were analysed by spectrophotometry using the 
Nanodrop 2000 (Thermofisher Scientific, UK). The Nanodrop provided an 
approximate concentration of total RNA, for use in downstream Bioanalyzer 
analysis (section 2.8.4). The instrument was blanked with 1 µL of DEPC water 
and the absorbance of RNA samples at 260 nm was analysed. The ratio of the 
absorbance at the 260nm and 280nm was used to assess RNA purity, a ratio of 
~2.0 was considered to be pure, a reduction in the ratio is indicative of 
contamination from protein or phenol or other contaminants, which absorb 
strongly at 280nm (Desjardins and Conklin, 2010). The 260/230 ratio is the 
secondary measure of RNA purity, expected values are ~2.0-2.2, a considerably 
lower ratio may indicate the presence of contaminants that absorb at 230 nm 
such as, ethanol and phenol (Desjardins and Conklin, 2010). 
 
2.7.4 Microfluidic analysis of RNA by Bioanalyzer 2100 
 
For quantification of RNA integrity and an accurate concentration of intact RNA 
samples, microfluidic analysis was performed with the bioanalyzer 2100 (Agilent 
Technologies, UK) and Agilent RNA 6000 nano kit (Agilent Technologies, UK) as 




The 100 bp RNA 6000 NanoLadder was prepared by heat denaturing at 70°C for 
2 minutes then chilled on ice, aliquots of prepared ladder were stored at -80°C. 
Nano gel matrix was prepared by filtering 550 µL of gel through a spin filter 
column at 10,000 x g for 10 minutes at room temperature. The filtered gel matrix 
was used immediately or stored at 4°C for up to 4 weeks.  RNA 6000 NanoDye 
concentrate was vortexed for 10 seconds and pulse centrifuged for 5 seconds in 
a 5418 centrifuge (Eppendorf, Germany). One microlitre of dye was added to 65 
µL of gel. The gel-dye mix was centrifuged at 13,000 x g for 10 minutes at room 
temperature in a 5418 centrifuge (Eppendorf, Germany). 
 
RNA Samples were diluted to approximately 250 ng/µL, within the optimal range 
(25-500 ng/µL) with DEPC water and heat denatured in a heat block at 70°C for 
2 minutes. The RNA 6000 Nano chip was added to chip priming station, to which 
9 µL of gel-dye mix was added. The gel was dispersed throughout the chip by 
applying gentle pressure to the 1 mL syringe plunger on the chip priming station, 
until the syringe was held under the clip. The plunger was depressed for 30 
seconds, then the clip was released, after 5 seconds the syringe plunger was 
carefully pulled to the 1 mL position. A further 9 µL of gel-dye mix was then added. 
Five microliters of RNA 6000 Nano marker were added to the ladder and sample 
wells, followed by 1 µL of RNA ladder to the ladder well and 1 µL of RNA sample 
to each sample well. One microlitre of marker was added to the wells, which did 
not contain sample. The chip was vortexed for 60 seconds at 2400 RPM using 
an IKA vortex mixer (Agilent Technologies, UK). Chip was analysed using 
Bioanalyzer 2100 via Agilent 2100 expert software, which generates microfluidic 
gel images, electropherograms and RNA integrity numbers (RIN), which were 
downloaded. 
 
2.7.5 Reverse transcription of RNA 
 
To reverse transcribe total RNA for the synthesis of complementary (c)DNA, the 
High Capacity RNA to cDNA Kit (Applied Biosystems, USA) was used per 
manufacturer’s instructions. The reactions contained 2 µg of RNA in a final 
volume of 20 µL, containing 1 X RT buffer, 1X RT enzyme mix and DEPC water 
39 
 
in 0.2 mL thin-walled reaction tubes. A control negative reverse transcriptase was 
prepared, where 1X RT enzyme mix was replaced with DEPC water. Reactions 
were incubated at 37°C for 60 minutes, then heat inactivated at 95°C for 5 
minutes in a thermal cycler (2720 Thermal Cycler Applied Biosystems, UK). It 
was assumed that the cDNA synthesis reaction was 100 % efficient producing 2 
µg of cDNA for each 20 µL reaction therefore, a final concentration of 0.1 ng/µL. 
cDNA was diluted to 5 ng/µL using DEPC water before use in quantitative reverse 
transcriptase polymerase chain reaction (qRT-PCR) experiments or stored at -
20°C. 
 
2.8 Quantification of gene expression 
2.8.1 Oligonucleotide design and preparation 
 
Oligonucleotides, targeting mRNA transcripts of interest were designed to span 
exon boundaries to avoid genomic DNA amplification, with annealing 
temperatures between 58-60°C, 16-25 bp in length, 40-60 % guanine and 
cytosine content and amplicon size of 100-200 bp. Annealing temperatures were 
calculated using OligoCalc (JustBio, 
https://www.justbio.com/index.php?page=oligocalc); (Kibbe, 2007) and in silico 
analysis to evaluate oligonucleotide self-complementarity and specificity was 
performed using the nucleotide basic local alignment tool (BLAST; 
https://blast.ncbi.nlm.nih.gov/Blast.cgi) hosted by the National Centre for 
Biotechnology Information (NCBI; Altschul et al., 1990). Alignment of transcript 
variants was performed using, Aligner (JustBio, 
https://www.justbio.com/index.php?page=aligner). All oligonucleotides shown in 
Table 2.3 were purchased from MWG Eurofins (Ebersberg, Germany), diluted to 




qRT-PCR experiments contained 25 ng of cDNA, 200 nM of forward and reverse 
oligonucleotides (MWG Eurofins, Germany) and 1X PrecisionPLUS qRT-PCR 
mastermix (PrimerDesign, UK) in a final volume of 20 µL. Reactions were 
prepared in BrightWhite 96-well plates (Primer Design, UK) in triplicate. 
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Transcripts were amplified and quantified using StepOnePlus qRT-PCR system 
(Applied Biosystems, UK) using SYBR green detection chemistry with the 
instrument settings: 95°C for 10 minutes followed by 40 cycles of; 95°C for 15 
seconds and 58-60°C annealing temperatures for 1 minute. Negative controls 
included negative reverse transcription and a no template control (NTC), where 
RNA samples were substituted with an equal volume of DEPC water in the qRT-
PCR experiment. Specific amplification was determined via melt curve analysis 
(Taylor et al., 2010). The melt curves were generated by heating the final PCR 
product from 60°C to 95°C in 0.3°C increments followed by a final 15 second 
hold. Melt curves and test samples were compared to NTC to differentiate 
between the desired product and unwanted primer oligomers or potential 
genomic DNA contamination. 
 
2.8.3 Identification of reference genes 
 
To analyse candidate reference genes, geNorm oligonucleotide kit (Primer 
Design, UK) and qBase+ software (Biogazelle, Belgium) were used. A panel of 6 
candidate reference genes (ACTB, GAPDH, EIF4A2, RPL13A SDHA and 
YWHAZ) were screened against LNCaP cells in duplicate using the reaction set 
up outlined in section 2.8.2. The reference genes, with the most consistent 
expression across all treatments were ACTB, GAPDH and RPL13A.
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2.8.4 Quantification of fold change in gene expression 
 
The average cycle threshold (CT) value of ACTB, GAPDH and RPL13A were 
used in the cube root to calculate the geometric mean and used as an internal 
control. The expression of unknown target genes was then analysed relative to 
the reference genes ACTB, GAPDH and RPL13A. The fold change in gene 
expression was calculated using the 2(∆∆-Ct) method (Livak and Schmittgen, 
2001). Fold change values were calculated using Excel for Mac (Microsoft) and 
plotted as graphs using GraphPad Prism v8 (GraphPad Software Inc). Results 
shown as the mean of three independent experiments ± standard error of the 
mean (SEM). 
 
2.9 Statistical analysis 
 
Statistical analysis was carried out using GraphPad Prism v.8 (GraphPad 
Software Inc). Results are shown as the mean ± standard error of the mean 
(SEM) where n=3 or as the mean ± standard deviation (SD) where n=2. For fold 
change in gene expression data the significance was determined by using a one-
way ANOVA with Geisser-Greenhouse correction and Tukey’s multiple 
comparisons where *p< 0.05, ** p< 0.01, *** p< 0.001, **** p< 0.0001.
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3. Chapter 3: Establishing a model for the analysis of exosomes derived 




In the tumour microenvironment, NE-like cells may communicate with epithelial 
prostate cells by releasing exosomes (Lin et al., 2017). Exosomes potentially 
drive the progression of PCa and shift the epithelial cell population to resistant 
NE-like cells and trigger aggressive neuroendocrine prostate cancer (NEPC) 
formation (Lin et al., 2017). The role, if any, of exosomes within the NEtD process 
and PCa progression is unclear, therefore, investigating exosomes released from 
NEtD prostate cancer cells in vitro may clarify this. 
 
LNCaP cells are androgen sensitive human PCa epithelial cells, which are an 
established in vitro model central to investigating PCa (Sampson et al., 2013). 
When deprived of androgens, LNCaP cells undergo neuroendocrine trans-
differentiation (NEtD); (Yuan et al., 2006). Charcoal stripping of FCS (CS-FCS) 
is the most common and well established method of androgen deprivation (AD) 
in vitro (Shen et al., 1997; Fraser et al., 2019) and it reduces the androgen content 
of FCS by approximately 86% (Cao et al., 2009). Phenol red is also omitted from 
culture medium as it is a weak oestrogen, thus, preventing stimulation of AR and 
interference with NEtD of LNCaP cells (Sikora et al., 2016). 
 
CS-FCS is commercially available however, exosome depleted CS-FCS is not, 
therefore, exosome depleted CS-FCS was created by ultracentrifugation (Théry 
et al., 2006). However, ultracentrifugation may extract factors such as albumin 
(Caradec et al., 2014), which is associated with androgen binding (Sedelaar and 
Isaacs, 2009), growth factors or androgen binding proteins (Ludwig et al., 2019); 
(Figure 3.1). It has not been reported whether ultracentrifugation of FCS or CS-
FCS affects LNCaP cell culture and NEtD. Therefore, it is possible that the culture 
medium of exosome depleted control (dC) LNCaP cells may be partially androgen 
deprived and reduced growth factors, which may interfere with cellular function 
(Figure 3.1A). Exosome depletion of LNCaP cells grown in AD conditions may 
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induce a further effect of AD, cellular functions and NEtD of LNCaP cells (Figure 
3.1B). In order to investigate the potential impact of exosome depletion of FCS, 
LNCaP cells were grown in culture medium supplemented with either FCS, 
exosome depleted FCS, CS-FCS or exosome depleted CS-FCS. The differing 
conditions allowed analysis of the impact of exosome depletion on LNCaP cells 
and AD-induced NEtD of LNCaP cells. 
 
Exosomes have been isolated from PCa cell lines, including LNCaP cells, 
cultured in exosome depleted medium, (Corcoran et al., 2012; Mizutani et al., 
2014; Lin et al., 2017). However, those investigating exosomes released from 
LNCaP cells fail to acknowledge how exosome depletion of FCS may affect 
LNCaP cell function. FCS-derived exosomes are  taken up by cardiac progenitor 
cells, and can influence cellular functions such as proliferation and migration 
(Angelini et al., 2016), therefore, it is necessary to ascertain the effects of 




Figure 3.1 Schematic highlighting the potential effects of exosome depletion of serum on culture of LNCaP cells. 
Exosome depletion of FCS and CS-FCS by ultracentrifugation causes loss of albumin, androgen binding proteins and growth 
factors, it is unknown how this may affect LNCaP cells in culture. A. It is possible that the androgen concentration, cell 
proliferation and morphology of LNCaP cells may be affected when grown in the presence of exosome depleted FCS (dFCS). 
B. Exosome depletion of CS-FCS (dCS-FCS) may cause further androgen deprivation, further affect cell proliferation and 
neuroendocrine transdifferentiation (NEtD) of LNCaP cells. Created using Servier Medical Art by Servier. 
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3.2 Study aims and research questions 
3.2.1 Overall aim: 
 
To establish a robust in vitro model to investigate exosome release from 




1. Develop a protocol, which removes exosomes from CS-FCS. 
2. Analyse the effect of exosome depletion on morphological and 
molecular characteristics of AD-induced NEtD LNCaP cells. 
 
3.2.3 Research questions: 
 
1. Do LNCaP cells still undergo NEtD in exosome depleted CS-FCS 
media? 
2. Does exosome depletion affect the NEtD morphology of LNCaP cells? 
3. Does exosome depletion alter the expression of key markers of 
androgen signalling and NEtD in LNCaP cells? 
 
3.3 Results 
3.3.1 Analysing the effect of exosome depletion on NEtD of LNCaP model 
– cell morphology analysis 
 
LNCaP cells were grown for 15 days in control (C), exosome depleted control 
(dC), AD and exosome depleted (d)AD culture conditions and morphology was 
analysed using brightfield microscopy to assess evidence of NEtD at regular 
intervals (Figure 3.2). At day 0, LNCaP cells grown in each of the four conditions 
display characteristic epithelial morphology (Horoszewicz et al., 1983; Gaupel et 
al., 2013). Throughout the 15-day treatment, control LNCaP cells retained their 
epithelial morphology and resembled cells at 0 days (Figure 3.2, panel I to V). 
There were no observed differences in size, shape or growth rate of exosome 
depleted control LNCaP cells compared to control LNCaP cells, showing that 




Figure 3.2: Exosome depletion does not affect AD induced NE-transdifferentiation of LNCaP cells. Representative brightfield 
microscopy images of LNCaP cells cultured for 15 days under control (C), exosome depleted control (dC), androgen deprived (AD) and 
exosome depleted AD (dAD) conditions at 0, 3, 7, 10 and 15 days (X 200 magnification); (n=3). Arrows indicate the presence of protrusions 
at 3, 7, 10 and 15 days and appear neuronal-like by 15 days. Magnification at X 400 is also shown to give an enlarged view of neuronal-
like projections at day 10. Scale bars are representative of 1 µm.
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After 3 days in AD conditions LNCaP cells exhibited evidence of NEtD showing 
an emergence of cytoplasmic protrusions (indicated by arrows Figure 3.2, panel 
XIV). At days 7 and 10 protrusions became more extensive and more defined 
(Figure 3.2, panel XV and XVI respectively). By 15 days of AD, neurite-like 
protrusions identified in AD LNCaP cells increased in complexity showing 
branching of the protrusions and cells adopted a neuronal-like morphology 
(Figure 3.2, panel XVII). Indicating, there had been a shift from an epithelial to 
neuronal-like phenotype of LNCaP cells. Exosome depleted AD LNCaP cells also 
displayed neuronal-like morphology and resembled AD LNCaP cells throughout 
(Figure 3.2, panel XIX to XXII), evidencing that exosome depletion does not affect 
morphological changes associated with AD-induced NEtD. 
 
3.3.2 Analysing the effect of exosome depletion on expression of molec-
ular markers of AD-induced NEtD of LNCaP cells 
 
Next, it was assessed whether exosome depletion of CS-FCS affected AD-
induced NEtD of associated protein markers to establish if exosome depletion 
affected AD-induced NEtD at the protein level. 
 
The AR regulates prostate growth and development (Lonergan and Tindall, 
2011). No change in AR expression was observed in LNCaP cells grown in 
control or exosome depleted control conditions (Figure 3.3A). AR expression in 
AD and exosome depleted AD conditions was also comparable to expression in 
control LNCaP cells. Stability of AR across the different conditions indicates that 
exosome depletion did not affect the expression of the AR (Figure 3.3A). 
 
Prostate specific antigen (PSA) is a target gene of the AR, when activated by 
androgen AR induces transcription of PSA (Akbaş et al., 2015). PSA was only 
detected in control LNCaP cells and was undetectable following AD (Figure 3.3B, 
lane 3), providing evidence that the AR was not activated and unable to induce 
AR-target genes, such as PSA. Therefore, the in vitro AD model has successfully 
reduced activation of the AR (Mao et al., 2009). Unfortunately, the PSA antibody 
was unreliable and failed to consistently detect PSA in known positive samples. 





Figure 3.3 Exosome depletion may affect expression of NEtD-associated 
markers in LNCaP cells. Representative immunoblot analysis of protein 
expression in LNCaP cells cultured in control (C), exosome depleted control (dC), 
androgen deprivation (AD) or exosome depleted androgen deprived (dAD) 
conditions for 15 days. A. Androgen receptor (AR), B. Prostate specific antigen 
(PSA), C. Human achaete-scute homolog 1 (hASH1), D. Chromogranin A (CrgA). 
E.  Neuron specific enolase (NSE) and β-actin. Equal loading was assessed by 
β-actin, expression of β-actin was analysed on each membrane however, only 
one representative immunoblot is shown.  Molecular weights are indicated and * 
is representative of non-specific staining of hASH1 antibody (n=2). 
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hASH1 is a neuronal marker involved in cell commitment and neuronal 
differentiation (La Rosa et al., 2013), therefore expression of hASH1 is expected 
to increase with NEtD (Fraser et al., 2019). In control LNCaP cells, a faint band 
can be identified showing the expression of hASH1. Expression of hASH1 
appears to be induced by exosome depletion in control conditions (Figure 3.3C, 
lane 3) suggesting exosome depletion may affect hASH1 expression. AD LNCaP 
cells show induced hASH1 expression compared to control LNCaP cells. In 
exosome depleted AD LNCaP cells hASH1 expression remained evident, and 
somewhat stronger than AD alone (Figure 3.3C, lane 3). These findings suggest 
exosome depletion may affect hASH1 expression in control and AD LNCaP cells. 
 
Chromogranin A (CrgA) is a secretory protein that induces generation of 
secretory granules and is a precursor of several functional peptides (Gong et al., 
2007; Gkolfinopoulos et al., 2017). In control cells a protein of ~75 kDa was 
detected, corresponding to the CrgA precursor protein (Maina et al., 2016; Figure 
3.3, lane 4). This was also detected in exosome depleted control cells, suggesting 
exosome depletion did not affect the expression of the CrgA precursor protein 
(Figure 3.3, lane 4). Interestingly, following AD, LNCaP cells expressed CrgA 
proteins at 75 kDa and 70 kDa. The 70 kDa protein corresponds to the presence 
of an intermediate CrgA (Maina et al., 2016). This suggests that AD-induced 
NEtD initiates processing of the CrgA precursor protein (Figure 3.3, lane 4). In 
exosome depleted AD LNCaP cells, precursor and intermediate CrgA can be 
identified however, the 70 kDa intermediate CrgA protein appears less abundant 
(Figure 3.3, panel 4). These results suggest exosome depletion combined with 
AD may supress processing of the CrgA precursor protein. 
 
NSE is found within cells of neuronal origin and is associated with NE-
transdifferentiation (Isgrò et al., 2015). NSE was expressed under control 
conditions and expression remained comparable in control exosome depleted 
LNCaP cells (Figure 3.3, lane 5). There was a marginal increase in the expression 
of NSE under AD compared to control cells, the increase in NSE expression was 




β-actin was used as a control for equal loading, the expression of β-actin was 
equal across all conditions (Figure 3.3E, lane 5). Changes in protein expression 
were not associated with unequal protein loading but the effect of exosome or 
androgen depletion. 
 
Increased expression of key markers associated with NEtD shows AD-induced 
NEtD of LNCaP cells. However, exosome depletion of control and AD LNCaP 
cells affected expression of hASH1 and CrgA. These results suggest that 
exosome depletion may impact upon the NEtD of LNCaP cells however, further 
molecular analysis is required. 
 
3.3.3 Identifying stable reference genes for exosome depleted AD-in-
duced NEtD LNCaP model 
 
qRT-PCR was used to assess changes in protein expression were accompanied 
by changes in gene expression. Before gene analysis could be completed it was 
crucial to identify appropriate reference genes for normalisation of gene 
expression data. Exosome depletion of FCS may remove growth factors, 
cytokines or other non-EV products therefore, it was necessary to check whether 
this caused global effects on gene expression (Ludwig et al., 2019). Total RNA 
was extracted from cells grown in control, exosome depleted control, AD, and 
exosome depleted AD conditions and quantified. There was no change in cell 
confluence between conditions however, there was a noticeable reduction in total 
RNA concentration in exosome depleted compared to non-exosome depleted 
samples by approximately 5X. Analysis of RNA quality via Bioanalyzer confirmed 
that each RNA sample had appropriate RIN values (>8) and the RNA was of good 
quality (data not shown); (Fleige and Pfaffl, 2006; Mueller et al., 2016). This 
provided evidence that the reduction in RNA concentration was not caused by 
degradation but possibly a result of exosome depletion. 
 
Expression of six references genes: β-actin (ACTB), eukaryotic translation 
initiation factor 4A2 (EIF4A2), glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH), ribosomal protein L13a (RPL13A), succinate dehydrogenase complex 
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subunit A (SDHA) and 14,3,3 protein zeta/delta (YWHAZ) was analysed in 
control, exosome depleted, AD and exosome depleted AD LNCaP cells by qRT-
PCR. Expression of these reference genes is also of importance, as there is no 
documented data demonstrating the reference genes used when LNCaP cells 
are grown in exosome depleted conditions. 
 
The cycle threshold (CT) value is the number of cycles required for the fluorescent 
signal to cross the threshold by exceeding the background fluorescent signal 
(Wong and Medrano, 2005). Low CT values are indicative of a greater abundance 
of target transcripts and therefore, expression of the target gene (Heid et al., 
1996). geNorm identifies the most stable reference genes across all growth 
conditions. Therefore, the average CT values from all four growth conditions were 
plotted to identify which genes were the most stable and could be used as 
reference genes to normalise future gene expression experiments. ACTB, 
GAPDH and RPL13A had the lowest CT values, which were also the most stable 
as the Ct values for these genes were within a narrow range (between 15-18 CT; 
Figure 3.4A). Whilst EIF4A2 did not have large variability in CT value, the CT 
values were higher than that of ACTB, GAPDH and RPL13A (18-19 Ct; Figure 
3.4A), indicating a reduction in target transcript abundance for EIF4A2. SDHA 
and YWHAZ showed significant variability in CT values (9-19 and 9-17 Ct 
respectively; Figure 3.4A) under control, exosome depleted, AD and exosome 




Figure 3.4: Identifying stable reference genes in exosome-depleted model 
of AD-induced NEtD in C, dC, AD and dAD LNCaP cells. A. Box and whisker 
plot of the mean cycle threshold (Ct) values for reference genes β-actin (ACTB), 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH), ribosomal protein L13A 
(RPL13A), eukaryotic translation initiation factor 4A2 (EIF4A2), succinate 
dehydrogenase complex flavoprotein subunit A (SDHA) and 14-3-3 protein 
zeta/delta (YWHAZ) in control (C), exosome depleted control (dC), androgen 
deprived (AD) and exosome depleted androgen deprived (dAD) LNCaP cells, Ct 
values are expressed as mean ± SEM (n=3). B. Average expression stability of 
reference genes YWHAZ, EIF4A2, SDHA, ACTB, RPL13A and GAPDH based 
on the Ct values shown in panel A and analysed by qbase+ software using their 




The qbase+ software calculates the M value of the reference targets and reflects 
their relative stability; the higher the M value, the less stable the reference gene 
(Le Bail et al., 2013). Figure 3.4B shows the graph produced by qbase+ software 
demonstrating ACTB, GAPDH and RPL13A had the lowest geNorm M values 
(>0.5) and, thus were most stable (Figure 3.4B). ACTB and GAPDH have 
previously been identified as stable reference genes within LNCaP cells (Zhao et 
al., 2018) therefore, the data are in keeping with that of others. The output 
obtained from qbase+ stated that use of the three reference genes, ACTB, 
GAPDH and RPL13A was optimal when used in the geometric mean (cubed root 
of the average CT values) to provide rigid analysis, less variation in results and 
reliable data. Therefore, the geometric mean of ACTB, GAPDH and RPL13A, 
was used for the normalisation of gene expression data. 
 
3.3.4 Analysing the effect of exosome depletion on the expression of key 
genes associated with NEtD 
 
It was important to assess if affects to neuronal markers caused by exosome 
depletion at the protein level were reflected in gene expression data. Expression 
of androgen signalling markers (AR and kallikrein related peptidase 3 (KLK3), 
which encodes PSA), neuroendocrine markers (enolase 2 (ENO2), encoding 
NSE, beta tubulin class III (TUBB3) and synaptophysin (SYP)) and regulators of 
neurogenesis (human achaete-scute homolog 1 (ASCL1) encoding hASH1, RE-
1 silencing transcription factor (REST) and prostate specific gene 1 (PTOV1)) 
were analysed by qRT-PCR (Figure 3.5). 
 
In line with AR protein data (Figure 3.3A), there was no significant change 
observed in AR expression in exosome depleted control LNCaP cells when 
compared to control LNCaP cells (Figure 3.5A). AR expression was significantly 
induced in AD LNCaP cells versus control LNCaP cells (3.5-fold; p<0.0001), 
additionally exosome depletion of AD did not affect AR induction when compared 
to exosome depleted control cells (3.1-fold; p<0.0001); (Figure 3.5A). However, 
there was significant difference (p=0.0262) in AR expression between AD and 
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exosome depleted AD LNCaP cells, suggesting AD combined with exosome 
depletion affects AR expression. 
 
Depletion of exosomes did not affect KLK3 expression, however, KLK3 
expression was significantly downregulated (47-fold; p<0.0001) by AD, which 
suggests loss of androgen signalling and activation, in line with the observed loss 
of PSA protein expression (Figure 3.3A). Downregulation of KLK3 expression in 
exosome depleted AD when compared to exosome depleted control LNCaP cells 
was not as dramatic as that observed in AD cells, but it was significant 
demonstrating interruption of AR signalling (7.5-fold; p=0.0001; Figure 3.5A). The 
significant difference in KLK3 gene expression between AD and exosome 
depleted AD LNCaP cells (p=0.0022) suggests exosome depletion in 
combination with AD affects KLK3 expression. 
 
ENO2 (encoding NSE) is a marker of neuronal cells (Isgrò et al., 2015) and is 
associated with neuroendocrine tissues (Wiedenmann et al., 1986). As expected, 
ENO2 expression was unaffected by exosome depletion in control LNCaP cells 
(p=0.2375; Figure 3.5B). After AD, there was a 4.3-fold increase of ENO2 
expression, which was mirrored by exosome depleted AD LNCaP cells by a 
comparative 4.8-fold increase (p=0.0012 and p<0.0001 respectively; Figure 
3.5B). Induction of EN02 correlates with increased NSE protein expression 
(Figure 3.3D). 
 
Unfortunately, chromogranin A (CHGA) was not included in qRT-PCR analysis, 
as the repetitive sequences of bases within the CHGA sequences prevented the 
design of specific oligonucleotides. Therefore, the neuron specific marker, 
TUBB3 was included. TUBB3 was increased as progenitor cells differentiate into 
neurons (Nierode et al., 2019), therefore, it was anticipated that expression would 
increase with AD. TUBB3 expression was unaffected in exosome depleted 
control compared to control LNCaP cells (Figure 3.5B). Following AD, TUBB3 
expression was significantly increased (6-fold; p<0.0001), this trend was also 





Figure 3.5: Assessing the effect of exosome depletion on NEtD LNCaP cells. 
Cells were grown in control (C), exosome depleted control (dC), androgen 
deprived (AD) or exosome depleted androgen deprived (dAD) for 15 days, RNA 
was extracted, and relative gene expression was assessed by qRT-PCR. A. 
Androgen receptor (AR) and kallikrein-3 (KLK3). B. Enolase 2 (ENO2), class III 
β-tubulin (TUBB3) and synaptophysin (SYP). C Achaete-scute homolog 1 
(ASCL1), RE-1 silencing transcription factor (REST), and prostate tumour over 
expressed gene 1 (PTOV1). Data were analysed by ∆∆Ct (Livak and Schmittgen, 
2001) and normalised to the geometric mean of ACTB, GAPDH and RPL13A to 
obtain the fold change in gene expression. Data are expressed as the mean fold 
change ± SEM (n=3). Data were analysed by one-way ANOVA and Tukey’s post 
hoc analysis; *p<0.05, **p<0.01, ***p<0.001 **** p<0.0001. 
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Expression of SYP, a broad spectrum neuroendocrine marker (Wiedenmann et 
al., 1986), was unchanged in exosome depleted control conditions compared to 
control LNCaP cells (Figure 3.5B). SYP expression increased slightly in AD 
LNCaP cells (1.5-fold; p=0.0928) compared to control (Figure 3.5B). Increased 
SYP expression was mirrored in exosome depleted AD cells (1.5-fold 
p=0.00792); (Figure 3.5B), showing exosome depletion did not affect SYP 
expression in control or AD LNCaP cells. 
 
ASCL1, a driver of neurogenesis (Raposo et al., 2015) was unaffected by 
exosome depletion in control cells and marginally increased in AD cells (1.25-
fold, not significant); (Figure 3.5C). These results contrast with induced hASH1 
protein expression of exosome depleted control and exosome depleted AD 
LNCaP cells (Figure 3.3C). This suggests that exosome depletion may impact on 
the expression of ASCL1. 
 
REST is the master repressor of neurogenesis (Mozzi et al., 2017), REST 
expression was unchanged in exosome depleted control cells (Figure 3.5C). 
Conversely, AD LNCaP cells exhibited a 2-fold; p=0.0002 increase in the 
expression of REST (Figure 3.5C), which was replicated in exosome depleted AD 
cells (p=0.0048). Indicating exosome depletion did not affect REST expression. 
 
PTOV1, is overexpressed in early and late stage prostate cancer (Benedit et al., 
2001). PTOV1 expression was significantly increased in exosome depleted 
control cells (1.24-fold; p=0.0022). AD cells show induced PTOV1 expression 
with a 2.5-fold increase p=0.0001, this result is replicated by exosome depleted 
androgen deprived cells, indicating exosome depletion affects PTOV1 in control 




The data shows exosome depletion did not affect control LNCaP cell morphology 
nor the morphological changes associated with AD-induced NEtD. Additionally, 
exosome depletion of CS-FCS did not appear to alter the ability of LNCaP cells 
to undergo NEtD and the extent of NEtD was unchanged. However, assessment 
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of protein and gene expression markers revealed that exosome depletion 
affected the expression of AR, KLK3, hASH1/ASCL1, PTOV1 and CrgA while all 




Neuroendocrine prostate cancer (NEPC) is the most lethal form of PCa (Lin et 
al., 2017). Release of neuropeptides by neuroendocrine (NE) cells in the tumour 
microenvironment (Abrahamsson, 1999) is thought to be the driver of 
neuroendocrine transdifferentiation (NEtD) of epithelial prostate cells to NE-like 
cells (Soundararajan et al., 2018). Recently, exosomes were proposed to play a 
role in NEPC progression (Lin et al., 2017). The isolation of exosomes from AD-
induced NEtD LNCaP cells provided an opportunity to study their potential role in 
NEPC. However, exosomes are not only released by LNCaP cells but are also 
found in FCS (Datta et al., 2018). Therefore, LNCaP cells grown in the presence 
of FCS are exposed to FCS exosomes, which may affect LNCaP cellular function, 
the NEtD process during AD and also interfere with LNCaP exosome isolation 
and analysis (Eitan et al., 2015; Szatanek et al., 2015; Angelini et al., 2016). The 
aim of this research was to create an in vitro model to evidence the involvement 
of exosomes in AD-induced NEtD of LNCaP cells. 
 
3.4.1 Establishing a model to assess exosomes released from NEtD 
LNCaP cells 
 
Creating a model to analyse and characterise exosomes derived from AD-in-
duced NEtD LNCaP cells was critical due to the presence of exosomes in FCS, 
a component of cell culture medium (Datta et al., 2018). FCS exosomes may 
interfere with analysis of exosomes released by NEtD LNCaP cells (Jeppesen et 
al., 2014). Nanoparticle tracking analysis (NTA) of freshly prepared culture me-
dium, confirmed there was a significant population of EVs prior to the addition of 
cells (Szatanek et al., 2015), emphasising the importance of depleting FCS as-
sociated EVs, which could otherwise skew downstream exosome isolation results 
(Shelke et al., 2014). 
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FCS associated RNA can be co-isolated with extracellular RNA from cells, which 
interferes with downstream analysis of EV RNA (Wei et al., 2016). miR-1246 
encodes one of the most abundantly expressed miRNAs in FCS and is only 
present within four species, bovine, human, orangutan and chimpanzee (Wei et 
al., 2016). Intriguingly, although there are no sequences homologous to hsa-miR-
1246 in the mouse genome, mature miR-1246 was consistently found in all 
mouse cell lines, when cultured in the presence of 10% FCS (Wei et al., 2016). 
This underscores the internal impact FCS exosomes can have on cells in culture 
and in turn influence downstream analysis and results from exosomes of interest. 
In addition to the co-isolation of RNA, proteomic and flow cytometry-based 
analysis of isolated exosomes suggested, isolated exosomal fractions often 
contain FCS exosomes and the extent of co-isolation depends on the method of 
isolation used (Gardiner et al., 2016). Soluble proteins frequently co-isolated with 
exosomes are albumin, immunoglobulins and matrix metalloproteases, which are 
abundant in serum (Caradec et al., 2014; Ludwig et al., 2019). There is a need to 
discriminate the true exosome content versus contaminating nucleic acids or 
proteins coating the surface of exosomes to prevent the presentation of false data 
due to the masking of true exosomes with FCS exosomes. 
 
FCS exosomes can be removed by ultracentrifugation, ultrafiltration, exosome 
precipitation kits, microfluidic techniques or by using commercially available pre-
depleted serum (Li et al., 2017). In this model, exosomes were depleted from 
FCS by ultracentrifugation, an established, cost effective and universally 
preferred method of exosome depletion (Soares Martins et al., 2018). 
Ultracentrifugation does not remove 100% of exosomes from FCS, analysis 
revealed FCS exosomes were reduced by 70 % (Lehrich et al., 2018). The 70% 
reduction of FCS exosomes ensures a reduced basal concentration of interfering 
exosomes, which can affect cellular function and also downstream analysis of 
exosomes of interest. Standardisation of exosome depletion has not been 
agreed, resulting in variations to the ultracentrifugation method including the 
model of centrifuge, the type of centrifuge rotor, the speed and duration samples 
are centrifuged (Livshits et al., 2015). These adaptations create divisions 
between those researching exosomes, contributing to a larger problem, as the 
field is no closer to reaching a standardised protocol. 
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Quantifying the success of exosome depletion, appears to have been somewhat 
overlooked by those researching exosomes and using exosome depleted FCS in 
cell culture conditions. Few acknowledge the extent of exosome depletion and 
also, what other factors may be depleted alongside FCS exosomes. Measuring 
depletion success is an important consideration as in different cellular models, 
cells may exhibit different effects due to the change in their culturing conditions. 
Previously Lehrich et al. (2018) used nanoparticle tracking analysis (NTA) to 
quantify the number of exosomes in FCS prior and following exosome depletion, 
to determine the percentage depletion. In the in vitro AD-induced NEtD model 
combined with exosome depletion, the extent of exosome depletion is not known 
and could suggest why there was no change in cell size, growth or confluence of 
LNCaP cells when morphology was observed. Thus, in future work the success 
of exosome depletion should be quantified. Performing dynamic light scattering 
(DLS) prior to and following exosome depletion, would allow quantification of the 
number of particles, which represent the exosome population. These data could 
then be used to identify the percentage of exosome depletion and the success of 
the process. It would be accepted that batch to batch variation may occur when 
performing exosome depletion of FCS. To ensure reproducible and consistent 
results a cut-off point for the percentage of depletion should be considered. 
Based on findings from Lehrich et al. (2018) a cut-off of 70% +/- 5% depletion 
should be considered when 18 hour ultracentrifugation is used for exosome 
depletion of FCS. 
 
As well as assessing the percentage of depletion, assessing proteins associated 
with FCS exosomes before and after exosome depletion of FCS may indicate the 
extent of depletion. Assessment of markers of exosome machinery such as ALG-
2 interacting protein X (Alix; (Szatanek et al., 2017) via immunoblotting from non-
exosome depleted and exosome depleted FCS may reveal a change in 
expression. It would be expected that Alix expression would be reduced in 
exosome depleted FCS. 
 
Commercially pre-depleted FCS may minimise variations in the 
ultracentrifugation method for exosome depletion however, it is costly. It was 
shown that pre-depleted FCS had a reduction of 75% in exosome content and 
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was able to support standard cell growth and diminished bovine miRNAs (Chen 
et al., 2013). A shortcoming of pre-depleted FCS is that manufacturers who 
produce pre-depleted FCS do not state the method of exosome depletion used. 
It is also unknown in what proportions other factors found in FCS are removed as 
this has not been quantified. Pre-depleted FCS could not be applied to the AD-
induced NEtD model as exosome depleted charcoal stripped FCS (CS-FCS) is 
not a commercially available product. CS-FCS is essential for androgen 
deprivation and induction of NEtD, which is central to the model used (Fraser et 
al., 2019). Therefore, if commercially available pre-depleted FCS was utilised, 
appropriate comparisons could not be drawn between exosome depleted control 
and exosome depleted AD conditions, further supporting the use of 
ultracentrifugation to produce exosome depleted CS-FCS. 
 
3.4.2 The consequence of exosome depletion of FCS 
 
FCS is fundamental to provide additional nutrients like fatty acids, cholesterol, 
endocrine factors, such as androgens, insulin, epidermal growth factor and cell 
attachment proteins like fetuin to cells in culture (Sedelaar and Isaacs, 2009). 
Whether exosome depletion of serum enhances or reduces the effects of LNCaP 
AD-induced NEtD cell morphology is unknown. However, Eitan et al. (2015) 
previously showed exosomes from FCS are internalised by cells and interact with 
lysosomes. Therefore, FCS exosomes may serve as carriers of signals or 
nutrients, promoting normal cell growth (Eitan et al., 2015). It was important to 
ascertain whether the potential loss of other essential supplements from FCS did 
not affect LNCaP cell growth under different experimental conditions. This would 
demonstrate whether the proposed model was appropriate for the study of 
exosomes isolated from NEtD LNCaP cells. 
 
FCS-derived exosomes in culture medium can have a significant influence on 
cellular function. Angelini et al. (2016) showed FCS-derived exosomes supported 
cell growth and migration of human cardiac progenitor cells. The size, yield and 
extracellular matrix production were affected when exosomes were depleted from 
FCS (Angelini et al., 2016), demonstrating the influence of FCS exosomes on 
cells in culture. Proliferation of cardiac progenitor cells increased, when FCS 
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exosomes were supplemented back into exosome depleted medium, in a dose 
dependent manner. Interestingly, when morphology was assessed no significant 
changes in the appearance of the cardiac progenitor cells were identified Angelini 
et al. (2016). Further, Shelke et al. (2014) revealed cell migration was reduced in 
airway epithelial cancer (A549) cells grown in culture medium containing 
exosome depleted FCS. FCS exosomes were added to exosome depleted 
medium, inducing transmigration. The FCS exosomes were labelled with PKH67, 
a fluorescent membrane dye and live cell imaging performed, the results 
displayed uptake of the FCS exosomes by A549 cells. Indicating that exosomes, 
which originate from FCS have a direct migratory effect on A549 cells (Shelke et 
al., 2014). These data indicate, that although morphological changes were not 
observed in LNCaP cells cultured in exosome depleted medium, if proliferation 
(MTT assay) and migration (scratch assay) assays were performed, such 
analysis may provide further data to elucidate the effect of exosome depletion on 
LNCaP cells. 
 
3.4.3 Androgen deprivation and exosome depletion 
 
Charcoal stripping of FCS reduces the androgen content by approximately 86%, 
and reduces the total serum testosterone concentration from 22.0 +/- 6.1 pg/mL 
to 5.0 +/- 0.49 pg/mL (Sedelaar and Isaacs, 2009). In healthy males, the normal 
range of total serum testosterone is 3-10 ng/mL, conversely in chemically 
castrated PCa patients, total serum testosterone concentrations are reduced to 
<0.5 ng/mL (Sedelaar and Isaacs, 2009). LNCaP cells are routinely cultured with 
normal FCS prior to culture with CS-FCS, resulting in residual androgens in 
culture, as well as low  concentrations of androgens in CS-FCS, which could 
potentially activate the AR (Davey and Grossmann, 2016). There are no data to 
indicate if the androgen concentration is affected by exosome depletion therefore, 
a change in the androgen concentration of culture conditions could impact AD 
and subsequent NEtD. 
 
In addition to reducing androgens, charcoal stripping of FCS also reduces 
vitamins, electrolytes and certain metabolites however, albumin was unaffected 
by charcoal stripping (Cao et al., 2009). Stability of albumin following charcoal 
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stripping is important, as albumin plays a role in binding free testosterone in 
serum. Sex hormone binding globulin (SHBG) and albumin are abundant within 
serum (Tan et al., 2015). Approximately 60% of testosterone and 
dihydrotestosterone (DHT) are bound to SHBG and the remaining 40% is bound 
to albumin (Heinlein and Chang, 2002). Albumin has a low affinity for androgens, 
therefore, continuously releases and rebinds serum testosterone, whereas SHGB 
replenishes free testosterone, which is lost via diffusion to stabilise total serum 
testosterone (Sedelaar and Isaacs, 2009). Therefore, albumin plays a critical role 
in regulating androgens and a reduction in the albumin concentration during 
exosome depletion of FCS may impact the androgen concentration in culture 
conditions. 
 
Albumin is frequently co-sedimented with exosomes during ultracentrifugation 
(Van Deun et al., 2014); indeed, albumin is a common contaminant of exosome 
pellets (Caradec et al., 2014; Lehrich et al., 2018). Therefore, androgen bound to 
albumin may also be co-sedimented in the ultracentrifugation process. Reduction 
in albumin content of FCS following ultracentrifugation may also reduce binding 
of free androgen to albumin in culture medium. This could reduce the androgen 
concentration in exosome depleted FCS therefore, cell culture medium 
containing exosome depleted FCS or CS-FCS is likely to have a reduced 
androgen content compared to non-exosome depleted culture medium. 
Moreover, in CS-FCS, where the concentration of androgens is already 
substantially reduced, androgens could be further diminished. If exosome 
depleted control medium was deprived of androgen it may be expected that 
exosome depleted cells display potential NEtD. Curiously, when morphology of 
exosome depleted control LNCaP cells was analysed, these cells did not exhibit 
NEtD and morphology reflected that of control LNCaP cells (Figure 3.2). Fraser 
et al. 2019 showed upon reintroduction of the synthetic androgen R1881, NEtD 
NE-like LNCaP cells lost their neurite-like extensions and 15 days post AD NE-
like cells resembled control cells. However neuronal markers, NSE and hASH1 
remained elevated, demonstrating the potential of morphology to mask many 




While NEtD may not have been morphologically evident, protein expression data 
revealed increased hASH1 expression in exosome depleted conditions when 
compared to their non-exosome depleted counterpart (Figure 3.3C). hASH1 is 
involved in the regulation of cell fate and commitment (Raposo et al., 2015), 
increased expression of hASH1 could suggest that cells cultured in exosome 
depleted conditions may influence NEtD through increased reduction of 
androgens in culture medium. Additionally, PTOV1, a marker of prostate cancer 
progression (Benedit et al., 2001) was upregulated in exosome depleted 
conditions versus control (Figure 3.5C), suggesting reduced androgens in 
exosome depleted control medium may promote NEtD. These data suggest that 
exosome depleted control growth medium has a reduced androgen concentration 
compared to control growth medium. 
 
The concentration of androgens in FCS prior to and following exosome depletion 
was not measured. Assessing protein concentration of factors such as albumin 
by radioimmunoassay (RIA) in FCS pre and post ultracentrifugation, may reveal 
whether exosome depletion affects the concentration of albumin and androgens 
to provide knowledge of the culture medium composition following exosome 
depletion. It would be suggested that androgen concentration in exosome 
depleted conditions should be reflective of their control (22 +/- 6.1 pg/mL) or AD 
(5 +/- 0.49 pg/mL) counterpart (Sedelaar and Isaacs, 2009). However, it is 
important that the concentrations are consistent within experiments to ensure 
reliability and reproducibility of results. 
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3.4.4 Exosome depletion of FCS may cause reduction in total RNA con-
centration 
 
The total RNA yield was reduced in LNCaP cells grown in exosome depleted cell 
culture medium however, microfluidic assay of RNA integrity did not provide any 
evidence to account for the reduced yield, as the RNA was fully intact. FCS-
derived RNA is enclosed in EVs however, there are other macromolecules, such 
as ribonucleoproteins (RNPs) and lipoprotein particles associated with FCS RNA 
that co-sediment with exosomes (Mateescu et al., 2017). The overlap in size and 
density of RNP and lipoproteins with exosomes accounts for the unavoidable co-
sedimentation of FCS-derived RNA (Driedonks et al., 2018). Here, FCS-derived 
RNA present in culture medium, is removed due to ultracentrifugation of FCS 
prior to the addition of cells, therefore, there is a reduced basal concentration of 
RNA. Co-sedimentation of FCS-derived RNA may account for the reduced total 
RNA yield from LNCaP cells grown in exosome depleted conditions compared to 
LNCaP cells grown in the presence of FCS. 
 
3.5 Conclusions and future work 
 
This study aimed to identify an appropriate model for the study of exosomes 
released from NE-like LNCaP cells by using exosome depletion of serum. The 
impact of exosome depletion on LNCaP cells has not been documented, 
therefore, morphological and molecular analysis of LNCaP cells grown in 
exosome depleted conditions was performed. No changes in cell morphology 
considering growth and appearance of the cell was observed. Exosome depleted 
control cells retained the epithelial morphology and exosome depleted AD cells 
showed neuronal-like protrusions associated with a shift in phenotype from 
epithelial to neuronal-like LNCaP cells. This suggests exosome depletion does 
not affect LNCaP cell growth or NEtD. However, protein and gene expression 
markers of androgen signalling, NE cells and neurogenesis (AR, KLK3, 
hASH1/ASCL1, PTOV1 and CrgA) were shown to be affected. More work may 
be required to ensure that the model is appropriate to study NE-like exosomes 




To link protein and gene expression data, validation of chromogranin A gene 
(CHGA) would be beneficial. CHGA is a marker used in the clinic for the diagnosis 
of NEPC alongside other markers such as NSE (Gkolfinopoulos et al., 2017). 
These data would add to the evidence collected here and also provide links 
between in vivo NEPC and the in vitro AD-induced NEtD model by using a more 
clinically relevant marker of NEPC (D’amico et al., 2014). Performing end-point 
PCR of control, exosome depleted control, AD and exosome depleted AD LNCaP 
cell samples, may elucidate if the multiple bands corresponding to precursor and 
intermediate CrgA protein and identified in CrgA protein expression (Figure 3.3D) 
are also identified in gene expression analysis. Also, including multiple time 
points of AD exosome depletion, may identify when expression of CHGA is 




4. Chapter 4: Isolation and characterisation of exosomes from AD-
induced neuroendocrine transdifferentiated LNCaP cells 
 
4.1 Introduction 
4.1.1 Exosomes and PCa/ NEtD 
 
Exosomes are involved in cellular communications by inducing signals directly 
through surface molecules or by transfer of their cargo to recipient cells (Patel et 
al., 2019). PCa cells, including LNCaP cells release exosomes, which can be 
isolated and characterised (Vlaeminck-Guillem, 2018). exosomes released from 
androgen sensitive (LNCaP) and androgen independent (PC3 and DU145) PCa 
cell lines can increase cellular proliferation of other PCa (Soekmadji et al., 2017), 
transfer cell specific cargo (Read et al., 2017) and initiate formation of the pre-
metastatic niche (Itoh et al., 2012). These data illustrate the ability of exosomes 
to manipulate PCa cells in vitro (Vlaeminck-Guillem, 2018). 
 
In the prostate adenocarcinoma microenvironment, neuroendocrine (NE) cells 
are thought to release potent neuropeptides to induce neuroendocrine 
transdifferentiation (NEtD) of neighbouring epithelial prostate cells to NE-like cells 
(Soundararajan et al., 2018). Exosomes may also mediate NEtD via crosstalk of 
exosomes released in the tumour microenvironment (Lin et al., 2017). In this 
chapter an in vitro model of androgen deprivation (AD) that transdifferentiated 
control, epithelial LNCaP cells to NE-like LNCaP cells was applied. It is possible 
that exosomes released from epithelial and NE-like cancer cells drive cancer 
growth. However, whether exosome release drives different aspects of tumour 
growth or tumour types remains, as yet, unknown. Isolating and characterising 
exosomes released from these two different lineages of PCa cells created an 
opportunity to assess the profile of exosomes and to examine the potential 
differences in exosome number, size and content. 
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4.1.2 Isolation and characterisation of exosomes released from NEtD 
LNCaP cells 
 
Typically, exosome isolation methods do not exclusively isolate exosomes as 
there is a biochemical overlap between exosomes and other EVs such as 
microvesicles (Li et al., 2017). Exosomes can be isolated by various methods, 
including differential ultracentrifugation, exosome precipitation, size exclusion 
chromatography, ultrafiltration and density gradients (Witwer et al., 2013). The 
most widely applied method of exosome isolation is differential ultracentrifugation 
where exosomes and EVs are separated by particle density, size and shape 
(Jeppesen et al., 2014). 
 
 
Figure 4.1: Exosome isolation, precipitation and purification. A. Conditioned 
medium is collected and pre-cleared of cells, cellular debris and non-extracellular 
vesicles via differential ultracentrifugation at increasing speeds and durations. 
Supernatant is incubated with precipitation buffer overnight. B. To pellet 
exosomes the medium and buffer mixture is ultracentrifuged. C. The exosome 
pellet is then purified via size exclusion chromatography columns. Created using 




In this research, a commercially available precipitation kit was used to isolate 
exosomes from cleared medium via polyethylene glycol (PEG; Figure 4.1A). Pre-
cipitated Exosomes can then be collected by centrifugation (Figure 4.1B) and 
purified by column chromatography (Figure 4.1C; Gurunathan et al., 2019). Dy-
namic light scattering (DLS) was employed to provide physical characterisation 
and immunostaining for biochemical analysis of exosomes isolated from AD-in-
duced NEtD LNCaP cells. DLS analyses fluctuations of scattering intensity of 
particles in Brownian motion to estimate particle size and concentration (Lane et 
al., 2015). Multiple proteins such as cytosolic proteins (ALIX and Hsp70) and a 
transmembrane protein (CD9) were used in combination for immunoblotting to 
provide robust results (Théry et al., 2018). 
4.2 Study aim and research questions 
4.2.1 Overall aim: 
 





To characterise and investigate the profile of exosomes released from 
control versus AD-induced NEtD LNCaP cells. 
 
4.2.3 Research Questions: 
 
1. Does exosome depletion of FCS/CS-FCS alter the expression of key 
markers of the exosomal machinery in LNCaP cells? 
2. Does AD-induced NEtD of LNCaP cells alter the expression of the 
exosome machinery? 
3. Does AD-induced NEtD of LNCaP cells increase the number of 
exosomes released? 






4.3.1 Identification of exosomal associated markers in androgen deprived 
LNCaP cell model 
 
It was important to assess if exosome depletion of control and AD LNCaP cell 
culture conditions affected the expression of exosomal machinery markers. 
LNCaP cells were cultured in control (C), exosome depleted control (dC), AD or 
exosome depleted AD (dAD) conditions for 15 days and gene expression of 
exosomal machinery markers (ALIX, TSG101, RAB27A, VAMP7, and CD9) were 
assessed by qRT-PCR (Figure 4.2). 
 
Expression of ALIX and TSG101, associated with sorting and packaging of cargo 
into intraluminal vesicles (Hessvik and Llorente, 2018), RAB27A, involved in the 
multivesicular body docking (Bebelman et al., 2018) and the transmembrane 
protein, CD9 (Witwer et al., 2013) were unaffected by exosome depletion in 
control LNCaP cells. Expression was comparable to that in LNCaP cells grown in 
non-depleted control conditions (Figure 4.2A-C), suggesting that exosome 
depletion did not affect exosome machinery markers. 
 
Curiously, expression of VAMP7, which induces fusion of MVBs with the plasma 
membrane (Mcgough and Vincent, 2016) was increased 3-fold (p=0.4813; not 
significant) in exosome depleted control conditions compared to non-depleted 
control conditions. There was considerable variability in VAMP7 expression in 
exosome depleted control LNCaP cells therefore, it is not certain induction of 




Figure 4.2: Assessing the effect of exosome depletion on expression of 
exosomal markers in NEtD LNCaP cells. Cells were grown in control (C), 
exosome depleted control (dC), androgen deprived (AD) or exosome depleted 
androgen deprived (dAD) conditions for 15 days, RNA was extracted and relative 
expression of A. Markers of sorting and packaging (ALG-2-interacting protein X 
(ALIX) and tumour susceptibility gene 101 (TSG101)). B. Markers of docking and 
fusion (Ras-associated binding protein 27A (RAB27A) and vesicle associated 
protein 7 (VAMP7)). C. Tetraspanin, CD9 were assessed by qRT-PCR. Data 
were analysed by Ct and normalised to the geometric mean of ACTB, GAPDH 
and RPL13A to obtain the fold change in gene expression. Data are expressed 
as the mean ± SEM (n=3) and were analysed by one-way ANOVA and Tukey’s 
post hoc analysis; *p<0.05, **p<0.01, ****p<0.0001. D. Schematic diagram 
highlighting the location of exosomal genes in exosome biogenesis. 
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By contrast, ALIX (2.31-fold; p<0.0001), TSG101 (2.04-fold; p<0.0001), RAB27A 
3.08-fold; p<0.0001), VAMP7 expression (1.62-fold; p<0.0001) and CD9 (2.2-
fold; p=0.0032); were significantly increased in AD LNCaP cells compared to 
control LNCaP cells (Figure 4.2A-C), suggesting AD conditions induce the 
expression of the exosomal machinery in LNCaP cells. 
 
Gene expression was analysed in exosome depleted AD LNCaP cells. Like 
control conditions, exosome depletion of AD medium had little effect on the 
expression of the exosomal machinery as expression was comparable to 
exosome rich AD conditions. Confirmed by gene expression of ALIX (2.06-fold; 
p=0.5203), TSG101 (2.04-fold; p=0.9880) and VAMP7 (1.97-fold; p=0.1545); 
(Figure 4.2A-B). Interestingly, exosome depletion of AD did alter RAB27A (3.72-
fold; p=0.0145) and CD9 (1.66-fold; p=0.0158), suggesting that a combined effect 
of AD and exosome depletion affects expression of these exosome machinery 
markers. 
 
Together, this shows that exosome depletion did not alter the expression of 
exosome machinery. Curiously, LNCaP cells exposed to AD or exosome 
depleted AD conditions had induced expression of exosome machinery markers. 
Therefore, induction of exosome machinery may increase exosome production in 
AD-induced NEtD LNCaP cells. From herein, all samples and analysis were 
performed on exosome depleted control and exosome depleted AD samples as 
the depletion process did not affect LNCaP cells. 
 
4.3.2 Identifying the presence of exosomes isolated from AD-induced 
NEtD LNCaP cells 
 
The impact of AD on the number of exosomes released from AD LNCaP cells 
was analysed using DLS (Figure 4.3). Control and AD LNCaP cells were grown 
for 7 days and the conditioned culture medium was collected for the isolation of 
exosomes. Previously, LNCaP cells were cultivated in AD conditions for 15 days 
prior to gene expression analysis, here, LNCaP cells were only exposed to AD 
for 7 days. This time point was used as NEtD is actively in process therefore, 
exosomes isolated here would be reflective of this time point. DLS analysis shows 
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control and AD samples contain a heterogeneous population of particles samples 
(Figure 4.3A). The presence of two peaks suggests two populations of EVs, one 
at 30-100 nm thought to represent exosomes (Mcgough and Vincent, 2016) and 
one at 100-1000 nm thought to represent microvesicles (Doyle and Wang, 2019). 
 
The average diameter of exosomes isolated from control LNCaP cells was 42.38 
nm and this increased to 66.59 nm in AD LNCaP cells (Figure 4.3B). The average 
width of exosome isolated from control LNCaP cells was 8.02 nm and increased 
to 14.38 nm in AD LNCaP cells (Figure 4.3C). Interestingly, the average 
percentage of exosomes isolated from control cells increased from 13.9 % in 
exosome depleted cells to 21.63 % in AD cells (Figure 4.3D). These results 
indicate AD of LNCaP cells increases the size and number of exosomes 
produced. 
 
Microvesicles isolated from control conditions had an average diameter of 362.2 
nm, which increased to 457.25 nm in AD conditions (Figure 4.3E). The average 
width of microvesicles released from control LNCaP cells was 85.86 nm and 
increased to 103.62 in AD LNCaP cells (Figure 4.3F). In line with the observed 
increase in exosomes isolated from AD LNCaP cells, the average percentage of 
microvesicles decreased to 78% in AD LNCaP cells from 86% from control 
LNCaP cells (Figure 4.3G). AD conditions marginally increased microvesicle size 




Figure 4.3: Analysing the profile of extracellular vesicle populations 
secreted by AD LNCaP cells. Conditioned medium from exosome depleted 
control (dC) and exosome depleted AD (dAD) LNCaP cells was collected after 7 
days and exosomes isolated. A. Representative example of the profile of 
populations isolated from dC and dAD LNCaP cells showing peaks 
corresponding to exosomes and microvesicles. The profile of the vesicles was 
analysed by DLS assessing the average diameter (B and E), width (C and F) and 
overall percentage (D and G) of exosomes, (B-D) or microvesicles (E-F).  Data 
are expressed as the mean ± SEM (n=3) and were analysed by Welch’s t-test. 
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4.3.3 Analysing exosomes isolated from AD-induced NEtD LNCaP cells 
 
The profile of exosomes isolated from control and AD LNCaP cells were analysed 
using known exosome markers (ALIX, Hsp70 and CD9) via immunoblotting. 
Radioimmunoprecipitation assay (RIPA) buffer is the most common method of 
exosome lysis as it allows identification of the highest number of exosomal 
proteins (Subedi et al., 2019). LNCaP cells were used as a positive comparator 
as these were the source of exosomes. Cells were lysed with NP-40 buffer as 
this was the standard lysis method used here. 
 
In control LNCaP cells two bands corresponding to ALIX were detected, at ~95 
kDa and a very faint band at ~90 kDa (Figure 4.4B, lane 2). Expression of both 
bands was increased in AD LNCaP cells (Figure 4.4B, lane 3), in line with the 
observed increase in ALIX gene expression in AD LNCaP cells (Figure 4.2A). 
The 95 kDa ALIX protein was identified in exosomes isolated from control LNCaP 
cells, however, was undetectable in exosomes isolated from AD LNCaP cells 
(Figure 4.4B, lane 5). Hsp70 was detected in control LNCaP cells and expression 
remained consistent in AD LNCaP cells (Figure 4.4C, lane 2 and 3 respectively). 
Hsp70 was also detected in exosomes isolated from control cells however, 
expression was very faint in AD LNCaP-derived exosomes (Figure 4.4C, lane 5). 
To detect CD9, non-reducing and non-denaturing conditions are required as this 
is a transmembrane protein (Andreu and Yáñez-Mó, 2014). There was a small 
but noticeable increase in CD9 expression in AD LNCaP cells compared to 
control LNCaP cells (Figure 4.4D, lane 3), in line with gene expression data 
(Figure 4.3C). CD9 was identified in exosomes isolated from control cells and 
expression was comparable to the control cell lysate. Expression of CD9 was not 
clear in exosomes isolated from AD LNCaP cells as a faint and distorted protein 
was identified. Low exosomal protein yield limited analysis of the profile of 
exosomes isolated from cells. These data indicate AD of LNCaP cells induces 
exosome machinery proteins however, the experiment should be repeated to 
ensure the loading control supports these findings. These data do, however, 





Figure 4.4: Analysing the profile of markers of exosomes isolated from 
control and AD LNCaP cells. Representative immunoblot analysis (n=3) 
showing protein expression in exosomes isolated from exosome depleted control 
(dC) and exosome depleted AD (dAD) after 7 days. dC and dAD cells were grown 
for 15 days and used as a control. Panel A shows a schematic description of the 
samples present in each lane; the first two samples were prepared with NP-40 
lysis buffer whilst the last two lanes were prepared with 1X RIPA lysis buffer. 
Expression of known markers ALG-2-interacting protein (ALIX; B), heat shock 
protein 70 (Hsp70; C) and CD9 (D) were analysed by immunoblotting. CD9 
analysis was performed in non-denaturing and non-reducing conditions. 
Molecular weights are indicated, and equal loading was assessed by β-actin (E). 
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4.3.4 Characterising exosomal machinery markers in AD-induced NEtD 
LNCaP cells 
 
Results obtained from exosomal protein analysis were inconclusive due to the 
low exosomal protein yield (0.06 µg/µL) and subsequent loading of 3.6 µg of 
exosome protein was insufficient and limited this avenue of research. To 
overcome this, the profile of exosomal machinery (ALIX, Hsp70, CD9) in control 
and AD LNCaP cells was analysed via immunoblotting. It was hypothesised that 
changes in exosome machinery, could reflect changes in the number of 
exosomes released from LNCaP cells. It was important to optimise lysis 
conditions first to ensure protein detection therefore, NP-40 and 1X RIPA buffers 
were used. 
 
Using NP-40 lysis conditions, ALIX expression was increased between control 
and AD LNCaP (Figure 4.5A, lane 2 and 4 respectively) and expression of Hsp70 
increased marginally in AD LNCaP cells compared to control (Figure 4.5B, lane 
4 and 2 respectively). Intriguingly, expression of CD9 was considerably increased 
in AD LNCaP cells compared to control LNCaP cells (Figure 4.5C, lane 4 and 2 
respectively). These data are in line with observed increase in gene expression 
under AD conditions (Figure 4.2), demonstrating that AD conditions induce genes 
involved in sorting and packaging (ALIX), chaperone (Hsp70) and 
transmembrane (CD9) exosomal machinery markers. 
 
When LNCaP cells were lysed with RIPA buffer ALIX, Hsp70 and CD9 expression 
was increased in AD LNCaP cells compared to control LNCaP cells however, 
detection of ALIX, Hsp70 and CD9 in control and AD LNCaP cells was 
considerably reduced compared to samples prepared with NP-40 lysis buffer. It 
was notable that when LNCaP cells were lysed with RIPA buffer the considerable 
increase of CD9 in AD conditions was not seen, suggesting the lysis condition 
masked the AD-dependent increase in CD9 expression (Figure 4.4C, lane 4). 
 
Together, these data indicate that AD induced expression of proteins associated 
with sorting and packaging of exosomal cargo, chaperone proteins and 
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transmembrane proteins. It is anticipated an increase of these markers in AD 
LNCaP cells, correlated to induced exosome production, as the exosome profile 




Figure 4.5: Analysing exosome machinery in LNCaP cells. Representative 
immunoblot analysis (n=2) showing protein expression in LNCaP cells cultured 
in exosome depleted control (dC) and exosome depleted androgen deprived 
(dAD) conditions for 15 days. dC and dAD LNCaP cells were lysed in either 1X 
radioimmunoprecipitation (RIPA) or a NP-40 lysis buffer. Expression of known 
markers ALG-2-interacting protein (ALIX; A), heat shock protein 70 (Hsp70; B) 
and CD9 (C) were analysed by immunoblotting. CD9 analysis was performed in 
non-denaturing and non-reducing conditions. Molecular weights are indicated 






The aim of this chapter was to isolate and characterise exosomes from AD-
induced NEtD LNCaP cells. Before investigating exosomes released from AD 
LNCaP cells, it was important to ascertain the effect of exosome depletion on key 
exosome machinery markers as the effect, if any, was undocumented. Gene 
expression data revealed exosome depletion did not affect expression of key 
exosome machinery markers (ALIX, TSG101, RAB27A, VAMP7 and CD9) 
however, AD conditions induced expression of these markers. Exosomes were 
successfully isolated and DLS showed that AD increased the size and number of 
exosomes isolated from LNCaP cells. Microvesicles were also isolated, and AD 
slightly increased their size however, the number of microvesicles decreased in 
AD with concurrent increase in exosomes. Together, these data suggest that AD 
of LNCaP cells induced expression of exosome machinery and this, in turn, 
increased exosome production. 
 
4.4.1 The potential role of exosomes in PCa and NEtD 
 
Exosomes are involved in cellular communication by either inducing signals 
directly via surface molecules or transfer of vital proteins and/or nucleic acids to 
recipient cells (Patel et al., 2019). Exosomes released in PCa have been linked 
to cellular proliferation (Soekmadji et al., 2017) of treated cell and pre-metastatic 
niche formation via transfer of cell specific cargo (Itoh et al., 2012). Of particular 
interest, exosomes are thought to contribute to neuroendocrine 
transdifferentiation (NEtD); (Lin et al., 2017; Bhagirath et al., 2019). 
 
Exosomes have been shown to have a potential role in NEtD. Treatment of 
DU145 cells, an androgen independent cell line, with IL6, an alternative treatment 
to AD induces NEtD via peroxisome proliferator activated receptor gamma and 
adipocyte differentiation-related protein (Lin et al., 2017). Exosomes isolated from 
IL6 treated DU145 cells were added to un-treated DU145 cells, increasing the 
number of adipocyte differentiation-related protein positive cells (Lin et al., 2017). 
These findings by Lin et al. (2017) indicate that proteins associated with AD-
induced NEtD in LNCaP cells could be packaged as cargo and transferred to 
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untreated LNCaP cells to induce NEtD. Treatment of a non-malignant prostate 
epithelial cell line, RWPE1 with exosomes derived from IL6 treated DU145 cells 
induced dendrite-like extensions; a feature of NEtD (Lin et al., 2017). This reveals 
the ability of exosomes to induce NEtD in neighbouring cells in a paracrine 
manner by the sorting and transfer of adipocyte differentiation-related protein (Lin 
et al., 2017). This research demonstrates the potential for exosomes to package 
and transfer NEtD associated cargo to neighbouring PCa cells to drive NEtD, a 
feature of tumour progression in these cells, providing evidence of the 
involvement of exosomes in driving neuroendocrine tumour progression. 
 
4.4.2 PCa exosomes and associated cargo 
 
Pro-neuronal transcription factors associated with NEtD of PCa, BRN2 and 
BRN4, were upregulated in EVs released from CRPC-neuroendocrine xenografts 
compared to CRPC-adenocarcinoma xenografts (Bhagirath et al., 2019). These 
data suggest that exosomes released from cells of a different lineage, such as 
epithelial control and AD LNCaP cells may contain and transfer different cargo to 
neighbouring cells to propagate NEtD. Enzalutamide, an androgen receptor 
inhibitor, was used to treat LNCaP cells. Exosomes released from Enzalutamide 
treated cells were isolated and added to non-treated LNCaP cells, which caused 
induction of BRN2, BRN4 and neuronal genes chromogranin A and 
synaptophysin (Bhagirath et al., 2019). This finding demonstrates horizontal 
transfer of these mRNA to neighbouring cancer cells and dissemination of factors 
associated with NEtD. Although EVs were isolated from xenografts rather than 
LNCaP cells, an increased size and number of exosomes were released by 
CRPC-neuroendocrine xenografts compared to CRPC-adenocarcinoma 
(Bhagirath et al., 2019). Supporting data in this chapter, which showed increased 
exosome size and number in AD LNCaP cells compared to control LNCaP cells 
(Figure 4.3A-D). Enzalutamide resistant LNCaP cells released EVs with 
significantly increased BRN2 and BRN4 mRNA (Bhagirath et al., 2019), these 
could act as an adaptive mechanism for PCa cells to survive under selective 
pressure of AR pathway inhibitors (Bhagirath et al., 2019). Therefore, it is 
possible that AD induced NEtD LNCaP cells may release exosomes containing 
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different cargo than epithelial control LNCaP cells, and these exosomes may 
confer growth and survival advantages to neighbouring PCa cells. 
 
Enrichment of proteins in EVs induced cellular proliferation of PCa cells 
(Soekmadji et al., 2017). LNCaP cells treated with dihydrotestosterone (DHT), a 
potent androgen, released CD9 enriched EVs. AD cells were treated with CD9 
enriched LNCaP-derived exosomes, which induced cellular proliferation of AD 
LNCaP cells independent of DHT (Soekmadji et al., 2017). These data are of 
particular interest as it aligns with the data in this research, which showed that 
CD9 mRNA (Figure 4.2C) and protein (Figure 4.5C) expression was increased in 
LNCaP cells grown in AD conditions. Soekmadji et al. (2017) showed LNCaP 
cells grown in AD conditions had an increased EV yield 3-fold concomitant with 
an ~8 % increase in EV yield in AD conditions in research in this chapter. 
Interestingly EVs were larger (120 nm) compared to exosomes analysed in this 
chapter (66.59 nm; Figure 4.3B). However, depending on the isolation method 
different populations of EVs can be isolated from the same cells (Ludwig et al., 
2019). Differential ultracentrifugation was used by Soekmadji et al. (2017) 
whereas, precipitation with size exclusion chromatography was used in this 
research. Therefore, differences in EV size may be attributed to the isolation 
method. 
 
Following AD CD9 expression was considerably increased (Figure 4.5C), which 
may be linked to increased production and release of exosomes. It has been 
shown that exosomes isolated from patients with advanced and CRPC exhibited 
higher CD9 expression than those with non-metastatic PCa or healthy volunteers 
(Mizutani et al., 2014). Thus, the more aggressive the cancer the higher the 
concentration of exosomes (Mizutani et al., 2014), which is in line with data 
presented here showing AD LNCaP cells have greater expression of CD9 
compared to control LNCaP cells. In the prostate, CD9 may be involved in ligand-
independent activity of AR, which when activated, could regulate AR activity 
(Levina et al., 2015). CD9 is also considered to be a metastasis inhibitory factor 
(Zöller, 2009) therefore, during AD, where cells are progressing to a NE 
phenotype, CD9 may be upregulated to prevent metastasis. Data suggests that 
CD9 is implicated in PCa in various ways and that increased CD9 mRNA and 
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protein expression in AD LNCaP cells is a means of regulating exosome 
production, the AR and metastasis. 
 
Significant upregulation of RAB27A, essential for docking of multivesicular bodies 
at the plasma membrane, was identified in exosome depleted AD conditions 
(Figure 4.5B), which has not been previously described. Interestingly, 
overexpression of RAB27A is implicated in promoting cell proliferation, enhancing 
cell invasion, and increasing chemoresistance of cancer (Hendrix and de Wever, 
2013) such as breast cancer (Hendrix et al., 2010), bladder cancer (Ostenfeld et 
al., 2014), lung adenocarcinoma (Li et al., 2014) and melanoma (Peinado et al., 
2012). It could be postulated that exosome depletion in combination with AD 
upregulates RAB27A expression to promote tumorigenesis. 
 
Exosomes released by LNCaP cells were shown to transfer cargo to cells of a 
different lineage (Read et al., 2017). This underlines the importance of 
investigating the profile of epithelial (control) and NE-like (AD) LNCaP cells, to 
determine if exosomes released from NE-like cells could promote NEtD of 
epithelial cells in the tumour microenvironment. AR packaged in exosomes 
released by LNCaP cells was transferred to AR-null PC3 cells (Read et al., 2017). 
The AR was shown to be functional through translocation to the nucleus and 
activation of target genes such as prostate specific antigen (PSA), showing 
functional receptors in EVs can be transported to the nucleus of adjacent cells to 
modulate expression of responsive genes (Read et al., 2017). This is of 
importance as such mechanisms may prompt cells of one lineage to engage with 
another, generating an appropriate microenvironment for tumour growth and 
survival. Therefore, as there are differences in the number and profile of 
exosomes released from control and AD LNCaP cells, these exosomes may 
confer advantages for NEtD and subsequent aggressive tumour expansion. 
 
4.4.3 PCa exosomes and pre-metastatic niche formation 
 
In addition to communication within the tumour microenvironment, it is thought 
exosomes can promote pre-metastatic niche formation. Prostate tumours are 
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prone to metastasise to bone and have substantial crosstalk with bone cells in 
the bone microenvironment (Ibrahim et al., 2010). Exosomes isolated from 
hormone refractory PCa cells could facilitate osteoblast differentiation (Itoh et al., 
2012). Osteoblast differentiation associated transcription factor, Ets1, was highly 
expressed in PC3 and DU145-derived exosomes and osteoblast differentiation 
was induced by culture of exosomes containing Ets1 with osteoblasts. 
Osteoblastic differentiation was also seen in murine pro-osteoblastic MC3T3-E1 
cells cultured with PC3 and DU145-derived exosomes (Itoh et al., 2012). This 
supports the link between exosome release and ability to cause metastatic 
organotropism to the bone (Roudier et al., 2003). Therefore, exosomes can 
contribute to the formation of the pre-metastatic niche as oncogenic proteins 
enclosed in exosomes can spread to adjacent tissues and be taken up by organ 
specific cells (Pan et al., 2017). These data could suggest that culture of NE-like 
LNCaP-derived exosomes with osteoblasts could promote metastasis. 
 
4.4.4 PCa exosomes and cellular stress 
 
Cancer cells are frequently exposed to chemotherapy, radiation and the host 
immune system where cellular stress responses are crucial for their survival (Xu 
et al., 2018). Rotenone-induced mitochondrial damage increases exosome 
release from PCa stem cells, it is possible that cellular stress induced by AD  may 
also increase exosome release (Kumar et al., 2014). PCa stem cells were treated 
with Rotenone, which induced CD9, CD61, CD81 and TSG101 mRNA in 
exosomes released from these cells (Kumar et al., 2014). However, expression 
of these exosome machinery markers was only assessed in exosomes released 
from PCa stem cells and did not include assessment of these markers in the cells. 
Therefore, increased exosomes in circulation may enhance the potential for 
greater PCa progression via the exchange of cargo from NE-like cells and 
promotion of NEtD. 
 
Androgen-mediated autophagy is known to promotes cell growth by augmenting 
intracellular lipid accumulation, shown to be necessary for PCa cell growth (Shi 
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et al., 2013). Interestingly, there is an overlap of several proteins, which are as-
sociated with exosome biogenesis and autophagy such as components of the 
ESCRT and SNAREs (Gudbergsson and Johnsen, 2019). Exosome release is 
also known to be upregulated in PCa patients compared to healthy individuals, 
which suggests that there is the potential for the AR to influence EV biogenesis 
(Hessvik and Llorente, 2018). 
 
4.4.5 Exosomes as biomarkers in PCa 
 
Prostate Specific Antigen (PSA) is a clinically useful protein biomarker for 
diagnosis of PCa, however, PSA has a poor sensitivity and specificity and is 
known to have a high risk of overdiagnosis and overtreatment (Duijvesz et al., 
2013). To prevent unnecessary invasive prostate biopsies, provide patients with 
optimal treatment and discriminate between benign prostate diseases and the 
different types of PCa, novel molecular biomarkers are urgently needed (Duijvesz 
et al., 2013). The first exosome-based cancer diagnostic blood test became 
commercially available in 2016 for non-small cell lung cancer patients and it is 
hoped this test can be diversified for other cancers (Sheridan, 2016). 
 
Non-invasive detection of nucleic acids such as miRNAs via liquid biopsy have 
been shown to be promising biomarkers for PCa to differentiate PCa types, 
benign prostate hyperplasia and healthy individuals and enhances therapeutic 
efficiency (Tai et al., 2020). EVs from serum of recurrent PCa patients showed 
upregulation of miR-141 and miR-375 compared to patients with non-recurrent 
PCa, providing a potential diagnostic tool to distinguish these PCa types (Bryant 
et al., 2012). Circulating exosomes isolated from PCa patients undergoing 
radiotherapy displayed differential expression of miRNAs (miR21 and let-7) 
induced by radiotherapy (Malla et al., 2018). High expression of exosomal miR-
1246 was specifically observed in stage IV metastatic PCa patients as compared 
to Stage II/III (Bhagirath et al., 2018). More recently, the neuronal transcription 
factors BRN2 and BRN4 were upregulated in exosomes from PCa patients with 
neuroendocrine features opposed to PCa patients with adenocarcinoma features 
(Bhagirath et al., 2018). Thus, investigating exosomes released from AD-induced 
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NEtD LNCaP cells provides an important avenue to contribute to the use of 
exosomes as biomarkers for PCa. Further investigation of exosomes released 
from control and AD LNCaP cells could provide invaluable information regarding 
the use of exosomes as biomarkers for PCa, identifying the stage of PCa, 
treatment response or for therapeutic intervention. 
 
4.4.6 The impact of methodology on exosome isolation 
 
This research implemented exosome depletion of cell culturing conditions to 
ensure low background interference of exosomes from FCS. Gene expression of 
exosomal machinery markers was analysed to investigate the effect exosome 
depletion may have on these genes. Exosome depletion of control or AD 
conditions did not impact the expression of the exosome machinery markers 
ALIX, TSG101, RAB27A and CD9. There is a notable gap in the literature with 
regard to the effect of exosome depletion on AD-induced NEtD as researchers 
do not investigate the impact of culturing conditions upon markers associated 
with exosome biogenesis and release in exosome source cells. The lack of 
evidence prompts caution when interpreting data. Primarily research is focused 
on exosome cargo therefore, there is a distinct lack of analysis performed at a 
cellular level to make comparisons between the releasing cells and exosomes. 
 
ISEV detailed recommendations in the MISEV18, which cover EV separation, 
isolation, characterisation and functional studies, encouraging consistency and 
comparability between research groups (Théry et al., 2018). When characterising 
exosomes, recommendations outlined by MISEV18 state that quantification 
methods provide the most valuable information when separation methods with 
highest expected specificity are used and, therefore, when high recovery low 
specificity methods are used (e.g. precipitation) more than one quantification 
method should be employed (Théry et al., 2018). MISEV18 also highlights that 
including source cell and exosome data is important for robust analysis (Théry et 
al., 2018). It is possible that exosome depletion can remove essential proteins 
and growth factors, which may decrease growth-promoting effects and cause 
cellular stress (Ludwig et al., 2019). Cells exposed to cellular stresses such as 
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irradiation and hypoxia release an increased number of exosomes and cargo can 
differ between normal and stress states (Hessvik and Llorente, 2018). Therefore, 
investigating exosome machinery prior to and following exosome depletion would 
reveal if the release of exosomes is influenced by potential cellular stress induced 
by exosome depletion. 
 
In this research, precipitation combined with size exclusion chromatography was 
used to isolate exosomes from LNCaP cells, which aligned with research by 
others in the field (Welton et al., 2015; Malla et al., 2018; Wang et al., 2019). 
Despite successful exosome isolation revealed by DLS, quantification of 
exosomes by Bradford assay showed exosomal protein yield was very low (0.06 
µg/µL), resulting in inconclusive characterisation. This was a problem as there 
was insufficient exosome material for exosome analysis. Others have compared 
exosome isolation methods to investigate exosome yield and purity (Lane et al., 
2015; Soares Martins et al., 2018). A combined method of precipitation and size 
exclusion chromatography was compared to single methods of precipitation and 
ultracentrifugation, which showed that combined precipitation and size exclusion 
chromatography produced the highest exosome yield and purity (Lane et al., 
2015; Soares Martins et al., 2018). However, analysis was performed using 
serum and plasma patient samples as opposed to cell lines and only required 
200 µL of starting material. Tang et al. (2017) showed that 100 mL of culture 
medium from A459 cells (lung cancer) was required to produce 50 µg of exosomal 
protein. The volume of starting material in this research was 20 mL, which 
produced 3.6 µg of exosomal protein, it is possible that doubling the volume would 
have increased the amount of protein however, this was not feasible due the high 
cost of CS-FCS required for culture medium. 
 
Guidance from the manufacturer of the exosome precipitation kit suggested that 
further elution of the chromatography column would result in co-elution of 
ribonucleoprotein particles and protein from culture conditions therefore, 
contaminating the sample. As much as a further elution step may increase yield, 
it would decrease the purity of the exosome sample therefore, the decision was 
taken to not include a further elution step. It is also possible that adhesion of 
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exosomes to polycarbonate bottles may have attributed to low exosome yield as 
multiple of these were required for the preparation of one sample. The 
resuspension of exosomes in a small volume (100 µL) meant it was difficult to 
ensure all exosomes were collected from the bottles therefore, contributing to a 
further loss of exosome yield. In future work implementing measures to increase 
the volume of starting material of exosomes should allow increased exosome 
yield and better characterisation of exosomes released from control and AD 
LNCaP cells. 
 
4.4.7 Characterisation of exosomes released from NEtD LNCaP cells 
 
Characterisation of exosomes should be performed by analysing physical and 
biochemical/compositional properties of exosomes (Doyle and Wang, 2019). 
Dynamic light scattering (DLS) was used to provide an understanding of exosome 
size and concentration. However, when there is a heterogeneous mix of particles 
in the sample, scattered light by smaller particles is harder to detect and can skew 
data towards larger particles therefore, DLS may underestimate the 
concentration of exosomes in the sample (Lane et al., 2015). It could mean that 
the concentration of exosomes was higher than the concentration provided by the 
DLS. Data obtained from this method of characterisation should, therefore, be 
used with caution and it should be acknowledged that improvements to analysis 
may provide more robust results. Recommendations by MISEV18 also suggest 
that complementary techniques should be used for physical characterisation such 
as nanoparticle tracking analysis (NTA) and transmission electron microscopy 
(TEM); (Théry et al., 2018). Like DLS, NTA uses light scattering technologies 
however, is able to provide more accurate sizing information amongst 
heterogenous populations by using antibody mediated fluorophore labelling of 
exosomes with a fluorescent laser (Théry et al., 2018). Carnell-Morris et al., 
(2017) detailed a protocol, which used a mouse monoclonal Qdot-conjugated 
antibody to detect placental EVs, the antibody was specific for the 
syncytiotrophoblast marker placental alkaline phosphatase. TEM creates an 
image by electron interference when an electron beam crosses the sample, 
allowing visualisation and image capture for measurement of isolated particles 
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(Szatanek et al., 2017). As DLS only provides accurate results for monodisperse 
populations following recommendations by MISEV18 and implementation of NTA 
and TEM in future work would ensure robust analysis of the size and 
concentration of particles isolated from control and AD LNCaP cells (Théry et al., 
2018). 
 
4.4.8 Biochemical analysis of exosomes released from NEtD LNCaP cells 
 
Typically, exosome analysis is performed using immunoblotting staining or pro-
teomic analysis (Gurunathan et al., 2019). Wide accessibility and detection of 
surface and internal exosomal proteins explains why immunoblotting is one of the 
most commonly used methods of biochemical analysis (Doyle and Wang, 2019). 
However, immunoblotting comes with its limitations as large amounts of exoso-
mal protein often are required to provide a minimal amount of information (Doyle 
and Wang, 2019). The results obtained from immunoblotting were inconclusive, 
due to low exosomal protein yield and therefore, restricted how much protein 
could be resolved and analysed. The selection of an appropriate buffer for exo-
some lysis can be challenging as the number of proteins identified varies depend-
ing on the cell type and isolation method used (Hosseini-Beheshti et al., 2012). 
Low protein yield and inconclusive immunoblot results prompted the comparison 
RIPA and NP-40 buffer for cell lysis of control and AD LNCaP cells. RIPA buffer 
is the most commonly used method of exosome protein isolation as it allows the 
identification of the highest number of exosomal proteins (Subedi et al., 2019). 
However, NP-40 lysis of control and AD LNCaP cells showed more intense pro-
tein expression of ALIX, Hsp70 and CD9 compared to RIPA buffer, which ap-
peared to reduce protein recovery of ALIX, Hsp70 and CD9. The chemical com-
position of RIPA buffer makes this a much stronger detergent that may compro-
mise protein integrity and conformation sites where antibodies would bind, result-
ing in potential underestimated protein expression or mistaken for a change in 
expression (Ji, 2010). Therefore, for accurate analysis of protein expression, the 
lysis condition to best analyse proteins of interest should be considered. It is no-
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table that protein analysis was conducted in cell lysates and not exosomes, there-
fore, to characterise exosomal protein, RIPA lysis buffer is required to disrupt the 
lipid bilayer (Subedi et al., 2019). 
 
MISEV18 suggests that when immunoblot analysis is performed proteins should 
be used to demonstrate the presence of exosomes such as transmembrane 
(CD9) and cytosolic (ALIX and Hsp70); (Théry et al., 2018). In future, the addition 
of major components of non-EV co-isolated proteins such as albumin should be 
included in immunoblot analysis to evaluate the degree of purity of the EV 
preparation. Results obtained demonstrated exosomes were successfully 
isolated from LNCaP cells and visible differences were identified in exosome and 
microvesicle populations in control and AD conditions. However, improving 
methods to increase the yield of exosomes will allow improved characterisation 




This research aimed to identify if exosome depletion and AD of culture conditions 
affected exosomal machinery markers in LNCaP cells. Also, to characterise the 
profile of exosomes released from control and AD LNCaP cells. It is unknown 
what role, if any, exosomes play in NEtD of cells in the prostate tumour 
microenvironment. Exosome depletion, in combination with AD, affected RAB27A 
and CD9 gene expression however, all other markers were unaffected. 
Interestingly, gene expression data showed induction of exosomal machinery 
markers under AD and exosome depleted AD culture conditions. Exosomes were 
successfully identified by DLS, revealing an increased size and number of 
exosomes and microvesicles released from exosome depleted AD LNCaP cells. 
Assessment of protein markers saw induced expression of ALIX, Hsp70 and CD9 
under exosome depleted AD conditions. Together these analyses suggest that 
LNCaP cells exposed to AD induced NEtD have augmented exosomal machinery 
markers and induced exosome production, suggesting exosomes may be 
implicated in NEtD of PCa and tumour progression.
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5. Chapter 5: Manipulation of exosome release from control and AD-
induced neuroendocrine transdifferentiated LNCaP cells 
 
5.1 Introduction 
5.1.1 The role of GW4869 in the blockade of exosome release 
 
Exosome biogenesis is driven by ESCRT or ceramide pathways (Zhang et al., 
2019). The ceramide pathway is facilitated by neutral sphingomyelinases, a 
family of enzymes, which convert sphingomyelin into ceramide (Catalano and 
O’Driscoll, 2020). Sphingomyelinases are predominantly localised on the anti-
cytoplasmic leaflets of the plasma membrane. Ceramide molecules 
spontaneously associate and tightly bind to other ceramide molecules, forming 
ceramide enriched membrane microdomains (Zhang et al., 2009). The resultant 
ceramide microdomains can induce the budding and formation of interluminal 
vesicles into multivesicular bodies, as an early part of the exosome process 
(Figure 5.1; Catalano and O’Driscoll, 2020). The neutral sphingomyelinase 
inhibitor, GW4869 is pharmacological compound most commonly used to block 
the generation of exosomes (Essandoh et al., 2015). GW4869 targets the neutral 
sphingomyelinase pathway by inhibiting ceramide-mediated inward budding of 
multivesicular bodies and release of mature exosomes from these multivesicular 
bodies (Menck et al., 2017); (Figure 5.1). However, GW4869 only inhibits 
ceramide-mediated exosome release, not ESCRT-mediated exosome release, 





Figure 5.1: Manipulation of extracellular vesicle release via GW4869. (A) Microvesicles are formed via the budding and shedding from 
the plasma membrane. Exosome biogenesis occurs via ceramide and endosomal sorting complex required for transport (ESCRT) 
pathways, cargo is loaded in intraluminal vesicles (ILV) contained in multivesicular bodies (MVB), which are transported to and fused with 
the plasma membrane for exosome release. (B) The sphingomyelinase pathway inhibitor GW4869 blocks the formation and subsequent 
release of exosomes via the ceramide mediated exosome biogenesis pathway, which reduces exosome release and also increases 
microvesicle release. Created using Servier Medical Art by Servier. 
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In contrast to exosomes, microvesicles are generated by outward budding and 
fission of the plasma membrane (Menck et al., 2017). While exosomes and 
microvesicles are released by different modes of biogenesis there are similarities 
in their appearance, they can overlap in size and often have a common 
composition, which can contribute to the challenge to ascertain their origin when 
isolated (Van Neil et al., 2018). Interestingly, the activity of neutral 
sphingomyelinase is not specific to exosome biogenesis and has been linked to 
the increased shedding of microvesicles from the plasma membrane however, 
the mechanism is not yet understood but altered membrane fluidity is thought to 
contribute to this process (Menck et al., 2017). 
 
5.1.2 The role of Monensin in the induction of exosome release 
 
Ionophores are a class of compounds that form complexes with cations to facili-
tate their transport across lipophilic membranes (Aowicki and Huczynski, 2013). 
The most widely studied ionophore is Monensin, a polyether antibiotic isolated 
from Streptomyces cinnamonensis (Kim et al., 2016). Monensin is employed in 
veterinary medicine for treatment of poultry feed to control the protozoa coccidi-
osis or to improve food metabolism in ruminants (Aowicki and Huczynski, 2013). 
Treatment of coccidia with Monensin disrupts the normal transport of Na+ and K+ 
ions, directly affecting asexual and sexual development of coccidia (Novilla, 
2011). Failure of ion transport due to disruption in cellular K+ and H+ also occurs 
in bacteria as cell energy is exhausted by trying to maintain homeostasis causing 




Figure 5.2: Manipulation of exosome release via Monensin. (A) Microvesicles are formed via the budding and shedding from the plasma 
membrane. Exosome biogenesis occurs via ceramide and endosomal sorting complex required for transport (ESCRT) pathways, cargo is 
loaded in intraluminal vesicles (ILV) contained in multivesicular bodies (MVB), which are transported to and fused with the plasma 
membrane for exosome release. (B) Monensin acts on the Na+ antiporter on endosomes, increasing the intravesicular Na+ and subsequent 




Exosome release can be manipulated in vitro via the use of Monensin, treatment 
of cells with Monensin induces exosome release by acting on the Na+/H+ anti-
porter on acidic organelles such as endosomes, causing swelling of these vesi-
cles (Savina et al., 2003). Monensin also induces a Ca2+ influx via activity of the 
Na+/Ca2+ antiporter (Figure 5.2B; Dömötör et al., 1999). A rise in intracellular Ca2+ 
concentration is a universal intracellular signal necessary to induce regulated se-
cretion in most cell types (Savina et al., 2003). Treatment of cells in vitro with 
Monensin causes the formation of enlarged multivesicular bodies subsequently 
leading to the increased release of exosomes from these multivesicular bodies 
(Figure 5.2B); (Savina et al., 2005). 
 
Monensin has been shown to have potential uses in human medicine as an anti-
cancer therapeutic based on its’ ability to induce apoptosis in a variety of cancer 
cells such as lung cancer cells (Choi et al., 2013), ovarian cancer cells (Deng et 
al., 2015) and pancreatic cancer cells (Wang et al., 2018). Monensin was also 
repositioned as a potential anti-cancer drug for prostate cancer (Kim et al., 2016). 
The exact mechanism of action Monensin uses to induce apoptosis in cancer 
cells is not yet known however, it may involve Ca2+ dependant apoptosis and 
reactive oxygen species (Kim et al., 2016). 
 
5.1.3 Employing GW4869 and Monensin to manipulate exosomes release 
in disease 
 
GW4869 and Monensin have been implemented in various in vitro cell models to 
explore exosomes and their potential role in disease. GW4869 was used to 
identify the role exosomes may play in sepsis-induced inflammatory response 
and cardiac dysfunction (Essandoh et al., 2015). Blockade of exosome release 
by GW4869 diminished sepsis-induced cardiac inflammation, attenuated 
myocardial depression and prolonged survival, suggesting a role for exosome 
communication within the immune system and sepsis (Essandoh et al., 2015). 
 
GW4869 and Monensin were used to investigate if exosomes were involved in 
the dissemination of prions (Guo et al., 2016). Treatment of MoRK13 (mouse 
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kidney) cells with GW4869, to inhibit exosome release, showed a decrease in 
intercellular prion transmission. Conversely, Monensin stimulated exosome 
release, corresponding to an increase in intercellular transfer of prion infectivity 
(Guo et al., 2016). This demonstrated that manipulation of the exosome 
biogenesis pathway can highlight the role of exosome communication in prion 
disease. 
 
5.1.4 Employing GW4869 and Monensin to manipulate exosome release 
in PCa 
 
GW4869 has been previously used in PCa cell lines for the investigation of 
exosome communication in PCa. For example, Panigrahi et al. (2018) used 
GW4869 to limit hypoxia-induced exosome release from LNCaP cells (Panigrahi 
et al., 2018). Whilst Bhagirath et al. (2019) used GW4869 to limit exosome 
release from LNCaP and explore the role of exosome communication in PCa 
(Bhagirath et al., 2019). Reduction in exosomes affected the neural transcription 
factors BRN2 and BRN4, cellular levels of BRN2 were increased and decreased 
exosome associated BRN2. BRN4 was increased in exosomes following AD, 
treatment with GW4869 attenuated this increase (Bhagirath et al., 2019). The 
impact of increasing exosome release via Monensin in PCa has not been 
investigated. 
 
The role exosomes play in NEtD in PCa is not fully understood; to examine their 
potential role, GW4869 and Monensin were used to manipulate the release of 
exosomes and microvesicles. As exosomes have been implicated in NEtD and 
communication (Lin et al., 2017; Bhagirath et al., 2018), impeding or enhancing 
exosome release may reduce or increase NEtD formation and subsequent 
aggressive tumour formation. It was also hypothesised that increasing the 
number of exosomes released by control and AD LNCaP cells, would increase 
the exosomal starting material to allow better characterisation of exosomes 
released from control and AD LNCaP cells.
96 
 
5.2 Study aims and research questions 
 
5.2.2 Overall aim: 
To dissect whether exosomes play a role in NEtD AD LNCaP cells. 
 
5.2.3 Objectives: 
1. To determine the appropriate concentrations of GW4869 and 
Monensin to treat control and AD-induced NEtD LNCaP cells. 
2. To examine the impact of GW4869 and Monensin on NEtD of 
LNCaP cells following AD. 
3. To examine the impact of GW4869 and Monensin release from 
LNCaP cells. 
 
5.2.4 Research Questions: 
1. Does manipulation of exosome release enhance or impede NEtD 
of LNCaP cells following AD? 
2. Is the expression of the AR signalling, markers of NEtD and the 
exosomal machinery in control and AD-induced NEtD LNCaP cells 
altered by GW4869 and Monensin treatment? 
3. Does GW4869 or Monensin treatment of control and AD-induced 




5.3.2 Effect on cell viability after treatment of control and AD-induced 
NEtD LNCaP cells with different concentrations of GW4869 and 
Monensin 
 
The effects of GW4869 or Monensin on cell viability of control and AD LNCaP 
cells were analysed by MTT assay, assessing a range of concentrations derived 
from the literature (Figure 5.3A; Savina et al., 2003; Wilson et al., 2014; Guo et 
al., 2016; Panigrahi et al., 2018; Bhagirath et al., 2019). 
 
Analysis of increasing concentrations of the exosome inhibitor GW4869 
(Essandoh et al., 2015), showed cell growth was inhibited in a dose dependent 
manner in control and AD LNCaP cells (Figure 5.3B). At higher concentrations 
control and AD LNCaP cells showed similar sensitivity to GW4869 (86% +/- 18 % 
and 86% +/- 16 % respectively at 50 μM GW4869). However, as the concentration 
decreased control cells appeared to be more sensitive to GW4869 treatment than 
AD LNCaP cells (107 % +/- 9 % and 126 % +/- 13 % respectively at 10 μM 
GW4869). The concentration, which produced the greatest cell viability at the 
highest concentration of GW4869 for control and AD LNCaP cells was 25 μM 
GW4869 (108 % +/- 9 % and 115 % +/- 16 % respectively; Figure 5.3B). 
Comparable concentrations were used by others to limit exosome release from 




Figure 5.3: Analysing the effect of GW4869 and Monensin on LNCaP cell 
viability. A. LNCaP cells were seeded in control medium, after 24 hours for 
androgen deprivation (AD) medium was replaced with AD medium, control (C) 
medium was also replaced. On day 3, C and AD LNCaP cells were exposed to 
increasing concentrations of GW4869 (B) or Monensin (C) or their respective 
vehicle (Veh.) 4.5 % DMSO (B) or 0.1 % ethanol (C) for 24 hours. Cell viability 
was assessed via MTT assay, measuring the absorbance at 550 nm. Untreated 
(Unt.) C or AD cell viability was taken to be 100%, viability of treatments was 
expressed as a percentage of untreated control or untreated AD cells and 
presented as mean ± SEM (n=3). Solid line indicates 100 % cell viability.
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To avoid potential cytotoxic effects of DMSO the concentration should be 0.1 % 
or below (Sumida et al., 2011). A miscalculation of the GW4869 stock concentra-
tion resulted in a higher than desired concentration of DMSO in GW4869 working 
concentrations. Therefore, the highest DMSO concentration of 4.6 % found in 
100 μM GW4869 was used as the vehicle control. As expected LNCaP cell via-
bility was considerably affected by 4.6 % DMSO treatment (Figure 5.3B) however, 
as the concentration of GW4869 decreased the concentration of DMSO also de-
creased resulting in a range of DMSO concentrations (4.6 %, 2.3 %, 1.15 %, 0.46 
% and 0.23 % corresponding to 100, 50, 25, 10 and 5 μM respectively; all other 
DMSO concentrations were 0.01%). Therefore, in the 25 μM GW4869, the DMSO 
concentration was 1.15 %, higher than the intended concentration but was in 
keeping with the literature (Panigrahi et al., 2018; Bhagirath et al., 2019). 
 
Monensin, has not previously been used to induce exosome release in PCa. 
Therefore, a range of concentrations (20 to 0.1 μM) were used, based upon 
findings in other cell lines (Savina et al., 2003; Wilson et al., 2014; Guo et al., 
2016) to identify an appropriate Monensin dose for  use in LNCaP cells. In the 
presence of Monensin, cell growth was inhibited dose-dependently (Figure 5.2C). 
Differences in sensitivity to Monensin was minimal between control and AD 
LNCaP. The concentration of Monensin which produced the highest viability for 
control and AD LNCaP cells was 2 μM, (88 % +/- 8 % and 89.9 % +/- 11 % cell 
viability respectively; Figure 5.2C). This was in line with Wilson et al (2014) who 
used 2 μM Monensin to stimulate exosome release in A549 human lung 
carcinoma cells, (Wilson et al., 2014). Monensin’s vehicle control, EtOH was used 
at a concentration of 0.1% throughout, and had a marginal effect on control and 
AD cell viability (Figure 5.3B).
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5.3.3 Exosomes released from AD LNCaP cells promote NEtD 
 
The effects of GW4869 or Monensin on LNCaP cell morphology have not been 
documented previously therefore, it was important to assess if manipulation of 
exosome release via GW4869 or Monensin altered LNCaP cell morphology. 
LNCaP cells were seeded in control medium, after 24 hours control medium was 
removed and replaced with either fresh control medium or AD medium. On day 
3, 25 µM GW4869, 2 µM Monensin and their respective vehicle controls (DMSO 
and EtOH) were added to control and AD LNCaP cells and incubated for 24 
hours. Brightfield microscope images were taken at day 0 and 3 representing 
control and AD LNCaP cells respectively as well as at 4 days to assess the effects 
of GW4869 and Monensin (Figure 5.4). 
 
Untreated control LNCaP cells displayed characteristic epithelial morphology 
(Gaupel et al., 2013) throughout (Figure 5.4, panel II). Control LNCaP cells 
treated with 25 μM GW4869 for 24 hours had increased granularity and single 
cells could not be distinguished as they formed clusters compared to untreated 
control LNCaP cells (Figure 5.4, panel V). As expected, untreated AD LNCaP 
cells showed the presence of neuronal-like projections from the cell body, 
characteristic of NEtD (Yuan et al., 2006), demonstrating a change from epithelial 
phenotype at day 0 to neuronal-like phenotype at day 3 (Figure 5.4, panel III). On 
day 4, there was a slight increase in the presence of neuronal-like morphology. 
Intriguingly, 25 µM GW4869, increased granularity and clustering of AD LNCaP 
and reduced appearance of NE-like projections. LNCaP cell bodies resembled a 
more characteristic epithelial morphology compared to untreated AD LNCaP cells 
at day 3, suggesting a regression of the NE-like phenotype (Figure 5.4, panel IX). 
After 24 hours of Monensin treatment, AD LNCaP cells showed an enhanced NE-
phenotype as increased complexity demonstrated by increased branching on 
projections was identified (Figure 5.4, panel XI). This indicates that manipulation 




Figure 5.4: Monensin induces a neuroendocrine-like phenotype in control LNCaP cells. A. Schematic diagram indicating the 
treatment timeline of LNCaP cells with GW4869 or Monensin, showing the number of days LNCaP cells were cultured in control (C), 
androgen deprived (AD) and C or AD plus GW4869 or Monensin. B. Representative brightfield microscopy images of C or AD LNCaP cells 
at days 0, 3 and 4 (X 200 magnification). Cells were treated with 25 µM GW4869 or 2 µM Monensin or vehicle controls, 1.15 % DMSO or 
0.1 % ethanol (EtOH) for 24 hours (n=2). Arrows indicate the presence of neurite-like protrusions. Scale bars are representative of 1 µm.
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Treatment of control LNCaP cells with Monensin showed extensive granule 
formation and clustering of the cells (Figure 5.4, panel VII). Curiously, in the 
presence of Monensin, control LNCaP cells appeared to develop NE-like 
protrusions and the cells displayed a NE-like phenotype (Figure 5.4, panel VII). 
Protrusions are a key characteristic of a neuroendocrine-like phenotype (Figure 
5.4, panel III), treatment with Monensin and thus, manipulation of exosome 
communication may independently initiate NEtD in control LNCaP cells. 
 
When treated with DMSO, control LNCaP cells displayed cell bodies which were 
epithelial in shape, however, they appeared more granular compared to 
untreated control cells (Figure 5.4, panel IV). EtOH alone did not appear to affect 
control LNCaP cell morphology and they resembled untreated control epithelial 
morphology (Figure 5.4, panel VI). The neurite-like projections identified in DMSO 
and EtOH treated AD LNCaP cells at day 4 were not as evident as untreated AD 
LNCaP cells at day 3, cells also appeared more granular. This suggests that 
1.15 % DMSO and 0.1 % EtOH slightly affects the AD phenotype (Figure 5.4, 
panel VIII and panel X respectively). 
 
These data suggest exosomes and microvesicles may contribute to induction and 
maintenance of NEtD in LNCaP cells as the exosome inhibitor GW4869 
appeared to reduce the NE-like morphology in AD LNCaP cells compared to 
untreated AD LNCaP cells. Monensin treatment induces a NE-like phenotype in 
control LNCaP cells and increased projections and branching of AD LNCaP cells, 
suggesting increased exosomes, and/or microvesicles, can drive NEtD of PCa. 
 
5.3.4 Analysing the effect of GW4869 and Monensin treatment on the pro-
file of exosomes released from LNCaP cells 
 
Next the impact of GW4869 or Monensin on the profile of exosomes and 
microvesicles isolated from control and AD LNCaP cells was analysed via 
dynamic light scattering (DLS) (Figure 5.5 and Figure 5.6). Control and AD 
LNCaP cells were grown for 3 days, then exposed to GW4869 and Monensin and 
their vehicle controls DMSO and EtOH respectively. After 24 hours the 
conditioned culture medium was collected for the isolation of EVs and DLS used 
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to assess the profile of isolated vesicles (Figure 5.6A). Previously, LNCaP cells 
were cultivated in AD conditions for 15 days prior to gene expression analysis. 
Here, LNCaP cells were only exposed to AD for 4 days. This time point was 
selected as morphological analysis revealed that transformation of LNCaP cells 
from an epithelial to NE-like phenotype, and thus the beginning of the NEtD 
process, is evident at day 3 and therefore, this is an important window into the 
initiation of this process (Chapter 3, Figure 3.2). This data is preliminary therefore, 
it is not possible to be overly conclusive, further repeats would be included in 
future work.  
 
As before, a heterogenous population of particles were isolated from untreated 
control and AD LNCaP cells as seen by the presence of 2 peaks corresponding 
to exosomes (5 nm – 30 nm) and microvesicles (100 nm – 1000 nm); (Figure 
5.5). In keeping with previous findings (Chapter 4, Figure 4.3A), AD conditions 
increased the number of exosomes released from LNCaP cells compared to 
control cells with little effect on microvesicles; seen as the rightward shift in the 
peak corresponding to exosomes in AD LNCaP cells (Figure 5.5). Exosome size 
was also increased from 9.3 nm to 11.9 nm whilst microvesicle size remained 
unchanged at approximately 400 nm (Figure 5.6B). 
 
By inhibiting ceramide-mediated biogenesis of exosomes, GW4869 is thought to 
reduce the number of exosomes produced by cells (Essandoh et al., 2015). 
Treatment with GW4869 decreased the peak corresponding to exosomes and 
induced a leftward shift in the peak corresponding to microvesicles in control and 
AD LNCaP cells (Figure 5.5). This was seen here in control and AD LNCaP cells 
as exosomes were reduced from 79.1 % to 56.3% and 74.6 % to 52.5 % 
respectively (Figure 5.6C). GW4869 also had a consequential effect on 
microvesicles, as there was an increase in microvesicle release from 20.9% to 
29.9% in control LNCaP cells and from 25.4 % to 37.1% in AD LNCaP cells 
(Figure 5.6C). As expected, treatment with GW4869 decreased the average 
diameter of exosomes and microvesicles released from control and AD LNCaP 
cells from 9.3 nm to 8.7 nm and from 11.9 nm to 8.5 nm respectively (Figure 




Monensin induces an influx of Na+ and consequentially Ca2+, which is thought to 
be responsible for increased exosome biogenesis in cells (Savina et al., 2003). 
The peak corresponding to exosomes showed a slight leftward shift and a 
substantial leftward shift in the peak corresponding to microvesicles from control 
LNCaP cells exposed to Monensin treatment (Figure 5.5). LNCaP cells exposed 
to AD and Monensin showed a marginal increase in the exosome peak while 
microvesicle peak was reduced considerably (Figure 5.5). As expected, the 
number of exosomes from AD LNCaP cells increased from 74.6 % to 78.9 %, 
subsequently decreasing the number of microvesicles from 25.4 % to 21.1 % 
(Figure 5.6C). Control LNCaP cells did not show an increase as expected and 
rather showed a decrease from 74.6% to 64.5% and thus an increase in 
microvesicles from 20.9 % to 31.7 % (Figure 5.6C). Monensin treatment 
marginally reduced the size of exosomes from control and AD LNCaP cells, the 
size of microvesicles from control LNCaP cells were reduced and microvesicles 
from AD LNCaP cells remained unchanged (Figure 5.6B). 
 
DMSO and EtOH vehicle controls increased exosome release from 79% to 82 % 
and to 89 % respectively and decreased microvesicle release in control LNCaP 
cells from 20 % to 18 % and 11 % respectively. Whereas, exosome release was 
decreased from 75% to 64% and 67 % and microvesicle release increased from 
25% to 33 % and 32%in AD LNCaP cells (Figure 5.6C). This suggests that vehicle 
controls may also alter the profile of EVs released from LNCaP cells. The average 
diameter of exosomes from control LNCaP cells treated with DMSO was 
unaffected but reduced to 10 nm AD LNCaP exosomes (Figure 5.6B). 
Microvesicle diameter was 503 nm in control cells and decreased to 231 nm in 
AD LNCaP cells (Figure 5.6B). EtOH increased control and decreased AD 
exosomes to 11 nm and 10 nm respectively whereas, control and AD 
microvesicles were decreased 182 nm and 189 nm respectively (Figure 5.6B), 





Figure 5.5: Manipulation of exosome release alters the profile of 
extracellular vesicles isolated from LNCaP cells. Control and AD LNCaP cells 
were treated with 25 µM GW4869 or 2 µM Monensin or their respective vehicle 
control DMSO (1.15 %) or ethanol (EtOH; 0.1%) for 24 hours. Extracellular 
vesicles were isolated by precipitation and size exclusion chromatography and 
analysed via DLS.  Exosome and microvesicle profiles from each of the different 
treatments in control and AD LNCaP cells were aligned to highlight the profile 
change. The dotted lines indicate the position of the maximum peak of exosomes 





Figure 5.6: Manipulation of exosome release alters the size and number of 
extracellular vesicles isolated from LNCaP cells. A. Schematic diagram of 
LNCaP cell treatment timeline. Cells were seeded at day -1, and androgen 
deprived at day 0. On day 3 cells were treated with 25 µM GW4869 or 2 µM 
Monensin or their respective vehicle controls DMSO or ethanol (EtOH). 
Conditioned medium (CM) was collected on day 4 subsequently extracellular 
vesicles were isolated and analysed by DLS. B. Assessment of average diameter 
of exosomes (Exo) and microvesicles (MV) isolated from control (C) and 
androgen deprived (AD) LNCaP cells. C. Graphical representation of the 
percentage of the population that Exo and MV represent. No statistical analysis 
was performed as n=1.
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These findings demonstrate that GW4869 was successful in the limitation of 
exosome release from control and AD LNCaP cells and consequential increase 
of microvesicles release. Monensin induced exosomes from AD LNCaP cells but 
reduced exosomes from control LNCaP cells. This suggests AD may work 
synergistically with Monensin to induce exosome release. These data also 
indicate manipulation of EV release may be useful in elucidating their role in cell-
to-cell communication in NEtD of PCa. This data is preliminary therefore, it is not 
possible to be overly conclusive, to provide robust evidence further repeats would 
be included in future work.  
 
5.3.5 Analysing the effect of GW4869 and Monensin treatment on the ex-
pression of key genes associated with AR signalling and NEtD 
 
To assess the effect of GW4869 or Monensin treatment on key genes associated 
with AR signalling and NEtD, LNCaP cells were grown in control or AD conditions 
for 3 days. On day 3, cells were treated with 25 µM GW4869, 2 µM Monensin, or 
their respective vehicle control DMSO or EtOH. After 24 hours cells were 
harvested, and total RNA was extracted to analyse expression of critical genes 
via qRT-PCR. Morphological analysis of AD LNCaP cells indicated that inhibition 
of exosome release could reduce the NE-like phenotype whilst increased 
exosome release could induce a NE-like phenotype in control LNCaP cells and 
enhanced NE-like phenotype in AD LNCaP cells. Therefore, it was important to 
assess whether these results were translated in gene expression. 
 
Work in chapter 3 demonstrated that after 15 days of AD, androgen receptor (AR) 
expression was increased and kallikrein related peptidase 3 (KLK3; encoding 
PSA) expression was downregulated (Figure 3.5A). After 4 days AD, AR 
expression in LNCaP cells was marginally decreased and increased KLK3 
expression was observed (Figure 5.7A). This suggests that the gene expression 





GW4869 treatment of AD LNCaP cells triggered a downregulation of AR (-2.7-
fold) and KLK3 (-11-fold) expression; in Monensin treated AD LNCaP cells the 
downregulation of AR (-14-fold) and KLK3 (-9-fold) expression was substantial 
(Figure 5.7A). DMSO shows comparable effects with GW4869 as expression of 
AR and KLK3 were reduced in AD LNCaP cells. EtOH also slightly reduced 
expression of AR and KLK3 expression in AD LNCaP cells, however the effect of 
EtOH on AR expression is overwhelmed by the effect of Monensin (Figure 5.7A). 
 
AR and KLK3 should be expressed in control LNCaP cells however, AR 
expression was marginally downregulated (-2-fold) by GW4869 and further 
downregulated (-4.5-fold) in Monensin treated control LNCaP cells (Figure 5.7A). 
KLK3 expression was also markedly downregulated by GW4869 (-14-fold) and 
slightly downregulated in Monensin treated control cells (-1-fold). Of note, 
expression of AR and KLK3 with DMSO alone replicated the result observed for 
GW4869, suggesting that DMSO was masking the true effects of GW4869 or 
there was no effect. EtOH treatment did not affect expression of AR or KLK3 in 
control LNCaP cells, indicating that Monensin effects are dependent on the 
presence of the drug. These findings suggest that manipulation of exosome 
release may alter the expression of androgen signalling markers in LNCaP cells. 
 
In chapter 3, 15 days AD was accompanied by a significant increase in neuronal 
markers such as neuron specific enolase (ENO2) and class III β-tubulin (TUBB3) 
and slightly increased synaptophysin (SYP). Here, at 4 days of AD, induction of 
ENO2, TUBB3 and SYP (Figure 5.7B) was evident but considerably less than 15 
days demonstrating the temporal expression of these genes. GW4869 did not 
alter induction of ENO2 or SYP but increased TUBB3 expression (1.5-fold; Figure 
5.7B). It was thought the enhanced NE-like phenotype induced by Monensin 
(Figure 5.4) would increase neuronal marker expression, however, ENO2 
expression was unaffected by Monensin treatment and TUBB3 and SYP 
expression were notably reduced in AD LNCaP cells (Figure 5.7B), suggesting 




Figure 5.7: Assessing the effect of GW4869 or Monensin treatment on key 
genes associated with NEtD in LNCaP cells. Cells were grown in control (C), 
or androgen deprived (AD) conditions for 3 days, cells were then treated with 25 
µM GW4869 or 2 µM Monensin (MON) or their vehicle controls, DMSO (1.15 %) 
or ethanol (EtOH; 0.1 %) respectively and incubated for 24 hours. On day 4 RNA 
was extracted and relative expression of A. markers of androgen signalling 
androgen receptor (AR) and (KLK3) B. neuroendocrine markers neuron specific 
enolase (ENO2), class III β-tubulin (TUBB3), and synaptophysin (SYP) C. and 
markers of neurogenesis (ASCL1), RE-1 silencing transcription factor (REST) 
and (PTOV1) were assessed by qRT-PCR. Data were analysed by Ct and 
normalised to the geometric mean of ACTB, GAPDH and RPL13A to obtain the 
fold change in gene expression. Data is expressed as the mean ± SD (n=2) and 




Control epithelial LNCaP cells are expected to show little to no expression of 
neuronal markers yet intriguingly, Monensin treatment increased expression of 
ENO2, TUBB3 and SYP in LNCaP cells (Figure 5.7B). Aligning with the 
appearance of a NE-like phenotype after Monensin treatment (Figure 5.4). 
GW4869 also induced ENO2 and SYP expression in control cells however, 
TUBB3 was downregulated. Vehicle controls DMSO and EtOH showed slightly 
increased expression of all neuronal markers (ENO2, TUBB3 and SYP). These 
data indicate that manipulation of exosome release in control epithelial cells has 
a dramatic impact on expression of neuronal markers. 
 
Regulators associated with cell fate and neurogenesis were also assessed. 
Previous findings demonstrated that AD conditions increased expression of 
human achaete-scute homolog 1 (ASCL1; encoding hASH1), RE-1 silencing 
transcription factor (REST) and prostate specific gene 1 (PTOV1). GW4869 
considerably reduced ASCL1 expression but did not appear to alter REST or 
PTOV1 expression (Figure 5.7C). Monensin marginally reduced ASCL1 and did 
not appear to alter REST or PTOV1 expression (Figure 5.7C). Most interestingly, 
control LNCaP cells showed increased REST and PTOV1 when treated with 
GW4869 or Monensin (Figure 5.7C). DMSO and EtOH do not appear to affect 
the expression of ASCL1, REST or PTOV1 (Figure 5.7C.). These results indicate 
that at an earlier stage in the NEtD process marked expression of neuronal cell 
fate regulators are not evident. The exact molecular mechanism of NEtD is 
unknown therefore, the earlier time point of NEtD provides an insight into the 
temporal changes of gene expression. 
 
5.3.6 Analysing the effect of GW4869 and Monensin treatment on the ex-
pression of key genes of exosome machinery 
 
Next the impact of GW4869 and Monensin on expression of the exosomal 
machinery in control and AD LNCaP cells was analysed. Previous data revealed 
AD induced expression of exosomal machinery in LNCaP cells after 15 days 
(Figure 4.2); it was anticipated that the induction would be less marked after 4 
days of AD. 
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ALG-2 interacting protein X (ALIX) and tumour susceptibility gene 101 (TSG101) 
are associated with cargo sorting and packaging (Zaborowski et al., 2015). ALIX 
and TSG101 were induced by AD previously (Chapter 4, Figure 4.2), but not here, 
suggesting that ALIX and TSG101 are induced later in the NEtD process (Figure 
5.8). GW4869 or Monensin treatment in combination with AD, showed a slight 
downregulation of ALIX and more evident downregulation in TSG101 however, 
the downregulation was not significant due to the variability (Figure 5.8A). 
Expression of ALIX and TSG101 was slightly more evident in control cells treated 
with GW4869 or Monensin, suggesting an enhanced effect on control LNCaP 
cells (Figure 5.8A). In control and AD LNCaP cells the DMSO appeared to induce 
expression of ALIX and TSG101, whilst EtOH did not appear to alter expression 
of ALIX or TSG101 in control or AD LNCaP cells (Figure 5.8A). 
 
RAS-associated binding protein 27A (RAB27A) and vesicle associated protein 7 
(VAMP7), were induced by AD as previously shown (Figure 4.2), showing that 
the trends are consistent between 4 days and 15 days AD and that the model is 
robust and reproducible (Figure 5.8B). Treatment of AD LNCaP cells with 
GW4869 or Monensin did not further increase expression of RAB27A, suggesting 
AD may have already altered expression of the exosome machinery (Figure 
5.8B). However, treatment of control LNCaP cells with GW4869 and Monensin 
dramatically induced RAB27A expression (25-fold and 15-fold respectively) to 
expression levels comparable to AD LNCaP cells (Figure 5.8B). There is possible 
induction of VAMP7 caused by GW4869 and Monensin treatment of control 
LNCaP cells however, there was variability in expression (Figure 5.8B). The drug 
vehicles DMSO and EtOH may have an effect on RAB27A and VAMP7 




Figure 5.8: Assessing the effect of GW4869 or Monensin treatment on 
genes associated with exosomes in LNCaP cells. Cells were grown in control 
(C), or androgen deprived (AD) conditions for 3 days, then cells were treated with 
25 µM GW4869 or 2 µM Monensin (MON) or their vehicle controls, DMSO or 
ethanol (EtOH) respectively and incubated for 24 hours. On day 4, RNA was 
extracted and relative expression of A. Markers of sorting and packaging (ALG-
2-interacting protein X (ALIX) and tumour susceptibility gene 101 (TSG101)). B. 
Markers of docking and fusion (Ras-associated binding protein 27A (RAB27A) 
and vesicle associated protein 7 (VAMP7)). C. Tetraspanin, CD9 were assessed 
by qRT-PCR. Data were analysed by Ct and normalised to the geometric mean 
of ACTB, GAPDH and RPL13A to obtain the fold change in gene expression. 
Data are expressed as the mean ± SD (n=2) and was analysed by one-way 
ANOVA and Tukey’s post hoc analysis; *p<0.05, **p<0.01, ****p<0.0001. 
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DMSO and EtOH also increased RAB27A expression in AD and control LNCaP 
cells however, the extent of expression was less than their corresponding drug 
treatment (Figure 5.8B). Vesicle associated protein 7 (VAMP7), remained 
unaffected by treatment with GW4869, Monensin or EtOH in AD LNCaP cells 
however, DMSO upregulated VAMP7 upregulation (Figure 5.8B). VAMP7 
expression was also induced by GW4869 and to a lesser extent DMSO treatment 
in control LNCaP cells (Figure 5.8B). Monensin or EtOH treatment did not affect 
VAMP7 expression in control cells (Figure 5.8B). This suggests GW4869 and 
Monensin treatment may induce docking of multivesicular bodies via RAB27A but 
not fusion via VAMP7. 
 
Previously CD9 expression was induced after 15 days AD at gene and protein 
level (Chapter 4, Figure 4.2 And Figure 4.5) however, induction of CD9 was not 
yet evident at 4 days (Figure 5.8C). GW4869 and Monensin had little effect on 
CD9 expression in control cells however, expression decreased considerable 
decrease in AD cells (-0.5-fold and 2.5-fold respectively); (Figure 5.8C). The 
vehicle controls DMSO and EtOH showed minimal effects on CD9 expression in 
control LNCaP cells. DMSO upregulated CD9 expression (2.7-fold) in AD LNCaP 
cells, which may suggest DMSO is masking the effect of GW4869 on CD9 
expression (Figure 5.8C). In AD LNCaP cells CD9 expression was marginally 
decreased by EtOH but did not interfere with effects of Monensin (Figure 5.8C). 
This suggests that induction of CD9 in NEtD occurs later in the process and 





The aim of this work was to dissect the potential role of exosomes in the process 
of neuroendocrine transdifferentiation (NEtD) in control and AD LNCaP cells. 
GW4869 was used to reduce exosome release while Monensin was used to 
promote exosome release. It was hypothesised that manipulating exosome 
biogenesis may indicate the potential role of exosomes in NEtD. Morphological 
data revealed GW4869 treatment of AD LNCaP cells reduced the neuronal-like 
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phenotype and appeared more epithelial. Conversely, Monensin enhanced 
neuronal-like morphology by increasing the complexity through the presence of 
branching. Most interestingly, control cells not exposed to AD, demonstrated a 
neuronal-like phenotype as projections appeared from the cell bodies and cells 
became thin and elongated. Gene expression analysis revealed that control 
LNCaP cells treated with Monensin had upregulated neuroendocrine and 
neurogenesis markers. Analysis of the profile of EVs via DLS demonstrated that 
GW4869 reduced the number of exosomes released and produced a 
consequential increase in the number of microvesicles from control and AD 
LNCaP cells. Monensin treatment increased the number and size of exosomes 
released from AD LNCaP cells however, a decrease was observed in control 
LNCaP cells. Collectively these results highlight the successful manipulation of 
the exosome biogenesis pathway in LNCaP cells and the potential role of 
exosome communication in NEtD of PCa. 
 
5.4.2 GW4869 as an inhibitor of exosome release 
 
The neutral sphingomyelinase (nSMase) inhibitor GW4869 has frequently been 
used to impede exosome release in multiple diseases such as cardiac 
dysfunction (Essandoh et al., 2015), neurodegenerative diseases (Guo et al., 
2016) and prostate cancer (Panigrahi et al., 2018; Bhagirath et al., 2019). 
Implementation of GW4869 provides a means of validation for the potential role 
of exosomes in disease. 
 
To limit exosome release from control and AD LNCaP cells 25 µM GW4869 was 
used. As aforementioned a miscalculation of the GW4869 stock concentration 
resulted in a higher concentration employed to treat LNCaP cells than was initially 
intended. To validate the release of neural transcription factors in exosomes 
derived from AD LNCaP cells, 20 µM GW4869 was used for 48 hours in AD-
induced NEtD model (Bhagirath et al., 2019). There were no documented toxic 
effects to the AD LNCaP cells after treatment of 20 µM GW4869 and the number 
of exosomes released by the AD LNCaP cells was reduced (Bhagirath et al., 
2019), aligning with the data in this chapter, which demonstrated that control and 
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LNCaP cell viability was unaffected by the use of 25 µM GW4869 treatment for 
24 hours and successfully limited exosome release. 
 
Hypoxia induced exosome secretion promoted survival of prostate cancer cells 
(Panigrahi et al., 2018), therefore, limiting exosome release from these prostate 
cancer cells would indicate whether exosomes provided PCa cells with a survival 
mechanism (Panigrahi et al., 2018). Treating LNCaP and PC3 cells with 10 µM 
or 20 µM GW4869 for 24 or 48 hours significantly decreased cell viability of 
LNCaP and PC3 cells, this result was attributed to the decreased cellular 
exosome release and was suggested that preventing cell-to-cell communication 
via exosomes reduced the ability to transfer key survival factors for PCa 
(Panigrahi et al., 2018). LNCaP cells used by Panigrahi et al. (2018) were not 
exposed to AD conditions however, their findings highlight the appropriate use of 
25 µM GW4869 for 24 hours in LNCaP cells. 
 
In a model of sepsis induced inflammatory response and cardiac dysfunction, 
RAW264.7 macrophages were treated with 10 and 20 µM GW4869 (Essandoh 
et al., 2015). Cytotoxic effects were not identified compared to vehicle control 
(0.005 % DMSO; (Essandoh et al., 2015)) and this, supports the use of 25 µM 
GW4869 to treat control and AD LNCaP cells. 
 
5.4.3 Monensin may manipulate exosome release via multiple mecha-
nisms 
 
Monensin is an FDA approved antibiotic used in veterinary medicine as a 
therapeutic coccidiostat in several target animal species (Novilla, 2011). In 
poultry farming, feed is treated with Monensin to reduce the proliferation of 
parasites thus, eliminating attenuation of stock breeding (Aowicki and Huczynski, 
2013). Asexual and sexual development of coccidia are affected as Monensin 
causes Na+ and K+ transport to fail (Novilla, 2011). Bacteria are affected similarly 
as they require energy to maintain cellular homeostasis, subsequent treatment 
with Monensin mediates antiporter activity by exchanging Na+ ions with H+ ions 
at the plasma membrane (Markowska et al., 2019). When bacteria have 
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expended all their energy trying to restore cellular homeostasis the organisms 
swell, lyse and die (Novilla, 2011). In cattle, Monensin is used to improve the 
efficiency of food metabolism by reducing energy and waste gas losses 
associated with formation of volatile fatty acids (Novilla, 2011). 
 
Monensin has also been repositioned in human medicine as an anticancer 
therapeutic based on its’ ability to induce apoptosis in a variety of cancer cells 
such as lung cancer cells (Choi et al., 2013), ovarian cancer cells (Deng et al., 
2015), pancreatic cancer cells (Wang et al., 2018) and most interestingly, 
prostate cancer cells (Ketola et al., 2010; Kim et al., 2016). It was suggested as 
a direct effect of Ca2+ dysregulation induced by Monensin that regulation of cell 
cycle and apoptosis associated proteins resulted in, induction of mitochondrial 
reactive oxygen species- and Ca2+-dependant apoptosis (Kim et al., 2016). 
 
At the cellular level, Monensin facilitates transport of Na+ ions across the plasma 
membrane (Novilla, 2011). This triggers the Na+/Ca2+ antiporter and subsequent 
ingression of Ca2+. An increase in intracellular Ca2+ is required to induce 
regulated secretion, thus Monensin can be used to enhance exosome release 
from cells (Savina et al., 2003). However, Ca2+ is an important signalling molecule 
essential for physiological functions such as cell cycle control, apoptosis, 
migration and gene expression (Y. F. Chen et al., 2013). Manipulating exosome 
release via Monensin may also manipulate and differentially affect other Ca2+-
dependant mechanisms in LNCaP cells accordingly, care must be taken to 




5.4.4 The use of Monensin to enhance exosome release 
 
A range of Monensin concentrations are used in the literature to manipulate 
exosome release from erythroleukemia cells (Savina et al., 2003), lung 
carcinoma cells (Wilson et al., 2014), mouse kidney and mouse hypothalamic 
cells (Guo et al., 2016). However, Monensin treatment has not previously been 
used for manipulation of exosome release in a model of PCa. 
 
Savina et al. (2003) showed that treatment of K562 human erythroleukemia cells 
with 7 µM Monensin for 7 hours markedly enhanced exosome release. In this 
chapter LNCaP cells were treated for 24 hours at a lower concentration, it may 
be notable for future work that different time points of Monensin treatment could 
be assessed to ensure optimal treatment conditions. In line with the work in this 
chapter, A459 human lung carcinoma cells were treated with 2 µM Monensin for 
24 hours (Wilson et al., 2014). Monensin was used to demonstrate how the 
exosome release mechanism is linked to the multifaceted receptor, sortilin by 
enhancing exosome release (Wilson et al., 2014). There were no documented 
cytotoxic effects on A459 cells after treatment with 2 µM Monensin for 24 hours, 
concomitant with findings here that LNCaP cells had enhanced exosome release 
and no cytotoxic effects when treated with 2 µM Monensin. To investigate the 
relationship between exosome release and intracellular prion dissemination, 
MoRK13 and GT1-7 cells were stimulated with Monensin, which corresponded 
to an increase in intracellular transfer of prion infectivity (Guo et al., 2016). 
MoRK13 cells were treated with 7 µM Monensin for 48 hours, demonstrating the 
use of a higher concentration for a longer period of time (Guo et al., 2016). 
However, GT1-7 cells had increased sensitivity to Monensin and were treated 
with a considerably lower concentration of 7 nM Monensin for 48 hours (Guo et 
al., 2016). This highlights the variable sensitivity of different cell lines to Monensin 
and therefore, conducting cell viability or toxicity assays allows appropriate 
selection of the Monensin concentration for the chosen cell line. Guo et al. (2016) 
also replaced the culture medium on the day of Monensin treatment, thereby 
preventing interference of exosomes that were released by cells prior to 
Monensin treatment. This may provide a more accurate representation of the 
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exosomes released via treatment with Monensin. Taken together, these works 
highlight that the concentration and length of treatment is cell dependent and 
appropriate cytotoxicity assays should be performed before Monensin use. In this 
chapter LNCaP cells were exposed to AD, Monensin has not previously been 
used to induce exosome release in this model and consequently may be an 
additional factor which alters the effect of Monensin on AD LNCaP cells. 
 
5.4.5 Manipulating exosome release alters LNCaP cell morphology 
 
GW4869 treatment regressed the neuronal-like phenotype of AD LNCaP cells 
suggesting that a reduction of exosome release, may reduce NEtD and restore 
epithelial morphology in AD LNCaP cells. There is plasticity in NEtD and when 
AD LNCaP cells are treated with synthetic androgen the cellular morphology 
reverts back to parental LNCaP epithelial morphology (Shen et al., 1997; Fraser 
et al., 2019). It is possible, therefore, that exosomes are involved in the 
maintenance of the NEtD phenotype and when the number of exosomes is 
reduced, the neuronal-like phenotype cannot be maintained. Preventing the 
release of exosomes by drugging the exosome pathway may provide a means of 
preventing PCa progression and formation of NEtD. A similar result was identified 
in ovarian cancer where it was shown the transfer to and internalisation of CD44 
enriched ovarian cancer epithelial cell-derived exosomes by human peritoneal 
mesothelial cells elevated CD44 and decreased E-cadherin levels in mesothelial 
cells (Nakamura et al., 2017) This shows that at this stage the ovarian cancer 
cells are promoting aggressive cancer progression via cell-to-cell communication 
by exosomes and the associated epithelial mesenchymal transition associated 
cargo (Nakamura et al., 2017). A change in cellular morphology of mesothelial 
cells was also observed with ovarian cancer cell-derived exosome uptake, from 
their characteristic cobblestone-like to elongated spindle-like morphology 
(Nakamura et al., 2017). When exosome treated mesothelial cells were also 
treated with GW4869, the cobblestone morphology was restored in a dose 
dependent manner (Nakamura et al., 2017), showing that ovarian cancer-derived 
exosomes and their cargo can to drive epithelial mesenchymal transition in 
ovarian cancer. It is therefore, possible that exosomal cargo may be involved in 
119 
 
driving or maintaining NEtD of PCa and that when exosome release is limited by 
GW4869 it also limits transfer of exosomal cargo that can drive tumorigenesis. 
 
Morphological analysis revealed that control LNCaP cells, which had not been 
exposed to AD but were treated with Monensin displayed NE-like protrusions as-
sociated with a NE-like phenotype. Effects of Monensin on LNCaP cell morphol-
ogy however is undocumented, NEtD in PCa arises from distinct range of stress 
stimuli such as hypoxia (Danza et al., 2012), inflammation (Spiotto and Chung, 
2000), irradiation (Suarez et al., 2014) and potent androgen deprivation therapy 
(Cox et al., 1999).The multiple stressors proposed to drive NEtD indicate that 
under stress these cells are highly plastic. Thus, it is possible that the appearance 
of neuronal-like morphology in control LNCaP cells could be caused by Monensin 
imposing cellular stress and potential induction of NEtD via calcium dysregulation 
instead of a direct effect of exosomal cargo. There was no morphological evi-
dence of increased apoptosis or autophagy in Monensin treated LNCaP cells. 
Monensin treatment of PC3 PCa cells reduces expression of B-cell lymphoma 2 
(BCL2) and pro-caspase-3 and induces cleavage of the (ADP-ribose) polymer-
ase (PARP) protein contributing to Monensin triggered apoptosis in PC3 cells 
(Ketola et al., 2010). Further analysis of oxidative stress and apoptosis related 
genes such as thioredoxin-interacting protein (TXNIP), BCL2 and PARP may pro-
vide evidence of stress response to Monensin in AD LNCaP cells (Ketola et al., 
2010). 
 
5.4.6 Manipulation of exosome release alters gene expression in LNCaP 
cells 
 
AD LNCaP cells treated with GW4869, decreased active secretion of mRNA 
associated with NEtD in PCa into exosomes and increased intracellular mRNA 
levels (Bhagirath et al., 2019). This suggests that inhibition of exosome release 
may reduce the ability of PCa to confer survival and progression advantages to 
neighbouring cells via exosomes. Interestingly, a significant downregulation of 
AR mRNA in AD LNCaP cells by Monensin treatment was also observed in this 
research concomitant with previous findings. Treatment of LNCaP cells with 
Monensin induced a potent reduction in AR mRNA and protein expression 
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(Ketola et al., 2010) The reduction in AR signalling was enhanced when 
Monensin treatment coupled with AD (Ketola et al., 2010). 
 
KLK3 mRNA, which is associated with the AR, was also significantly 
downregulated in AD LNCaP cells treated with Monensin. These data suggest 
that in PCa, Monensin may alter multiple mechanisms and act on AR signalling 
as well as exosome release. This may be important in NEtD as NE-like cells are 
AR and PSA negative and loss of the AR is a mechanism of plasticity employed 
by PCa to avoid ADT (Hu et al., 2015) providing a link between exosomes 
released from AD LNCaP cells and their importance in NEtD. 
 
Ketola et al. (2010) showed that GW4869 can also reduce expression of 
exosome protein markers flotillin-1 and TSG101, in agreement with reduced 
exosome release (Ketola et al., 2010). mRNA analysis demonstrated that under 
AD conditions, GW4869 may reduce expression of ALIX, TSG101 and CD9, 
demonstrating the impact of GW4869 in downregulation of exosomal proteins. 
 
This is the first insight into the use of GW4869 and Monensin and their effects on 
gene expression in control and AD LNCaP cells. There are still many unknowns 
regarding the use of GW4869 and Monensin and it is unclear whether alterations 
in morphology and gene expression are a result of potential effects caused by 
the drugs. It is possible that in manipulating exosome release that the drugs are 
achieving the same effect and more work will need to be conducted to understand 
the effect of manipulating exosome release via GW4869 and Monensin at the 
molecular level. 
 
5.4.7 Manipulating exosome release alters the profile of extracellular ves-
icles isolated from LNCaP cells 
 
Treatment of the human breast cancer cell line (SKBR3) with GW4869 blocked 
exosome release but also stimulated budding of microvesicles at the plasma 
membrane (Menck et al., 2017). In this chapter, exosomes released from 
GW4869 treated control and AD LNCaP cells were reduced, however, an 
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increase in the number of microvesicles was observed (Figure 5.7). The data in 
this research therefore aligns with previous findings to show that in addition to 
blockade of exosome release, GW4869 enhances microvesicle release. Kosaka 
et al. (2010) identified that GW4869 reduced exosomal protein in a dose 
dependent manner, however, the exosomal protein composition did not differ 
from untreated exosomal protein. This indicates GW4869 is an appropriate 
method of exosome manipulation to investigate the role exosomes may play in 
AD-induced NEtD LNCaP cells and NEPC. 
 
GW4869 was shown to influence exosome-mediated tumour growth, as the 
number of lung metastases were reduced in tumour bearing mice (Fabbri et al., 
2012). The reduction is thought to result from reduced cell-to-cell exchange of 
exosomal miRNAs (Fabbri et al., 2012), suggesting that as GW4869 reduced the 
number of exosomes produced by AD LNCaP cells, there was a reduction in the 
exchange of exosomal cargo associated with NEtD, reducing the number of cells 
which undergo NEtD. 
 
Interesting work by Menck et al., (2017) showed treatment of SKBR3, breast 
cancer cells and murine L cells with GW4869 differentially affected the number 
of exosomes and microvesicles released. GW4869 treatment successfully 
reduced exosome release from SKBR3 and murine L cells and surprisingly, 
increased microvesicle release. These findings, therefore, align with data here, 
demonstrating that neutral sphingomyelinase inhibition differentially affects 
subcellular membranes and different EV sub populations. 
 
Treatment with Monensin enhanced the number of exosomes released from AD 
LNCaP cells, and the phenotype of control LNCaP cells which could suggest that 
their increased exosome release is associated with cancer progression via NEtD. 
It has been proposed that disruption of Ca2+ homeostasis is caused by enhanced 
proliferation and metastasis found in various cancers (Messenger et al., 2018). 
Therefore, the combined effect of increased Ca2+ by Monensin may account for 
the greater increase in exosome release from AD LNCaP cells compared with 




Those who have used GW4869 or Monensin to investigate the potential role of 
exosomes in disease do not provide data of the size or number of EVs, thus there 
is no evidence that treatment with these drugs alters the EV profile (Guo et al., 
2015; Panigrahi et al., 2018; Bhagirath et al., 2019). The conclusion that GW4869 
has reduced exosome release is based upon alterations in the cell specific cargo 
in the EVs and any changes to the size, number or populations identified are not 
stated. 
 
Cells secrete a wide range of EVs due to limitations in analytical techniques it is 
unclear what subpopulation of EVs are responsible for any given effect (Van Niel 
et al., 2018). This can be further complicated by the overlap in the range of sizes 
of exosomes and microvesicles, similar morphology and variable composition 
(Van Niel et al., 2018). Cargo from exosomes and microvesicles could differ or 
deliver different cargo to recipient cells. Future work should include investigation 
into exosomes and microvesicles to elucidate whether microvesicles may also 
contribute to NEtD in PCa. 
 
5.4.8 Limitations of exosome manipulation via GW4869 and Monensin 
 
DMSO is an organic solvent commonly used to dissolve lipophilic compounds, 
and should be used at 0.1 % or below in vitro (Sumida et al., 2011) The DMSO 
concentration used here was higher than intended, resulting in 1.15 % DMSO in 
25 µM GW4869 however, cell viability was only marginally affected. DMSO can 
induce adverse effects such as the differentiation of embryonic stem cell at non-
cytotoxic concentrations (Adler et al., 2006). Intriguingly, housekeeping genes 
such as ACTIN, GAPDH and PGK1 are sensitive to exposure to 0.5% (v/v) DMSO 
and above (Nishimura et al., 2008). In this chapter, ACTIN and GAPDH were 
included as housekeeping genes however, the CT values did not appear to be 
altered by the use of 1.15 % DMSO. These data suggest that DMSO may impact 
on the expression of genes associated with androgen signalling, NEtD and 
exosome machinery and it is possible that the DMSO may have masked effects 
of GW4869. It is, therefore, possible that GW4869 is having a greater effect than 
is identified due to interference by DMSO. In future, preparations of the working 
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GW4869 concentration should contain a concentration of 0.1 % or less DMSO to 
minimise the potential effects of DMSO on gene expression or exosome and 
microvesicle profiles. 
 
In previous chapters, gene expression data are representative of three replicate 
experiments however, time constraints limited gene expression analysis in this 
chapter to two replicates. The variation between the two replicates may indicate 
that observed changes in gene expression are not tangible and are instead, a 
product of variation. In future work a minimum of three replicates should be 
performed to support more robust analysis and provide a full data set. 
 
When the role of exosomes in PCa adaptation to hypoxia was analysed, 
Panigrahi et al. (2018) pre-treated PCa cells with GW4869 before exposure to 
hypoxic conditions (Panigrahi et al., 2018). Here LNCaP cells were treated as 
NEtD/AD was occurring. If LNCaP cells were pre-treated with GW4869 prior to 
AD it may alter the response of LNCaP cells to AD and provide evidence whether 
exosomes are involved in driving or maintaining NEtD induced by AD. 
 
5.4.9 Alternative methods of exosome manipulation 
 
Dynasore is an alternative drug to GW4869 used to manipulate exosome release. 
Dynamin2 has been described as an essential mediator of clathrin- and caveolin-
mediated endocytosis pathways (Macia et al., 2006). Blocking dynamin2 via 
dynasore can reduce internalisation of exosomes by cells (Su et al., 2018). 
Wilson et al. (2014) labelled purified exosomes with PKH67 dye to facilitate 
visualisation of exosome internalisation into HUVEC cells. Treatment with 
dynasore also reduced internalisation of fluorescently labelled transferrin, a 
specific ligand of the clathrin-mediated pathway and the internalisation of 
exosomes labelled with low density lipoprotein dye (Nanbo et al., 2013). These 
results indicate clathrin and/or caveolin-mediated endocytosis pathways may be 
involved in exosome internalisation by the recipient cell. Thus, dynasore should 
be used in future to reduce internalisation of exosomes released from AD-LNCaP 
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cells to provide evidence as to whether exosomes play a role in the maintenance 
of NEtD. 
 
Fluorescent membrane dyes to stain exosomes such as PKH67 or low-density 
lipoprotein (Dil) dyes should be considered to investigate the fate and potential 
role of exosomes in recipient cells and tissues (Mulcahy et al., 2014). This could 
permit tracking and visualisation of exosome uptake via confocal microscopy or 
flow cytometry. These dyes could be used to confirm exosome uptake by 
undifferentiated PCa cells or other NEtD PCa and therefore, may be useful to 
determine the role of exosomes in NEtD in PCa. 
 
Interference of endolysomal trafficking via the knockdown of two key players in 
endosomal trafficking N-Myc Downstream Regulated 1 (NDRG1) and Ras-
related protein Rab7 also significantly increases the release of exosomes (Ortega 
et al., 2019). However, these components are not specific to the exosome 
biogenesis pathway, highlighting the difficulty of dissecting one gene that affects 




In this work GW4869 and Monensin were used to impede and enhance exosome 
release from control and AD LNCaP cells respectively. Morphological analysis 
suggests exosomes are important for maintenance of NEtD as GW4869 
appeared to regress the NE-like phenotype in AD LNCaP cells and Monensin 
enhanced the NE-like phenotype in AD LNCaP cells. Enhanced exosomes also 
appeared to initiate an NE-like phenotype in control LNCaP cells; this translated 
in gene expression as there was upregulation of neuroendocrine associated 
markers suggesting that exosomes released from PCa cells may play a role in 
cell-to-cell communication. However, there was no conclusive evidence that 
exosomes specifically play a role in the NEtD of LNCaP cells. Further work will 
be required to investigate the exosomal cargo released from AD LNCaP to 
establish the role, if any, if exosomes in driving or maintaining NEtD.
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6. Chapter 6: Relevance, research conclusions, and future direction 
6.1 Relevance of research 
 
Prostate cancer (PCa) is the most frequently diagnosed cancer in men (Patel 
et al., 2019) with 48,500 new cases and 11,700 deaths reported annually in 
the UK (Cancer Research UK, 2017). The shift from androgen dependence to 
androgen independence is one of the most significant concerns in prostate 
cancer research, as conventional androgen deprivation therapy is only 
transiently successful (Cerasuolo et al., 2015). Although most patients receive 
symptomatic relief from therapeutic intervention by disrupting AR signalling, 
these treatments do not eradicate all PCa cell populations, resulting in castrate 
resistant prostate cancer (CRPC); (Terry and Beltran, 2014). A lethal subtype 
of CRPC, neuroendocrine prostate cancer (NEPC) arises to evade selective 
pressure of PCa therapies (radiotherapy, ADT, chemotherapy); (Lipianskaya 
et al., 2014). As a result epithelial PCa cells undergo lineage switching to 
become NE-like PCa cells (Beltran et al., 2019). NEPC tumours are extremely 
heterogeneous and lack biomarkers, which contributes to the inability to 
distinguish CRPC and NEPC to provide targeted and effective therapy 
(Clermont et al., 2019). NEPC generally represents late-stage PCa with 
extremely poor prognosis, despite treatment, survival of NEPC patients ranges 
from 7 months to 2 years (Davies et al., 2018). The high prevalence of PCa 
and increasing age of the population, make the recognition of alternative 
treatment methods for NEPC of significant importance (Marcu et al., 2010). 
Investigation of exosomes and their cargo as potential non-invasive and 
reproducible biomarkers for NEPC, may provide an opportunity to discriminate 
between different tumour types, monitor disease progression and provide 
novel opportunity for future disease targeting for patients with NEPC.
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6.1.1 Exosome depletion of FCS is an appropriate in vitro model to as-
sess exosomes released from LNCaP and NEtD LNCaP cells 
 
The overall aim of this work was to investigate the potential role of exosomes 
as a means of intracellular communication, involved in driving or maintaining 
the process of neuroendocrine transdifferentiation (NEtD) in PCa. 
 
The aim of chapter 3 was to establish a robust in vitro model to investigate 
exosome release from AD-induced NEtD LNCaP cells. Exosomes are 
released from all cells and biological fluids including FCS (Datta et al., 2018) 
and can be taken up by and influence recipient cells in vitro (Shelke et al., 
2014; Angelini et al., 2016). Exosome depleted CS-FCS is not commercially 
available therefore, differential ultracentrifugation was used to deplete CS-
FCS-derived exosomes. The effect exosome depletion may have had on AD-
induced NEtD has not previously been documented by those investigating 
exosomes in AD PCa, thus, the potential effects of exosome depletion on AD-
induced NEtD were unknown. CS-FCS exosomes were pelleted to produce 
clarified CS-FCS with a substantially reduced CS-FCS exosome content. 
Exosome depletion did not attenuate NEtD of LNCaP cells or alter the growth 
of NEtD or control cells. Therefore, an in vitro model to assess exosome 
release from LNCaP and NEtD LNCaP cells was successfully generated. This 
was of vital importance to ensure robust analysis of exosomes of interest. 
 
6.1.2 Androgen deprivation induces exosome machinery markers 
 
In chapter 4, the aim was to isolate and characterise exosomes released from 
AD-induced NEtD LNCaP cells, that androgen deprivation (AD) induces a 
neuronal-like phenotype and expression of neuroendocrine associated 
markers in LNCaP cells (Shen et al., 1997; Terry and Beltran, 2014; Fraser et 
al., 2019). CD9 may regulate AR activity and consequently, is involved in 
ligand-independent activity of AR (Levina et al., 2015). However, there has 
been no further investigation of the AR regulating other aspects of exosome 
machinery. Androgen-mediated autophagy promotes cell growth by 
augmenting intracellular lipid accumulation, shown to be necessary for PCa 
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cell growth (Shi et al., 2013). Autophagy and consequent cell growth are 
potentiated, in part, by androgen-mediated increases in reactive oxygen 
species (Shi et al., 2013). Four core autophagy genes (ULK1, ULK2, ATG4B, 
and ATG4D) are transcriptionally regulated by AR in PCa (Blessing et al., 
2017). There is a suggested interconnection of autophagy and exosome 
regulated secretory pathways as several proteins (components of the ESCRT 
and SNAREs) are involved in the regulation and biogenesis in autophagy and 
exosomes (Gudbergsson and Johnsen, 2019). Therefore, there is potential for 
the AR to influence EV biogenesis. EV release is enhanced in patients with 
CRPC and NEPC so, it is possible that the upregulation of exosomes is 
associated with autophagy regulated by the AR. 
 
This research is the first to investigate the expression of exosome machinery 
markers in LNCaP cells. AD has a significant impact on expression of 
exosome machinery involved in EV cargo packaging and docking and fusion 
with the plasma membrane therefore, the potential for AD to increase EV 
release could contribute to NEtD via intracellular communication (Figure 6.1). 
Exosome release was also enhanced in AD LNCaP cells as shown by 
Bhagirath et al. (2019), demonstrating a link between enhanced EV biogenesis 
and AD thus, by extension this may occur in vivo and in NEPC. The gene 
expression data presented in chapter 4 is significant, as it provides novel 
evidence that markers of exosome machinery are upregulated under AD 
conditions in LNCaP cells (Figure 6.1). Work by others (Bhagirath et al., 2019) 
has shown that exosomes are important in the transfer of mRNA associated 
with NEtD, together these findings suggest that exosomes may contribute to 






Figure 6.1: Differential expression of exosome machinery genes induced 
by AD. It was documented that upregulation of ALIX, TSG101, RAB27A, 
VAMP7 and CD9 by AD-induced NEtD of LNCaP cells was concomitant with 
increased release of exosomes by AD LNCaP cells in comparison to control 
LNCaP cells. Created using Servier Medical Art by Servier. 
 
6.1.3 Extracellular vesicle manipulation indicates a role for exosomes 
in NEtD in LNCaP cells 
 
In chapter 5, the aim was to manipulate EV release to dissect whether EVs 
play a role in NEtD of AD LNCaP. In order to determine the potential role of 
EV in NEtD of LNCaP cells EV release was manipulated using GW4869, to 
impede exosome release and Monensin, to enhance exosome release. 
Inhibition of EV release caused regression of the NEtD phenotype in AD 
LNCaP cells whereas enhanced EV release correlated with an enhanced 
NEtD phenotype in AD LNCaP cells. These findings emphasise the highly 
plastic nature of NEtD and indicate that exosomes may influence the lineage 
of the disease. The transition from an epithelial to neuronal-like phenotype was 
observed with augmented expression of neuroendocrine associated markers. 
These data are of considerable importance, as this is the first time that 
manipulation of exosome release has been shown to alter the phenotype of 
control and AD LNCaP cells. These findings support the hypothesis that EVs 
are implicated in intracellular communication in PCa and disease progression.
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6.2 Research limitations 
 
The data collected from this research indicated that exosomes have a potential 
role of mediating cell-to-cell communication in NEPC however, limitations 
prevented collection of further evidence. The number of exosomes collected was 
minimal and resulted in poor protein yield and inconclusive identification of 
exosome machinery markers. For robust identification of exosome machinery 
proteins exosome yield would need to be increased. Previous research has 
documented the need for hundreds of mLs of cell culture medium to provide 
enough exosomes for protein or gene analysis experiments (Tang et al., 2017). 
Therefore, future work would need to consider the upscale of cell culture to 
increase the number of exosomes collected for downstream analysis. A further 
limitation of this work is the inability to distinguish EV subtypes as there is an 
overlap in the size range of exosomes and microvesicles, similar morphology and 
variable composition (Van Niel et al., 2018). It is, therefore, not clear which 
subtype is responsible for any given outcome thus, further work is needed to 
improve isolation techniques and identify specific markers for differentiation of EV 
subpopulations. It is also accepted that the significance of the data may be limited 
by sample size thus, inclusion of a power calculation in future work would ensure 
significance. For example, to observe a significant effect of exosome release by 
GW4869 on LNCaP cells (80% power, 5% significance and two-sided test) 3 
replicates would be required based values from Bhagirath et al., (2019).  
 
6.3 Future Directions 
6.3.1 Exosomes as biomarkers in AD-induced NEtD LNCaP cells 
 
Exosomal cargo is representative of the parent cell thus, it is hypothesised that 
the exosome cargo may differ at different stages of the NEtD process. For 
example, at early stages, cargo may contain factors to drive NEtD, whilst at later 
stages of NEtD, exosomal cargo may alter to contain factors that maintain NEtD 
in the tumour microenvironment. Exosomes should be isolated from LNCaP cells 
throughout AD-induced NEtD and cargo assessed by mass spectrometry to 
identify if the exosomal cargo protein signature differs throughout NEtD. This 
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would contribute to the understanding of the role of exosomes in NEtD, as 
exosomes provide a snapshot of parent cells, NE-derived exosomes could differ 
from epithelial/adenocarcinoma-derived exosomes so, could be helpful to stratify 
PCa types. The application of miRNeasy micro kit (Qiagen, UK) to isolate 
exosomal RNA, followed by the use of TaqMan Array Human MicroRNA plates 
(Applied Biosystems, UK), can detect and accurately quantify 754 human 
miRNAs, to profile exosomal miRNA. The identification of enhanced exosome 
production, release and the differing cargo in PCa would be clinically useful for 
more effective diagnosis of PCa stage, frequent monitoring and provide more 
accurate treatment options. 
 
There are many known routes and suggested drivers of NEtD in PCa. Exosomes 
reflect the parent cell however; it is unknown if exosomes generated under 
different stresses may contain different cargo and thus drivers of NEtD. There is 
potential to use exosomes and their associated cargo, as biomarkers and by 
extension the stress state it is potentially under. It would be of interest to perform 
exosome purification and mass spectrometry to investigate the differential routes 
of NEtD and the cargo packaged in exosomes released from these cells. If 
successful, exosomal biomarkers could be used to efficiently diagnose NEtD and 
distinguish the route of NEtD induction. Knowledge of exosomal biomarkers could 
provide non-invasive and real-time biomarkers for PCa for a more precise and 
robust disease diagnosis, allow concurrent disease monitoring of NEPC 
development and allow stratification of PCa types. 
 
6.3.2 Do exosomes drive NEtD in LNCaP cells? 
 
In chapter 5 inhibition of exosome release via GW4869 caused regression of 
NEtD of LNCaP cell, suggesting exosomes are involved in maintenance of NEtD 
in LNCaP cells. To further validate these findings, blockade of exosome uptake 
by recipient cells should be investigated. The specific inhibitory agent dynasore 
can be used to block dymanin2, an essential mediator of clathrin- and caveolin-
mediated endocytosis pathways (Macia et al., 2006), reducing cellular 
internalisation of exosomes (Su et al., 2018). It is hypothesised that exosomes 
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derived from AD induced NEtD LNCaP cells will induce features of NEtD in 
untransformed, control epithelial cells via transfer of exosomal cargo, therefore 
exosomes should be isolated and purified from AD-induced NEtD LNCaP cells 
and added to epithelial LNCaP cells in culture. Morphology  would be monitored 
by brightfield microscopy and changes in gene expression analysed by qRT-
PCR. To demonstrate the importance of exosome internalisation and cargo in 
NEtD, AD exosomes would be applied to epithelial LNCaP cells with or without 
pre-treatment with dynasore. Exosomes uptake could also be confirmed by 
labelling with low-density-lipoprotein (Dil) dye, such as PKH67 and confocal 
microscopy to confirm uptake by epithelial LNCaP cells. This research would add 
to the current knowledge of exosome communication in PCa and ascertain 
whether exosomes play an essential role in NEtD of PCa. Identification of specific 
exosomal biomarkers to intercept the uptake of exosomes in recipient cells could 
reduce the dissemination of exosomal cargo associated with NEtD and further 
aggressive disease progression correlated with NEPC. 
 
6.3.3 Do differential time points affect the cargo within AD LNCaP cell ex-
osomes? 
 
In this research differences were found in the temporal expression profile of 
androgen signalling, neuroendocrine and exosome machinery genes, as 
expression was substantially less at 4 days than 15 days AD. AD enhances 
exosome release concomitant with previous research (Soekmadji et al., 2017; 
Bhagirath et al., 2019). Whether expression of exosome machinery is sequential, 
parallel or concomitant with AD-induced NEtD is unclear. Therefore, LNCaP cells 
should be exposed to a time course of 3, 7, 10, 14, 17, 21 days AD to pinpoint at 
what stage in the NEtD process exosome machinery genes and proteins (ALIX, 
TSG101, RAB27A, VAMP7, CD9) are induced in AD LNCaP cells. Knowledge of 
the time point at which, markers of exosome machinery are induced and whether 
the induction is sustained with relation to AD could provide a detailed and 
informed timeline of the upregulation of exosome production and how this 
correlates with NEtD. Using this knowledge, it would be possible to use GW4869 
and Monensin at different time points according to when AD influences exosome 
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machinery and more  effective EV manipulation to identify the potential role of 
EVs in PCa progression and NEtD. 
 
6.3.4 Are drivers of NEtD present in exosomes released from PCa cells? 
 
The presence of EVs in all biological fluids poses an opportunity to identify novel 
biomarkers for disease that are non-invasive and employed in real-time. 
Upregulation of several miRNAs miR-21, miR-145, miR-375) in urinary EVs from 
PCa patients have been implemented as efficient non-invasive biomarkers to 
stratify PCa from benign prostate hyperplasia or healthy patients (Foj et al., 2017; 
Xu et al., 2017). Recently, serum EV containing neural transcription factors, 
BRN2 and BRN4,  were significantly upregulated in CRPC with neuroendocrine 
characteristics compared to CRPC with adenocarcinoma characteristics 
(Bhagirath et al., 2019). There are a plethora of suggested drivers of 
neuroendocrine transdifferentiation, including ASCL1, EZH2, Notch, N-MYC, 
SOX2 and SRRM4 (Patel et al., 2019). Identifying these genes in EVs would add 
to our knowledge of NEtD in prostate cancer as a useful tool to distinguish 
between advanced PCa tumour types and aid tumour stratification. It would also 
be of interest to detect miRNA capable of inducing NEtD via the ExoCarta 
database to reveal candidate miRNAs or their apparent targets in EVs 
(Keerthikumar et al., 2016). This work should first be completed in vitro using 
NCI-H660 cells as they are derived from NEPC, to establish presence of miRNA 
in these EVs as biomarkers in a cellular model of PCa. Subsequent detection of 
miRNA within exosomes isolated from PCa patient blood or urine samples should 
be investigated for the clinical application of exosome biomarkers. The potential 
to selectively target neuronal factors via siRNA that are capable of inducing NEtD 
in PCa in EVs presents an increasingly important potential diagnostic tool for the 
differentiation of tumour type and disease progression. Monitoring and tracking 
of known NEtD markers via exosomes in blood or urine samples from PCa 
patients could be employed in lieu of invasive procedures such as biopsy.
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6.4 Final conclusions 
 
The overall survival of patients diagnosed with NEPC is less than two years, 
currently there are no biomarkers available to stratify this lethal form of PCa and 
treatment options are poor. Together, this body of work provides a platform for 
understanding the potential intracellular communicative role of EVs in NEtD of 
PCa, advocating their use for identification of novel, non-invasive and real-time 
biomarkers. These biomarkers could then be used to help stratify NEPC from 
other PCa types, monitor disease progression and treatment effects and provide 
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